{"answers": [{"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [157], "text": ["heterochromatin"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [146], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [74], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [20], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [17], "text": ["lead"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [105], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [33], "text": ["cutaneous squamous cell carcinoma"]}, {"answer_start": [95], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [95], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [95], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [95], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [95], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [95], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [95], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [95], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [95], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [95], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [0], "text": ["geck"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [260], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [191], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [115], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [95], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [94], "text": ["platelet-derived growth factor receptor-\u03b1"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [138, 391], "text": ["achalasia", "achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [219], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [245], "text": ["achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [58, 246], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [141, 297], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [73, 285], "text": ["achalasia", "achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [197], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [96], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [188], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [141], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [74], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [131], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [122], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [13], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [105], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [100], "text": ["achalasia"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [32, 144], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [26, 118], "text": ["suicide risk", "suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [151], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [16], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [47], "text": ["suicide risk"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [78], "text": ["companion imaging agent"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [237], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [77], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [156], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [114], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [96], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [119], "text": ["amyotrophic lateral sclerosis"]}, {"answer_start": [4], "text": ["tumor suppressor"]}, {"answer_start": [4], "text": ["tumor suppressor"]}, {"answer_start": [4], "text": ["tumor suppressor"]}, {"answer_start": [4], "text": ["tumor suppressor"]}, {"answer_start": [4], "text": ["tumor suppressor"]}, {"answer_start": [4], "text": ["tumor suppressor"]}, {"answer_start": [4], "text": ["tumor suppressor"]}, {"answer_start": [4], "text": ["tumor suppressor"]}, {"answer_start": [4], "text": ["tumor suppressor"]}, {"answer_start": [4], "text": ["tumor suppressor"]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [92], "text": ["optical coherence tomography."]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [38], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [58], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [24], "text": ["inner ear"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [95], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [94], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [83], "text": ["rotavirus disease"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [149], "text": ["tropomyosin receptor kinases"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [125], "text": ["cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [40, 201], "text": ["cystic fibrosis", "cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [81], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [52], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [3], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [51], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [49], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [80], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [60], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [40], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [82], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [72], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [61], "text": ["cystic fibrosis"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [50], "text": ["2.7%"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [105], "text": ["2017"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [34], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [196], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [84], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [45], "text": ["anaplastic lymphoma kinase"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [146], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [196], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [156], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [139], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [138], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [127], "text": ["neuronal ceroid lipofuscinosis type 2"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [207], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [32], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [140], "text": ["lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [0, 262], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [31, 259], "text": ["lysosomal acid lipase", "lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [175], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [186], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [160], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [149], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [12], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [143], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [122], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [26], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [31], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [0], "text": ["lysosomal acid lipase"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [28], "text": ["secreted protein content"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [110], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [166], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [9], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [83], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [0], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [58], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [56], "text": ["calcitonin gene-related peptide receptor"]}, {"answer_start": [23], "text": ["anticoagulant"]}, {"answer_start": [23], "text": ["anticoagulant"]}, {"answer_start": [23], "text": ["anticoagulant"]}, {"answer_start": [23], "text": ["anticoagulant"]}, {"answer_start": [23], "text": ["anticoagulant"]}, {"answer_start": [23], "text": ["anticoagulant"]}, {"answer_start": [23], "text": ["anticoagulant"]}, {"answer_start": [23], "text": ["anticoagulant"]}, {"answer_start": [23], "text": ["anticoagulant"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [74], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [102], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [142], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [140], "text": ["11p11.2p12"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [0], "text": ["intestinal epithelial cells"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [203, 389, 640, 739, 963], "text": ["epilepsy", "epilepsy", "epilepsy", "epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [238, 299], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [36, 228], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [38, 227], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [205], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [204], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [202], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [201], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [183], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [180], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [86], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [84], "text": ["epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [30, 78], "text": ["epilepsy", "epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [107], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [105], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [101], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [100], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [96], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [94], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [83], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [38], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [36], "text": ["epilepsy"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [300], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [119], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [14], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [166], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [144], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [58], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [38], "text": ["eosinophilic asthma"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [43], "text": ["histone acetyltransferase"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [245, 339], "text": ["toad venom", "toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [60], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [45], "text": ["toad venom"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [137], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [73], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [82], "text": ["pyrimidine biosynthesis"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [52], "text": ["deficiency of \u03b2-galactocerebrosidase"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [77], "text": ["environmental exposure record"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [60], "text": ["surfaceome predictor"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [247], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [209], "text": ["stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [86, 150, 254], "text": ["stress", "stress", "stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [126], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [171], "text": ["stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [71, 147], "text": ["stress", "stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [44], "text": ["stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [36, 121], "text": ["stress", "stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [116], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [52], "text": ["stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [51, 100], "text": ["stress", "stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [69], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [42], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [36], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [13], "text": ["stress"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [22], "text": ["foot"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [170, 238], "text": ["stomach", "stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [76], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [73], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [60], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [46], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [44], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [27], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [39], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [66], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [105], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [54], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [24], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [45], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [58], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [56], "text": ["stomach"]}, {"answer_start": [55], "text": ["adipokine"]}, {"answer_start": [55], "text": ["adipokine"]}, {"answer_start": [55], "text": ["adipokine"]}, {"answer_start": [55], "text": ["adipokine"]}, {"answer_start": [55], "text": ["adipokine"]}, {"answer_start": [55], "text": ["adipokine"]}, {"answer_start": [15], "text": ["adipokine"]}, {"answer_start": [15], "text": ["adipokine"]}, {"answer_start": [15], "text": ["adipokine"]}, {"answer_start": [15], "text": ["adipokine"]}, {"answer_start": [15], "text": ["adipokine"]}, {"answer_start": [15], "text": ["adipokine"]}, {"answer_start": [4], "text": ["adipokine"]}, {"answer_start": [4], "text": ["adipokine"]}, {"answer_start": [4], "text": ["adipokine"]}, {"answer_start": [4], "text": ["adipokine"]}, {"answer_start": [4], "text": ["adipokine"]}, {"answer_start": [4], "text": ["adipokine"]}, {"answer_start": [22], "text": ["adipokine"]}, {"answer_start": [22], "text": ["adipokine"]}, {"answer_start": [22], "text": ["adipokine"]}, {"answer_start": [22], "text": ["adipokine"]}, {"answer_start": [22], "text": ["adipokine"]}, {"answer_start": [22], "text": ["adipokine"]}], "context": ["the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "the fish analysis of the pepper tat elements showed a random distribution in heterochromatic and euchromatic regions, whereas the tomato tat elements showed heterochromatin-preferential accumulation", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "this paper sketches the early history and remembers the important contribution of henry burton, who described the gums to be bordered by a narrow leaden-blue line, about the one-twentieth part of an inch in width, whilst the substance of the gum apparently retained its ordinary colour and condition.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the second patient presented with abdominal pain and a burton's line. the lead level was 52\u03bcg/dl and free erythrocyte protoporphyrin was 262\u03bcg/dl.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "the patient's serum lead concentration was substantially elevated and he perhaps demonstrated burton's line.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "burton's line in lead poisoning.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "the fda greenlighted the pd-1 inhibitor cemiplimab to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for surgery or radiation.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "cemiplimab achieves responses in cutaneous squamous cell carcinoma.", "as a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (alk) proteins to treat non-small cell lung cancer. in this work, the mechanisms of brigatinib binding to wild type and four mutant alks were investigated to gain insight into the dynamic energetic and structural information with respect to the design of novel inhibitors. comparison between alk-brigatinib and alk-crizotinib suggests that the scaffold of brigatinib is well anchored to the residue met1199 of hinge region by two hydrogen bonds, and the residue lys1150 has the strong electrostatic interaction with the dimethylphosphine oxide moiety in brigatinib.", "as a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (alk) proteins to treat non-small cell lung cancer. in this work, the mechanisms of brigatinib binding to wild type and four mutant alks were investigated to gain insight into the dynamic energetic and structural information with respect to the design of novel inhibitors. comparison between alk-brigatinib and alk-crizotinib suggests that the scaffold of brigatinib is well anchored to the residue met1199 of hinge region by two hydrogen bonds, and the residue lys1150 has the strong electrostatic interaction with the dimethylphosphine oxide moiety in brigatinib.", "as a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (alk) proteins to treat non-small cell lung cancer. in this work, the mechanisms of brigatinib binding to wild type and four mutant alks were investigated to gain insight into the dynamic energetic and structural information with respect to the design of novel inhibitors. comparison between alk-brigatinib and alk-crizotinib suggests that the scaffold of brigatinib is well anchored to the residue met1199 of hinge region by two hydrogen bonds, and the residue lys1150 has the strong electrostatic interaction with the dimethylphosphine oxide moiety in brigatinib.", "as a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (alk) proteins to treat non-small cell lung cancer. in this work, the mechanisms of brigatinib binding to wild type and four mutant alks were investigated to gain insight into the dynamic energetic and structural information with respect to the design of novel inhibitors. comparison between alk-brigatinib and alk-crizotinib suggests that the scaffold of brigatinib is well anchored to the residue met1199 of hinge region by two hydrogen bonds, and the residue lys1150 has the strong electrostatic interaction with the dimethylphosphine oxide moiety in brigatinib.", "as a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (alk) proteins to treat non-small cell lung cancer. in this work, the mechanisms of brigatinib binding to wild type and four mutant alks were investigated to gain insight into the dynamic energetic and structural information with respect to the design of novel inhibitors. comparison between alk-brigatinib and alk-crizotinib suggests that the scaffold of brigatinib is well anchored to the residue met1199 of hinge region by two hydrogen bonds, and the residue lys1150 has the strong electrostatic interaction with the dimethylphosphine oxide moiety in brigatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "as a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (alk) proteins to treat non-small cell lung cancer.", "as a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (alk) proteins to treat non-small cell lung cancer.", "as a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (alk) proteins to treat non-small cell lung cancer.", "as a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (alk) proteins to treat non-small cell lung cancer.", "as a potent and selective drug, brigatinib exhibits high efficacy against wild-type and mutant anaplastic lymphoma kinase (alk) proteins to treat non-small cell lung cancer.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "geck: trio-based comparative benchmarking of variant calls.", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "population pharmacokinetic modeling of olaratumab, an anti-pdgfr\u03b1 human monoclonal antibody, in patients with advanced and/or metastatic cancer.<abstracttext label=\"background and objectives\">olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "phase i study of olaratumab in japanese patients with advanced solid tumors.olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "olaratumab (imc-3g3) is a fully human igg1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives: olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "background and objectives olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (pdgfr\u03b1).", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "comparison of early outcomes and quality of life after laparoscopic heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia.<abstracttext label=\"background and aim\" nlmcategory=\"objective\">this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "reduced postoperative pain scores and narcotic use favor per-oral endoscopic myotomy over laparoscopic heller myotomy.<abstracttext label=\"introduction\">per-oral endoscopic myotomy (poem) is a less invasive therapy for achalasia with a shorter hospitalization but with similar short- and long-term outcomes as a laparoscopic heller myotomy (lhm).", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "laparoscopic heller myotomy vs per oral endoscopic myotomy: patient-reported outcomes at a single institution.<abstracttext label=\"background\" nlmcategory=\"background\">although laparoscopic heller myotomy (lhm) has been the standard of care for achalasia, per oral endoscopic myotomy (poem) has gained popularity as a viable alternative.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "outcome of peroral endoscopic myotomy (poem) for treating achalasia compared with laparoscopic heller myotomy (lhm).<abstracttext label=\"objective\" nlmcategory=\"objective\">peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "systematic review and meta-analysis of perioperative outcomes of peroral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for achalasia.<abstracttext label=\"aims and objectives\" nlmcategory=\"objective\">laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "laparoscopic heller myotomy versus peroral endoscopic myotomy (poem) for achalasia: a systematic review and meta-analysis.<abstracttext label=\"objective\">to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim\nthis retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "background and aim this retrospective cohort study compared clinical outcomes and quality of life after peroral endoscopic myotomy (poem) against laparoscopic heller myotomy (lhm) for treatment of achalasia.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "although laparoscopic heller myotomy (lhm) is the current gold standard management for type iii achalasia, peroral endoscopic myotomy (poem) is conceivably superior because it allows for a longer myotomy.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "background per oral endoscopic myotomy (poem) has recently emerged as a viable option relative to the classic approach of laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "objective to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "peroral endoscopic myotomy (poem) is an emerging endoscopic treatment for achalasia and the long-term efficacy of poem remains to be evaluated.", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "to compare the outcome of per oral endoscopic myotomy (poem) and laparoscopic heller myotomy (lhm) for the treatment of esophageal achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "peroral endoscopic myotomy leads to higher rates of abnormal esophageal acid exposure than laparoscopic heller myotomy in achalasia", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "introduction\nachalasia is a rare disorder in children who are commonly treated by laparoscopic heller's myotomy (lhm).", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "this study compared the outcomes of poem with that of the standard laparoscopic heller myotomy (lhm) for achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives laparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "aims and objectives\nlaparoscopic heller myotomy (lhm) is the preferred surgical method for treating achalasia.", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "clinicians completed a standard suicide risk instrument (modified sad persons scale), a 10-point likert scale assessment of judgment of patient suicide risk (clinician prediction scale), and a measure of their emotional responses to the patient (therapist response questionnaire-suicide form).", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence. this article aims to determine the ability of the sad persons scale (sps) to predict future suicide in the emergency department.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale for suicide risk assessment: a systematic review.the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "beck's medical lethality scale (bmls) was administered to assess the degree of medical injury, and the sad persons mnemonic scale was used to evaluate suicide risk.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons suicide risk assessment scale is widely implemented in clinical settings despite limited supporting evidence.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "the sad persons scale (sps) is widely used for suicide risk assessment in clinical and educational settings.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate, vintafolide (ec145), to identify patients whose tumors express fr\u03b1.", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "in contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)tc-etarfolatide ((99m)tc-ec20), is in development for use as a companion diagnostic with the fr\u03b1-targeted folate conjugate,", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "objective: to assess the added prognostic value of the aggregated clinical and electrodiagnostic data, which define a given diagnostic category according to the awaji or revised el escorial criteria at time of diagnosis in patients with amyotrophic lateral sclerosis (als).", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "the awaji criteria, recently introduced to increase diagnosis sensitivity in amyotrophic lateral sclerosis (als), equate the diagnostic significance of neurogenic electrophysiological changes to clinical signs of lower motor neuron dysfunction.", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "introduction recently, some authors have claimed that the awaji criteria (ac) are not always more sensitive than the revised el escorial criteria (reec) in amyotrophic lateral sclerosis (als).", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "methods: this is a cross-sectional and descriptive study including a consecutive series of patients with sporadic amyotrophic lateral sclerosis according to awaji's criteria.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "the awaji criteria increases the diagnostic sensitivity of the revised el escorial criteria for amyotrophic lateral sclerosis diagnosis in a chinese population.", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "objective to assess the sensitivity and specificity of the awaji and revised el escorial diagnostic criteria (reec) in amyotrophic lateral sclerosis (als).", "the tumor suppressor p53 is a key regulator of apoptosis induced by various cellular stresses.", "the tumor suppressor p53 is a key regulator of apoptosis induced by various cellular stresses.", "the tumor suppressor p53 is a key regulator of apoptosis induced by various cellular stresses.", "the tumor suppressor p53 is a key regulator of apoptosis induced by various cellular stresses.", "the tumor suppressor p53 is a key regulator of apoptosis induced by various cellular stresses.", "the tumor suppressor p53 is a key regulator of apoptosis induced by various cellular stresses.", "the tumor suppressor p53 is a key regulator of apoptosis induced by various cellular stresses.", "the tumor suppressor p53 is a key regulator of apoptosis induced by various cellular stresses.", "the tumor suppressor p53 is a key regulator of apoptosis induced by various cellular stresses.", "the tumor suppressor p53 is a key regulator of apoptosis induced by various cellular stresses.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "retinal and choroidal changes in patients with parkinson's disease detected by swept-source optical coherence tomography.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "meniere's disease is a disease of the inner ear characterized by a triad of symptoms: vestibular symptoms, auditory symptoms, and pressure.", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "m\u00e9ni\u00e8re's disease (md) is a chronic, non-life threatening inner ear disease,", "meniere's disease is an inner ear disease,", "meniere's disease is an inner ear disease,", "meniere's disease is an inner ear disease,", "meniere's disease is an inner ear disease,", "meniere's disease is an inner ear disease,", "meniere's disease is an inner ear disease,", "meniere's disease is an inner ear disease,", "meniere's disease is an inner ear disease,", "meniere's disease is an inner ear disease,", "meniere's disease is an inner ear disease,", "meniere's disease is an inner ear disease,", "meniere's disease is an inner ear disease,", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background: the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "background the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "the rv3-bb human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "in the 2017 american society for clinical oncology annual meeting, larotrectinib (loxo-101), loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases (trk), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (ntrk)-fusion proteins in adult and pediatric patients.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "objective: to conduct a descriptive analysis of the sweat test (st), associating st results with epidemiological data, cftr (cystic fibrosis transmembrane conductance regulator) mutations and reasons to indicate the st, as well as correlating sweat sodium and sweat chloride concentrations in subjects.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat metabolome of screen-positive cystic fibrosis infants: revealing mechanisms beyond impaired chloride transport.the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "assessment of correlation between sweat chloride levels and clinical features of cystic fibrosis patients.the diagnosis is often delayed and the disease is advanced in most patients at the time of diagnosis.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background: sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "in cystic fibrosis (cf), sweat chloride concentration has been proposed as an index of cftr function for testing systemic drugs designed to activate mutant cftr.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background\nsweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "background sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "sweat chloride is of interest as a biomarker for cystic fibrosis, electrolyte metabolism disorders, electrolyte balance, and electrolyte loss during exercise.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "the sweat chloride test remains the gold standard for confirmatory diagnosis of cystic fibrosis (cf) in support of universal newborn screening programs.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride test is known to be a screening test for the cystic fibrosis due to the fact that electrolyte levels in sweat are elevated in patients.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "sweat chloride testing for diagnosis of cystic fibrosis (cf) involves sweat induction, collection and handling, and measurement in an analytical lab.", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objective sweat chloride measurement is considered a standard diagnostic tool for cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives sweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "objectives\nsweat chloride testing is the gold standard for diagnosis of cystic fibrosis (cf).", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "background sweat chloride test is the gold standard test for cystic fibrosis (cf) diagnosis.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "our study shows that 1 in 38 healthy individuals (2.7%) has a (likely) pathogenic variant in one of 59 medically actionable dominant disease genes for which the american college of medical genetics and genomics (acmg) recommends disclosure.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "the drug is being investigated or considered as a treatment for various bacterial infections and in june 2017 received approval in the usa for the treatment of acute bacterial skin and skin structure infections.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "importance: the identification of anaplastic lymphoma kinase (alk) rearrangements in 2-5% of non-small cell lung cancer (nsclc) patients led to the rapid clinical development of its oral tyrosine kinase inhibitor (tki). crizotinib was the first alk inhibitor approved and utilised in the treatment of alk+ nsclc patients in the second line setting first and subsequently in the first line one. since then many other alk inhibitors have been developed (ceritinib, alectinib, brigatinib, lorlatinib,etc) and the treatment paradigm of these patients has considerably drifted. the questions regarding their treatment at progression remains unanswered at the moment.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "lorlatinib (pf-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ros1), which has a kinase domain that is physiologically related to anaplastic lymphoma kinase (alk), and is undergoing phase i/ii clinical trial investigations for non-small cell lung cancers.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "purpose of review: we describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.recent findings: five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "lorlatinib (pf-06463922) is a promising oral anaplastic lymphoma kinase (alk) and ros1 inhibitor currently in phase iii clinical trials for treatment of non-small-cell lung cancer (nsclc) containing an alk rearrangement.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1. cln2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. this article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the usa for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with cln2, and subsequent approval in the eu for cln2 in all ages.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "<b>background</b>: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>methods</b>: in a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with cln2 disease who were between the ages of 3 and 16 years.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa: first global approval.cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "cerliponase alfa (brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (tpp1) being developed by biomarin pharmaceutical inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (cln2), a paediatric neurodegenerative disease caused by a deficiency in tpp1.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background: recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "background\nrecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (cln2) disease, a rare lysosomal disorder that causes progressive dementia in children.", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.previous studies have shown that cultured fibroblasts derived from patients with genetic defects in lysosomal acid lipase (i. e. the wolman syndrome and cholesteryl ester storage disease) are defective in their ability to hydrolyze the cholesteryl esters contained in plasma low density lipoprotein (ldl).", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "wolman's disease, also known as lysosomal acid lipase (lipa) deficiency, is a rare autosomal-recessive disorder characterized by complete absence of the lipa enzyme. the diagnosis of wolman's disease was made postnatally by biochemical testing, which indicated absence of lipa enzyme activity and gene sequencing, which confirmed homozygosity for the g66v mutation within the lipa gene.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "molecular defects underlying wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease.human lysosomal acid lipase/cholesteryl ester hydrolase (hlal) is essential for the intralysosomal metabolism of cholesteryl esters and triglycerides taken up by receptor-mediated endocytosis of lipoprotein particles.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "cholesteryl ester storage disease (cesd, omim #278000) and wolman disease (omim #278000) are autosomal recessive lysosomal storage disorders caused by a deficient activity of lysosomal acid lipase (cholesteryl ester hydrolase, lal).", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "acta 1006, 84-88], has been administered to cultured lymphoblastoid cells from normal subjects and from a patient affected with wolman disease, which is characterized by a deficiency of lysosomal acid lipase.", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "cholesteryl ester storage disease (cesd) and wolman disease (wd) are both autosomal recessive disorders associated with reduced activity and genetic defects of lysosomal acid lipase (lal).", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "we report successful long-term bone marrow engraftment in a patient with wolman disease resulting in continued normalization of peripheral leukocyte lysosomal acid lipase enzyme activity.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "background: lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from wolman disease to cholesterol ester storage disease.", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "these include wolman disease (wd) and cholesteryl ester storage disease (cesd) which both result from mutations in lipa, the gene that encodes lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background\nwolman disease (wd) is a rare lysosomal storage disorder that is caused by mutations in the lipa gene encoding lysosomal acid lipase (lal).", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "background: deficiency of lysosomal acid lipase (lal) causes wolman disease and cholesterol ester storage disease.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "a new mutation in the gene for lysosomal acid lipase leads to wolman disease in an african kindred.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "lysosomal acid lipase deficiency: wolman disease and cholesteryl ester storage disease.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "comparative analyses of the secreted protein content (exoproteome) revealed that many enzymes involved in carbohydrate hydrolysis were regulated by vdsec22 or vdsso1.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "background we evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "erratum: calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [corrigendum].", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "background\nwe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "objective\nto assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (em).", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.", "like other direct oral anticoagulants (doacs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring.", "like other direct oral anticoagulants (doacs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring.", "like other direct oral anticoagulants (doacs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring.", "like other direct oral anticoagulants (doacs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring.", "like other direct oral anticoagulants (doacs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring.", "like other direct oral anticoagulants (doacs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring.", "like other direct oral anticoagulants (doacs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring.", "like other direct oral anticoagulants (doacs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring.", "like other direct oral anticoagulants (doacs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a contiguous gene deletion syndrome involving 11p11.2p12 and characterized by multiple exostoses, biparietal foramina, genitourinary anomalies in males, central nervous system abnormalities, intellectual disability, and craniofacial abnormalities.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome is a rare contiguous gene deletion syndrome due to haploinsufficiency of the 11p11.2p12 region and is characterized by craniofacial abnormalities, developmental delay, intellectual disability, multiple exostoses, and biparietal foramina.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss, omim #601224) is a rare contiguous gene deletion syndrome caused by haploinsufficiency of genes located on the 11p11.2p12.", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "potocki-shaffer syndrome (pss) is a rare disorder caused by haploinsufficiency of genes located on the proximal short arm of chromosome 11 (11p11.2p12).", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "intestinal epithelial cells [fabp2 (fatty acid binding protein 2),", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "conclusions: in this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (cbt), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "this is an update of a cochrane review first published in 2012 (cochrane database of systematic reviews 2012, issue 6).<br><b>objectives</b>: to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.<br><b>search methods</b>: we searched the cochrane epilepsy group specialized register (16 february 2015), the cochrane central register of controlled trials (central, the cochrane library 16 february 2015) and medline (ovid, 1946 to 16 february 2015).", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for focal epilepsy.the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "losigamone add-on therapy for partial epilepsy.the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions\nthe results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions: the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "authors' conclusions\nthe results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed that losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with focal epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone can reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "the results of this review showed losigamone did reduce seizure frequency but was associated with more treatment withdrawals when used as an add-on therapy for people with partial epilepsy.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer antiepileptic drugs have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for partial epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "in recent years, many newer aeds have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "perspectives of losigamone in epilepsy treatment.patients with drug resistant epilepsy represent about 40% of the whole population of epileptic patients.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "objectives\nto investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "based on the study's results, lsg is an effective and safe add-on drug for refractory partial epilepsy in adults.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled add-on trials comparing losigamone with placebo for partial epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "selection criteria\nrandomized controlled, add-on trials comparing losigamone with placebo for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for partial epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "to investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "both trials assessed losigamone 1200 or 1500 mg/d as an add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for partial epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "losigamone add-on therapy for focal epilepsy.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "in particular, reslizumab is a humanized anti-il-5 monoclonal antibody that has been found to be an effective and safe add-on therapy, capable of decreasing asthma exacerbations and significantly improving disease control and lung function in patients experiencing persistent allergic or nonallergic eosinophilic asthma, despite the regular use of moderate-to-high doses of inhaled corticosteroids.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "since il-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting il-5/il-5r\u03b1 have been developed and/or marketed, including mepolizumab, reslizumab, and benralizumab.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab in eosinophilic asthma: a review.reslizumab (cinqaero<sup>\u00ae</sup>; cinqair<sup>\u00ae</sup>) is a humanized monoclonal antibody against interleukin-5 (il-5), a cytokine mediator of eosinophilic airway inflammation.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "reslizumab (cinquil\u2122) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "background\nreslizumab is a humanized anti-interleukin-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab is indicated as an add-on treatment for severe eosinophilic asthma in adults, on the basis of data from the breath phase iii clinical trial programme.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "reslizumab in the treatment of severe eosinophilic asthma", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "the transcriptional co-activator p300 is a histone acetyltransferase (hat) that is typically recruited to transcriptional enhancers and regulates gene expression by acetylating chromatin.", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "rcfs of cinobufagin to gamabufotalin, bufotalin, bufalin and resibufogenin were determined as 1.05, 0.895, 1.09 and 0.913, respectively. the characteristic chromatogram and qams established in this study could effectively control the quality of toad venom and provide scientific evidence for the improvement of the quality standard of the toad venom to be described in chinese pharmacopoeia", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "in the current study, gamabufotalin (gbt) was isolated from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "gamabufotalin, a bufadienolide compound from toad venom", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from toxoplasma gondii.the pyrimidine biosynthesis pathway in the protozoan pathogen toxoplasma gondii is essential for parasite growth during infection.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase (dhodh) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of malaria.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "dihydroorotate dehydrogenase, an enzyme catalyzing the only redox reaction of the pyrimidine biosynthesis pathway, is a well-characterized target for chemotherapeutical intervention.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "krabbe disease (kd) is a rare disease caused by the deficiency of \u03b2-galactocerebrosidase.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "the interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "o enable analysis of the human surfaceome, we developed the surfaceome predictor surfy, based on machine learning.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "the present paper addresses several psychological and biological variables, which may account for such dissociations, and aims to help researchers to rate the validity and psychobiological significance of salivary cortisol as an hpaa biomarker of stress in their experiments.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "background\nthe aim of this study was to evaluate salivary alpha-amylase (saa), considered a non-invasive biomarker for sympathetic nervous system (sns) activity, and salivary cortisol as possible pain-induced stress biomarker,\u00a0in horses with acute abdominal disease.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "conclusion\nsalivary cortisol concentration is positively correlated with occupational stress and increases with the increasing degree of occupational stress, and can be used as an objective biomarker for the identification and evaluation of occupational stress.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "methods\nin 323 children (5-10 years old) participating in the belgian chibs study, salivary cortisol samples, a biomarker for stress, was sampled when waking up, 30 and 60 min after wake up and in the evening on two consecutive weekdays.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "salivary cortisol is considered to be a safe and noninvasive measure of hypothalamic-pituitary-adrenal axis functioning, and is a commonly measured biomarker of the human stress response in pediatric research.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "finally, salivary cortisol has been used extensively as a biomarker of stress in a research setting, especially in studies examining psychological stress with repeated measurements.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "purpose\ncortisol is frequently assayed as a stress-responsive biomarker which changes over the course of minutes to meet the demands of a person's social context.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol as a biomarker in stress research.salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisol is commonly used as a clinical biomarker of endocrine status and also as a marker of psychosocial stress.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "salivary cortisone, as a biomarker for psychosocial stress, is associated with state anxiety and heart rate.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "the salivary cortisol level reflects psychological stress, and it is a good index to assess chronic stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "salivary cortisol is frequently used as a biomarker of psychological stress.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "cortisol is a classical biomarker for the stress levels of human beings.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "salivary cortisol as a biomarker in stress research.", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "ortisol as a stress biomarker", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "the cobb-stainsby forefoot arthroplasty combines partial phalangectomy (stainsby) with extensor tendon transfer to the metatarsal head (cobb).", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.<br>", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "these results suggest that (1) endogenous centrally released ghrelin participates in the regulation of food intake and body weight, (2) acyl ghrelin is secreted from the stomach, (3) intestinal hormones stimulate ghrelin release from the stomach, and (4) regulation of the diurnal rhythm of ghrelin is complex, since ghrelin secretion is augmented under conditions of both gastric emptying and filling.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "ghrelin, the only known orexigenic gut hormone, is secreted mainly from the stomach, increases with fasting and before meal initiation in humans and rats, and increases food intake after central or peripheral administration.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "objectives\nghrelin, a recently discovered hormone mainly secreted by the stomach, has several metabolic functions including regulation of food intake, energy homeostasis and body weight.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "most of the ghrelin produced in the body is secreted in the stomach, but it is also expressed in the hypothalamus, pituitary, pancreas, intestine, kidney, heart and gonads.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "<b>background</b>: ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "purpose\nghrelin is mainly secreted from the stomach and plays a role in appetite, weight gain, and the promotion of a positive energy balance.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is secreted by the stomach, the hypothalamus, and the placenta in humans and has growth hormone-secreting and orexigenic properties.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "ghrelin and feedback systems.ghrelin is produced primarily in the stomach in response to hunger, and circulates in the blood.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "background\na wide variety of functions has been attributed to ghrelin, a peptide hormone secreted in the stomach.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "objective\nghrelin is a hormone secreted mainly in the stomach which stimulates appetite and food intake.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "background\nghrelin is secreted mainly in the stomach and plays a role in food intake regulation.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "ghrelin secreted by the stomach stimulates the afferent vagus nerve and promotes food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "background & aims\nghrelin is secreted by the stomach and stimulates food intake.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a peptide hormone produced and secreted in the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a 28-amino acid peptide secreted mainly by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "ghrelin is a recently described hormone secreted by the stomach.", "leptin, adiponectin, and resistin are the most studied adipokines which play important roles in the regulation of cardiovascular homeostasis.", "leptin, adiponectin, and resistin are the most studied adipokines which play important roles in the regulation of cardiovascular homeostasis.", "leptin, adiponectin, and resistin are the most studied adipokines which play important roles in the regulation of cardiovascular homeostasis.", "leptin, adiponectin, and resistin are the most studied adipokines which play important roles in the regulation of cardiovascular homeostasis.", "leptin, adiponectin, and resistin are the most studied adipokines which play important roles in the regulation of cardiovascular homeostasis.", "leptin, adiponectin, and resistin are the most studied adipokines which play important roles in the regulation of cardiovascular homeostasis.", "resistin is an adipokine that induces insulin resistance in mice; serum concentrations are decreased by fasting and increased by feeding.", "resistin is an adipokine that induces insulin resistance in mice; serum concentrations are decreased by fasting and increased by feeding.", "resistin is an adipokine that induces insulin resistance in mice; serum concentrations are decreased by fasting and increased by feeding.", "resistin is an adipokine that induces insulin resistance in mice; serum concentrations are decreased by fasting and increased by feeding.", "resistin is an adipokine that induces insulin resistance in mice; serum concentrations are decreased by fasting and increased by feeding.", "resistin is an adipokine that induces insulin resistance in mice; serum concentrations are decreased by fasting and increased by feeding.", "the adipokine resistin has been proposed to link obesity, insulin resistance and diabetes.", "the adipokine resistin has been proposed to link obesity, insulin resistance and diabetes.", "the adipokine resistin has been proposed to link obesity, insulin resistance and diabetes.", "the adipokine resistin has been proposed to link obesity, insulin resistance and diabetes.", "the adipokine resistin has been proposed to link obesity, insulin resistance and diabetes.", "the adipokine resistin has been proposed to link obesity, insulin resistance and diabetes.", "leptin belongs to the adipokine family, which also contains adiponectin and resistin.", "leptin belongs to the adipokine family, which also contains adiponectin and resistin.", "leptin belongs to the adipokine family, which also contains adiponectin and resistin.", "leptin belongs to the adipokine family, which also contains adiponectin and resistin.", "leptin belongs to the adipokine family, which also contains adiponectin and resistin.", "leptin belongs to the adipokine family, which also contains adiponectin and resistin."], "id": ["5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c34ad63da8336e21a000007_0", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_1", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_2", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_3", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58962286df2b9174000007_4", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_5", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c58b99586df2b9174000012_6", "5c588efb86df2b9174000004_7", "5c588efb86df2b9174000004_7", "5c588efb86df2b9174000004_7", "5c588efb86df2b9174000004_7", "5c588efb86df2b9174000004_7", "5c588efb86df2b9174000004_8", "5c588efb86df2b9174000004_8", "5c588efb86df2b9174000004_8", "5c588efb86df2b9174000004_8", "5c588efb86df2b9174000004_8", "5c588efb86df2b9174000004_9", "5c588efb86df2b9174000004_9", "5c588efb86df2b9174000004_9", "5c588efb86df2b9174000004_9", "5c588efb86df2b9174000004_9", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c581e1507647bbc4b00001c_10", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_11", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_12", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_13", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_14", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c73ad367c78d69471000099_15", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_16", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_17", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_18", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_19", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_20", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_21", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_22", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_23", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_24", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_25", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_26", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_27", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_28", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_29", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_30", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_31", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_32", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c536b857e3cb0e23100001c_33", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_34", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_35", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_36", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_37", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_38", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c73ad027c78d6947100008d_39", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_40", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c7161f47c78d69471000066_41", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_42", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_43", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_44", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_45", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_46", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c61d278e842deac67000005_47", "5c5f1f371a4c55d80b00001a_48", "5c5f1f371a4c55d80b00001a_48", "5c5f1f371a4c55d80b00001a_48", "5c5f1f371a4c55d80b00001a_48", "5c5f1f371a4c55d80b00001a_48", "5c5f1f371a4c55d80b00001a_48", "5c5f1f371a4c55d80b00001a_48", "5c5f1f371a4c55d80b00001a_48", "5c5f1f371a4c55d80b00001a_48", "5c5f1f371a4c55d80b00001a_48", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5249077e3cb0e23100000b_49", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_50", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_51", "5c5310c37e3cb0e231000010_52", "5c5310c37e3cb0e231000010_52", "5c5310c37e3cb0e231000010_52", "5c5310c37e3cb0e231000010_52", "5c5310c37e3cb0e231000010_52", "5c5310c37e3cb0e231000010_52", "5c5310c37e3cb0e231000010_52", "5c5310c37e3cb0e231000010_52", "5c5310c37e3cb0e231000010_52", "5c5310c37e3cb0e231000010_52", "5c5310c37e3cb0e231000010_52", "5c5310c37e3cb0e231000010_52", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_53", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_54", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e05f37c78d69471000049_55", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e0f537c78d6947100004a_56", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_57", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_58", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_59", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_60", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_61", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_62", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_63", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_64", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_65", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_66", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_67", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_68", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_69", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_70", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c6e16eb7c78d6947100004e_71", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c51fe8907ef653866000007_72", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c0117fd133db5eb7800002a_73", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_74", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_75", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_76", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c72ade07c78d69471000070_77", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_78", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_79", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_80", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_81", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_82", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_83", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_84", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c6b810e7c78d6947100002e_85", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_86", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_87", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_88", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_89", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_90", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_91", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_92", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_93", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_94", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_95", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_96", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_97", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_98", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_99", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c72f6b17c78d6947100007f_100", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c8cd26a0101eac870000003_101", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_102", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_103", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_104", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_105", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_106", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_107", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c73acef7c78d69471000088_108", "5c920f13ecadf2e73f000010_109", "5c920f13ecadf2e73f000010_109", "5c920f13ecadf2e73f000010_109", "5c920f13ecadf2e73f000010_109", "5c920f13ecadf2e73f000010_109", "5c920f13ecadf2e73f000010_109", "5c920f13ecadf2e73f000010_109", "5c920f13ecadf2e73f000010_109", "5c920f13ecadf2e73f000010_109", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_110", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_111", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_112", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c72b7277c78d69471000073_113", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c8d15cf0101eac870000009_114", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_115", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_116", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_117", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_118", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_119", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_120", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_121", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_122", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_123", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_124", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_125", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_126", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_127", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_128", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_129", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_130", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_131", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_132", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_133", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_134", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_135", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_136", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_137", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_138", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_139", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_140", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_141", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5c73acec7c78d69471000086_142", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_143", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_144", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_145", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_146", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_147", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_148", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_149", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5ca0bf00ecadf2e73f000045_150", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c990241ecadf2e73f00002d_151", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_152", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_153", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5c9904eaecadf2e73f00002e_154", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_155", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_156", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5cb0856decadf2e73f000058_157", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5c9efde8ecadf2e73f000039_158", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0d647ecadf2e73f000059_159", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5cb0e4a6ecadf2e73f00005b_160", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_161", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_162", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_163", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_164", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_165", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_166", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_167", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_168", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_169", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_170", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_171", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_172", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_173", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_174", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9fb428ecadf2e73f000041_175", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5c9ff25eecadf2e73f000043_176", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_177", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_178", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_179", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_180", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_181", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_182", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_183", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_184", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_185", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_186", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_187", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_188", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_189", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_190", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_191", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_192", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_193", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5caa06d0ecadf2e73f000056_194", "5c840782617e120c34000006_195", "5c840782617e120c34000006_195", "5c840782617e120c34000006_195", "5c840782617e120c34000006_195", "5c840782617e120c34000006_195", "5c840782617e120c34000006_195", "5c840782617e120c34000006_196", "5c840782617e120c34000006_196", "5c840782617e120c34000006_196", "5c840782617e120c34000006_196", "5c840782617e120c34000006_196", "5c840782617e120c34000006_196", "5c840782617e120c34000006_197", "5c840782617e120c34000006_197", "5c840782617e120c34000006_197", "5c840782617e120c34000006_197", "5c840782617e120c34000006_197", "5c840782617e120c34000006_197", "5c840782617e120c34000006_198", "5c840782617e120c34000006_198", "5c840782617e120c34000006_198", "5c840782617e120c34000006_198", "5c840782617e120c34000006_198", "5c840782617e120c34000006_198"], "question": ["[PAD] [PAD] which genomic positions are preferentially selected for transposon insertion?", "[PAD] [PAD] [PAD] which genomic positions are preferably selected for transposon insertion?", "[PAD] [PAD] [PAD] [PAD] which genomic positions are best chosen for transposon insertion?", "what genomic loci are preferentially selected for insertion of transposons?", "[PAD] [PAD] [PAD] which genomic positions are preferably selected for transposon placement?", "[PAD] [PAD] [PAD] [PAD] [PAD] which genomic positions are preferred for transposon placement?", "what genomic positions are selected for transposon insertion as a matter of priority?", "[PAD] [PAD] [PAD] which genomic positions are chosen preferably for transposon insertion?", "[PAD] which genomic positions are preferably chosen for insertion of the transposon?", "[PAD] [PAD] [PAD] [PAD] [PAD] which genomic positions are preferred for transposon insertion?", "[PAD] [PAD] [PAD] [PAD] which genomic sites are selected primarily for transposon insertion?", "[PAD] [PAD] [PAD] [PAD] which genomic positions are predominantly selected for transposon activation?", "[PAD] [PAD] [PAD] which genomic sites are preferably selected for transposon insertion?", "[PAD] [PAD] [PAD] which genomic position is chosen preferentially for transposition insertion?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which genomic positions are preferred for transposition insertion?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what genetic status is most preferred for transposon insertion?", "[PAD] [PAD] which genomic position is preferentially selected for transposon insertion?", "[PAD] [PAD] [PAD] which genomic sites are favorably selected for insertion translocation?", "[PAD] [PAD] which genomic locations are preferentially selected for transposon insertion?", "[PAD] [PAD] [PAD] [PAD] [PAD] which genomic position is preferred for transposon insertion?", "[PAD] [PAD] which genomic location is preferentially selected for transposon insertion?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which genome positions are chosen for transposon insertion?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which genome positions are selected first for transposon insertion?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which genome position is preferred to include transposons?", "[PAD] which genomic positions are preferentially selected for insertion of transposons?", "[PAD] [PAD] what positions of the genome are preferentially chosen for transposon insertion?", "[PAD] [PAD] which genomic positions are preferentially chosen for transposon insertion?", "[PAD] [PAD] what genomic positions are preferentially selected for transposon insertion?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what geometric positions have been preferred for transposon placement?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which genome location was specifically chosen for transposon insertion?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which gene sites are preferred for transposition insertion?", "[PAD] [PAD] [PAD] [PAD] which genomic sites are preferentially selected for transduction insertion?", "[PAD] [PAD] [PAD] [PAD] which genomic positions are preferably selected for transposition insertion?", "[PAD] [PAD] which intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] what drunkenness is associated with burton's line?", "[PAD] [PAD] [PAD] which intoxication is related to the burton line?", "[PAD] [PAD] [PAD] what is toxicosis associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] what poisoning is associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication is associated with the burton line?", "[PAD] [PAD] what intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] what intoxication is associated with the burton line?", "[PAD] [PAD] [PAD] [PAD] which poisoning is associated with burton's line?", "[PAD] [PAD] what intoxication is associated with burton\u2019s line?", "[PAD] [PAD] what is the intoxication associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication belongs to burton's line?", "[PAD] what kind of intoxication is associated with the burton line?", "[PAD] [PAD] which intoxication is associated with burton\u2019s line?", "[PAD] [PAD] [PAD] [PAD] what poisoning is associated with burton's lineage?", "[PAD] [PAD] [PAD] which intoxication is associated with the barton line?", "[PAD] [PAD] [PAD] [PAD] what rush is associated with burton's line?", "[PAD] what intoxicants are associated with burton's line?", "[PAD] [PAD] what intoxication is connected with burton's line?", "[PAD] [PAD] [PAD] [PAD] burton's line is related to which drug?", "[PAD] [PAD] which intoxication is connected to burton's line?", "[PAD] [PAD] [PAD] what drunkenness is related to burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is drunk on the burton line?", "[PAD] [PAD] [PAD] [PAD] which addiction is related to burton's line?", "[PAD] [PAD] what are the addictions associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] which poisoning is associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication is related to the barton line?", "what kind of intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] what poisoning is associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] what alcoholism is associated with the burton line?", "[PAD] [PAD] [PAD] what poisoning accompanies burton's line?", "[PAD] [PAD] [PAD] [PAD] which drug is associated with burton's line?", "[PAD] [PAD] [PAD] what drunkenness is related to burton's lines?", "[PAD] [PAD] [PAD] what intoxication is associated with the burton dynasty?", "[PAD] [PAD] which intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] what drunkenness is associated with burton's line?", "[PAD] [PAD] [PAD] which intoxication is related to the burton line?", "[PAD] [PAD] [PAD] what is toxicosis associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] what poisoning is associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication is associated with the burton line?", "[PAD] [PAD] what intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] what intoxication is associated with the burton line?", "[PAD] [PAD] [PAD] [PAD] which poisoning is associated with burton's line?", "[PAD] [PAD] what intoxication is associated with burton\u2019s line?", "[PAD] [PAD] what is the intoxication associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication belongs to burton's line?", "[PAD] what kind of intoxication is associated with the burton line?", "[PAD] [PAD] which intoxication is associated with burton\u2019s line?", "[PAD] [PAD] [PAD] [PAD] what poisoning is associated with burton's lineage?", "[PAD] [PAD] [PAD] which intoxication is associated with the barton line?", "[PAD] [PAD] [PAD] [PAD] what rush is associated with burton's line?", "[PAD] what intoxicants are associated with burton's line?", "[PAD] [PAD] what intoxication is connected with burton's line?", "[PAD] [PAD] [PAD] [PAD] burton's line is related to which drug?", "[PAD] [PAD] which intoxication is connected to burton's line?", "[PAD] [PAD] [PAD] what drunkenness is related to burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is drunk on the burton line?", "[PAD] [PAD] [PAD] [PAD] which addiction is related to burton's line?", "[PAD] [PAD] what are the addictions associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] which poisoning is associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication is related to the barton line?", "what kind of intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] what poisoning is associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] what alcoholism is associated with the burton line?", "[PAD] [PAD] [PAD] what poisoning accompanies burton's line?", "[PAD] [PAD] [PAD] [PAD] which drug is associated with burton's line?", "[PAD] [PAD] [PAD] what drunkenness is related to burton's lines?", "[PAD] [PAD] [PAD] what intoxication is associated with the burton dynasty?", "[PAD] [PAD] which intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] what drunkenness is associated with burton's line?", "[PAD] [PAD] [PAD] which intoxication is related to the burton line?", "[PAD] [PAD] [PAD] what is toxicosis associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] what poisoning is associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication is associated with the burton line?", "[PAD] [PAD] what intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] what intoxication is associated with the burton line?", "[PAD] [PAD] [PAD] [PAD] which poisoning is associated with burton's line?", "[PAD] [PAD] what intoxication is associated with burton\u2019s line?", "[PAD] [PAD] what is the intoxication associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication belongs to burton's line?", "[PAD] what kind of intoxication is associated with the burton line?", "[PAD] [PAD] which intoxication is associated with burton\u2019s line?", "[PAD] [PAD] [PAD] [PAD] what poisoning is associated with burton's lineage?", "[PAD] [PAD] [PAD] which intoxication is associated with the barton line?", "[PAD] [PAD] [PAD] [PAD] what rush is associated with burton's line?", "[PAD] what intoxicants are associated with burton's line?", "[PAD] [PAD] what intoxication is connected with burton's line?", "[PAD] [PAD] [PAD] [PAD] burton's line is related to which drug?", "[PAD] [PAD] which intoxication is connected to burton's line?", "[PAD] [PAD] [PAD] what drunkenness is related to burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is drunk on the burton line?", "[PAD] [PAD] [PAD] [PAD] which addiction is related to burton's line?", "[PAD] [PAD] what are the addictions associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] which poisoning is associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication is related to the barton line?", "what kind of intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] what poisoning is associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] what alcoholism is associated with the burton line?", "[PAD] [PAD] [PAD] what poisoning accompanies burton's line?", "[PAD] [PAD] [PAD] [PAD] which drug is associated with burton's line?", "[PAD] [PAD] [PAD] what drunkenness is related to burton's lines?", "[PAD] [PAD] [PAD] what intoxication is associated with the burton dynasty?", "[PAD] [PAD] which intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] what drunkenness is associated with burton's line?", "[PAD] [PAD] [PAD] which intoxication is related to the burton line?", "[PAD] [PAD] [PAD] what is toxicosis associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] what poisoning is associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication is associated with the burton line?", "[PAD] [PAD] what intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] what intoxication is associated with the burton line?", "[PAD] [PAD] [PAD] [PAD] which poisoning is associated with burton's line?", "[PAD] [PAD] what intoxication is associated with burton\u2019s line?", "[PAD] [PAD] what is the intoxication associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication belongs to burton's line?", "[PAD] what kind of intoxication is associated with the burton line?", "[PAD] [PAD] which intoxication is associated with burton\u2019s line?", "[PAD] [PAD] [PAD] [PAD] what poisoning is associated with burton's lineage?", "[PAD] [PAD] [PAD] which intoxication is associated with the barton line?", "[PAD] [PAD] [PAD] [PAD] what rush is associated with burton's line?", "[PAD] what intoxicants are associated with burton's line?", "[PAD] [PAD] what intoxication is connected with burton's line?", "[PAD] [PAD] [PAD] [PAD] burton's line is related to which drug?", "[PAD] [PAD] which intoxication is connected to burton's line?", "[PAD] [PAD] [PAD] what drunkenness is related to burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is drunk on the burton line?", "[PAD] [PAD] [PAD] [PAD] which addiction is related to burton's line?", "[PAD] [PAD] what are the addictions associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] [PAD] which poisoning is associated with the burton line?", "[PAD] [PAD] [PAD] which intoxication is related to the barton line?", "what kind of intoxication is associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] what poisoning is associated with burton's line?", "[PAD] [PAD] [PAD] [PAD] what alcoholism is associated with the burton line?", "[PAD] [PAD] [PAD] what poisoning accompanies burton's line?", "[PAD] [PAD] [PAD] [PAD] which drug is associated with burton's line?", "[PAD] [PAD] [PAD] what drunkenness is related to burton's lines?", "[PAD] [PAD] [PAD] what intoxication is associated with the burton dynasty?", "[PAD] [PAD] cemiplimab is used for treatment of which cancer?", "[PAD] [PAD] [PAD] cemiplimab is used to treat which cancer?", "cemiplimab for the treatment of which cancer is it used?", "[PAD] [PAD] what type of cancer is cemiplimab used for?", "[PAD] [PAD] [PAD] what cancer treatment is cemiplimab used for?", "[PAD] [PAD] what cancers is cemiplimab used to treat?", "[PAD] [PAD] [PAD] [PAD] [PAD] for which cancer is temiplimab used?", "[PAD] [PAD] [PAD] [PAD] which cancer is cemiplimab used for?", "[PAD] [PAD] [PAD] what cancer is used to treat cemiplimab?", "[PAD] [PAD] [PAD] what cancer is cemiplimab used to treat?", "[PAD] [PAD] [PAD] which cancer is used to treat cemiplimab?", "[PAD] [PAD] [PAD] [PAD] what cancer is cemiplimab used for?", "[PAD] cemiplimab is used for the treatment of which cancer?", "[PAD] [PAD] [PAD] [PAD] what cancer is chemiplimab used to treat?", "[PAD] [PAD] [PAD] which cancer treatment is cemiplimab used for?", "[PAD] cemiplimab is used to treat which type of cancer?", "[PAD] [PAD] [PAD] is cemiplimab used to treat which cancer?", "[PAD] [PAD] [PAD] [PAD] what cancers do cemiplimab use?", "[PAD] [PAD] [PAD] [PAD] cemiplimab used to treat any cancer?", "[PAD] [PAD] cemiplimab is used to treat which cancers?", "[PAD] [PAD] [PAD] which cancer is cemiplimab used to treat?", "[PAD] [PAD] [PAD] cemiplimab is used to treat any cancer?", "[PAD] [PAD] cemilimab is used for the treatment of which cancer?", "[PAD] [PAD] [PAD] [PAD] [PAD] chemiplimab used to treat what cancer?", "[PAD] [PAD] [PAD] [PAD] which cancer is semiplimab used to treat?", "[PAD] [PAD] [PAD] what cancers is cemiplimab used for?", "[PAD] [PAD] [PAD] [PAD] what is cemiplimab used to treat?", "[PAD] for the treatment of which cancer is cemiplimab used?", "[PAD] [PAD] [PAD] cemiplimab is used to treat what cancer?", "[PAD] [PAD] what kind of cancer is cemiplimab used for?", "[PAD] cemiplimab is used to treat which types of cancer?", "[PAD] [PAD] [PAD] [PAD] cemiplimab is used to treat cancer.", "[PAD] cemiplimab is used to treat what kind of cancer?", "[PAD] cemiplimab is used to treat what type of cancer?", "[PAD] [PAD] cemilimab is used to treat what type of cancer?", "[PAD] cemiplimab is used in the treatment of which cancer?", "[PAD] [PAD] [PAD] [PAD] chemmlimab is used to treat which cancer?", "[PAD] [PAD] cemiplimab is used for treatment of what cancer?", "[PAD] [PAD] cemiplimab is used for treatment of which cancer?", "[PAD] [PAD] [PAD] cemiplimab is used to treat which cancer?", "cemiplimab for the treatment of which cancer is it used?", "[PAD] [PAD] what type of cancer is cemiplimab used for?", "[PAD] [PAD] [PAD] what cancer treatment is cemiplimab used for?", "[PAD] [PAD] what cancers is cemiplimab used to treat?", "[PAD] [PAD] [PAD] [PAD] [PAD] for which cancer is temiplimab used?", "[PAD] [PAD] [PAD] [PAD] which cancer is cemiplimab used for?", "[PAD] [PAD] [PAD] what cancer is used to treat cemiplimab?", "[PAD] [PAD] [PAD] what cancer is cemiplimab used to treat?", "[PAD] [PAD] [PAD] which cancer is used to treat cemiplimab?", "[PAD] [PAD] [PAD] [PAD] what cancer is cemiplimab used for?", "[PAD] cemiplimab is used for the treatment of which cancer?", "[PAD] [PAD] [PAD] [PAD] what cancer is chemiplimab used to treat?", "[PAD] [PAD] [PAD] which cancer treatment is cemiplimab used for?", "[PAD] cemiplimab is used to treat which type of cancer?", "[PAD] [PAD] [PAD] is cemiplimab used to treat which cancer?", "[PAD] [PAD] [PAD] [PAD] what cancers do cemiplimab use?", "[PAD] [PAD] [PAD] [PAD] cemiplimab used to treat any cancer?", "[PAD] [PAD] cemiplimab is used to treat which cancers?", "[PAD] [PAD] [PAD] which cancer is cemiplimab used to treat?", "[PAD] [PAD] [PAD] cemiplimab is used to treat any cancer?", "[PAD] [PAD] cemilimab is used for the treatment of which cancer?", "[PAD] [PAD] [PAD] [PAD] [PAD] chemiplimab used to treat what cancer?", "[PAD] [PAD] [PAD] [PAD] which cancer is semiplimab used to treat?", "[PAD] [PAD] [PAD] what cancers is cemiplimab used for?", "[PAD] [PAD] [PAD] [PAD] what is cemiplimab used to treat?", "[PAD] for the treatment of which cancer is cemiplimab used?", "[PAD] [PAD] [PAD] cemiplimab is used to treat what cancer?", "[PAD] [PAD] what kind of cancer is cemiplimab used for?", "[PAD] cemiplimab is used to treat which types of cancer?", "[PAD] [PAD] [PAD] [PAD] cemiplimab is used to treat cancer.", "[PAD] cemiplimab is used to treat what kind of cancer?", "[PAD] cemiplimab is used to treat what type of cancer?", "[PAD] [PAD] cemilimab is used to treat what type of cancer?", "[PAD] cemiplimab is used in the treatment of which cancer?", "[PAD] [PAD] [PAD] [PAD] chemmlimab is used to treat which cancer?", "[PAD] [PAD] cemiplimab is used for treatment of what cancer?", "what is the mechanism of action of brigatinib?", "[PAD] [PAD] [PAD] [PAD] how does brigatinib work?", "what is the mechanism of action of brigtinib?", "what is brigatinib's mechanism of action?", "[PAD] [PAD] what is the mechanism of action of brigadier general?", "what is the mechanism of action of brigatinib?", "[PAD] [PAD] [PAD] [PAD] how does brigatinib work?", "what is the mechanism of action of brigtinib?", "what is brigatinib's mechanism of action?", "[PAD] [PAD] what is the mechanism of action of brigadier general?", "what is the mechanism of action of brigatinib?", "[PAD] [PAD] [PAD] [PAD] how does brigatinib work?", "what is the mechanism of action of brigtinib?", "what is brigatinib's mechanism of action?", "[PAD] [PAD] what is the mechanism of action of brigadier general?", "[PAD] which algorithm has been developed for trio-based benchmarking of variant calls?", "[PAD] [PAD] what algorithm was developed for trio-based benchmarking of variant calls?", "[PAD] [PAD] [PAD] what algorithm has been developed for trio-based comparison of variant calls?", "[PAD] [PAD] [PAD] [PAD] [PAD] what algorithm was developed for triple scaling of variable calls?", "which algorithm has been developed for calibration based on the triple of optional calls?", "[PAD] what algorithm has been developed for benchmarking based on the variant call trio?", "[PAD] [PAD] [PAD] what algorithm has been developed to benchmark variant calls based on three?", "[PAD] [PAD] which algorithm has been developed for trio-based comparative analysis of variant calls?", "[PAD] what algorithm has been developed for benchmarking based on trio of variant calls?", "[PAD] [PAD] which algorithm has been developed for the trio-based variant calling benchmark?", "[PAD] [PAD] [PAD] what algorithm was developed for the trio-based comparison of call variants?", "[PAD] [PAD] [PAD] [PAD] [PAD] which algorithm was developed to compare call variants on a triple?", "[PAD] what algorithm has been developed for trio-based benchmarking of variant calls?", "[PAD] what algorithm has been developed for the trio-based comparison study of variant calls?", "[PAD] [PAD] which algorithm was developed for trio-based benchmarking of call variants?", "[PAD] [PAD] what algorithm has been developed for the three-basis comparison of variation calls?", "[PAD] [PAD] [PAD] what algorithm was developed for the trio benchmarking of variant calls?", "[PAD] what algorithm has been developed for benchmarking based on variant call trios?", "which algorithm has been developed for benchmarking based on a trio of variant calls?", "[PAD] [PAD] which algorithm was developed for trio-based benchmarking of variant calls?", "[PAD] [PAD] which algorithm has been developed for benchmarking variant calls based on three?", "[PAD] [PAD] [PAD] what algorithm has been developed for trio-based measurement of variant readings?", "[PAD] [PAD] [PAD] [PAD] which algorithms have been developed for trio-based variant call comparison?", "[PAD] [PAD] what algorithm was developed for three-way benchmarking of variable calls?", "[PAD] which algorithm was developed for the trio-based benchmarking of variant calls?", "[PAD] [PAD] what algorithms were developed for trio-based benchmarking of variant calls?", "[PAD] [PAD] [PAD] [PAD] [PAD] which algorithm has been developed for comparing a variant call trio?", "[PAD] which algorithm has been developed for trio -based benchmarking for variant calls?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which algorithm has been developed to triple test different calls?", "[PAD] what algorithm was developed for the comparative testing of variant combinations based on a trio?", "[PAD] [PAD] what algorithm was developed for benchmarking based on trio of variant calls?", "[PAD] [PAD] what algorithm has been developed for benchmarking trio-based call variants?", "[PAD] [PAD] [PAD] [PAD] what algorithm was developed for trio based benchmarking call variants?", "[PAD] [PAD] [PAD] [PAD] [PAD] which algorithm was developed to compare call variants based on three?", "[PAD] which algorithm was developed for the comparative analysis of variant calls based on the trio?", "what algorithm has been developed for benchmarking based on trios of variant calls?", "[PAD] [PAD] [PAD] [PAD] what algorithm is developed for third-party comparisons of dialect phones?", "[PAD] [PAD] [PAD] [PAD] what algorithm has been developed for comparing three-group variable calls?", "[PAD] [PAD] [PAD] which algorithm has been developed for tripartite comparison of variant calls?", "[PAD] [PAD] what algorithm has been developed for benchmarking trio-based variant calls?", "[PAD] [PAD] which algorithm has been developed for benchmarking based on three different calls?", "[PAD] what algorithm has been developed for benchmarking against triples of variant calls?", "[PAD] [PAD] [PAD] [PAD] what algorithm has been developed for benchmarking trio variable calls?", "[PAD] which molecule is targeted by olaratumab?", "[PAD] [PAD] what molecule does olaratumab target?", "[PAD] [PAD] [PAD] [PAD] which molecule targets olatumab?", "[PAD] [PAD] which molecule does olaratumab target?", "[PAD] [PAD] what molecules does olaratumab target?", "which molecule is the target of olaratumab?", "[PAD] [PAD] which molecule does olezumab target?", "[PAD] which molecule is olaratumab targeted at?", "[PAD] [PAD] which molecule is olaratumab targeting?", "[PAD] [PAD] [PAD] [PAD] what is olaratumab?", "what molecule is the target of olaratumab?", "[PAD] which molecule is olatratumab targeted at?", "[PAD] which molecule is targeted at olaratumab?", "[PAD] [PAD] what molecules does olalatumab target?", "[PAD] which molecule does olaratumab refer to?", "[PAD] which molecule is olaratumab directed to?", "[PAD] [PAD] which molecule is targeted by olaratomab?", "[PAD] [PAD] which molecule is olaratumab targeted?", "[PAD] [PAD] what molecule is olaratumab targeting?", "[PAD] which molecule is affected by olaratumab?", "[PAD] [PAD] [PAD] olaratumab targets which molecule?", "[PAD] which molecule is targeted by olaratumab?", "[PAD] [PAD] what molecule does olaratumab target?", "[PAD] [PAD] [PAD] [PAD] which molecule targets olatumab?", "[PAD] [PAD] which molecule does olaratumab target?", "[PAD] [PAD] what molecules does olaratumab target?", "which molecule is the target of olaratumab?", "[PAD] [PAD] which molecule does olezumab target?", "[PAD] which molecule is olaratumab targeted at?", "[PAD] [PAD] which molecule is olaratumab targeting?", "[PAD] [PAD] [PAD] [PAD] what is olaratumab?", "what molecule is the target of olaratumab?", "[PAD] which molecule is olatratumab targeted at?", "[PAD] which molecule is targeted at olaratumab?", "[PAD] [PAD] what molecules does olalatumab target?", "[PAD] which molecule does olaratumab refer to?", "[PAD] which molecule is olaratumab directed to?", "[PAD] [PAD] which molecule is targeted by olaratomab?", "[PAD] [PAD] which molecule is olaratumab targeted?", "[PAD] [PAD] what molecule is olaratumab targeting?", "[PAD] which molecule is affected by olaratumab?", "[PAD] [PAD] [PAD] olaratumab targets which molecule?", "[PAD] which molecule is targeted by olaratumab?", "[PAD] [PAD] what molecule does olaratumab target?", "[PAD] [PAD] [PAD] [PAD] which molecule targets olatumab?", "[PAD] [PAD] which molecule does olaratumab target?", "[PAD] [PAD] what molecules does olaratumab target?", "which molecule is the target of olaratumab?", "[PAD] [PAD] which molecule does olezumab target?", "[PAD] which molecule is olaratumab targeted at?", "[PAD] [PAD] which molecule is olaratumab targeting?", "[PAD] [PAD] [PAD] [PAD] what is olaratumab?", "what molecule is the target of olaratumab?", "[PAD] which molecule is olatratumab targeted at?", "[PAD] which molecule is targeted at olaratumab?", "[PAD] [PAD] what molecules does olalatumab target?", "[PAD] which molecule does olaratumab refer to?", "[PAD] which molecule is olaratumab directed to?", "[PAD] [PAD] which molecule is targeted by olaratomab?", "[PAD] [PAD] which molecule is olaratumab targeted?", "[PAD] [PAD] what molecule is olaratumab targeting?", "[PAD] which molecule is affected by olaratumab?", "[PAD] [PAD] [PAD] olaratumab targets which molecule?", "[PAD] which molecule is targeted by olaratumab?", "[PAD] [PAD] what molecule does olaratumab target?", "[PAD] [PAD] [PAD] [PAD] which molecule targets olatumab?", "[PAD] [PAD] which molecule does olaratumab target?", "[PAD] [PAD] what molecules does olaratumab target?", "which molecule is the target of olaratumab?", "[PAD] [PAD] which molecule does olezumab target?", "[PAD] which molecule is olaratumab targeted at?", "[PAD] [PAD] which molecule is olaratumab targeting?", "[PAD] [PAD] [PAD] [PAD] what is olaratumab?", "what molecule is the target of olaratumab?", "[PAD] which molecule is olatratumab targeted at?", "[PAD] which molecule is targeted at olaratumab?", "[PAD] [PAD] what molecules does olalatumab target?", "[PAD] which molecule does olaratumab refer to?", "[PAD] which molecule is olaratumab directed to?", "[PAD] [PAD] which molecule is targeted by olaratomab?", "[PAD] [PAD] which molecule is olaratumab targeted?", "[PAD] [PAD] what molecule is olaratumab targeting?", "[PAD] which molecule is affected by olaratumab?", "[PAD] [PAD] [PAD] olaratumab targets which molecule?", "[PAD] which molecule is targeted by olaratumab?", "[PAD] [PAD] what molecule does olaratumab target?", "[PAD] [PAD] [PAD] [PAD] which molecule targets olatumab?", "[PAD] [PAD] which molecule does olaratumab target?", "[PAD] [PAD] what molecules does olaratumab target?", "which molecule is the target of olaratumab?", "[PAD] [PAD] which molecule does olezumab target?", "[PAD] which molecule is olaratumab targeted at?", "[PAD] [PAD] which molecule is olaratumab targeting?", "[PAD] [PAD] [PAD] [PAD] what is olaratumab?", "what molecule is the target of olaratumab?", "[PAD] which molecule is olatratumab targeted at?", "[PAD] which molecule is targeted at olaratumab?", "[PAD] [PAD] what molecules does olalatumab target?", "[PAD] which molecule does olaratumab refer to?", "[PAD] which molecule is olaratumab directed to?", "[PAD] [PAD] which molecule is targeted by olaratomab?", "[PAD] [PAD] which molecule is olaratumab targeted?", "[PAD] [PAD] what molecule is olaratumab targeting?", "[PAD] which molecule is affected by olaratumab?", "[PAD] [PAD] [PAD] olaratumab targets which molecule?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with heller laparoscopic myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what disease is treated with lhm?", "[PAD] [PAD] what disease is treated with laparoscopic heller miotomy (lhm)?", "what disease is treated with geller\u2019s laparoscopic myotomy (lhm)?", "what disease is treated with laparoscopic heller's myotomy (lhm)?", "[PAD] what diseases can be treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what diseases are treated with laparoscopic heller myotomy (lhm)?", "[PAD] what disease is treated with laparoscopic heller's mitomy (lhm)?", "which disease is treated with heller's laparoscopic myotomy (lhm)?", "[PAD] what are the diseases treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heleri myotomy (lhm)?", "[PAD] what disease is treated with heller myotomy (lhm) laparoscopy?", "[PAD] [PAD] what condition is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] what disease is treated with laparoscopic heller myotomy (mlh)?", "je! what disease is treated with laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] [PAD] [PAD] [PAD] which diseases are treated with heller myotomy (lhm)?", "what disease is treated with laparoscopic geller's myotomy (lhm)?", "[PAD] [PAD] what disease is treated by laparoscopic heller myotomy (lhm)?", "[PAD] [PAD] which disease is treated with helical laparoscopic myotomy (lhm)?", "[PAD] [PAD] what is evaluated with the sad persons scale?", "[PAD] what is being evaluated with the sad persons scale?", "[PAD] [PAD] [PAD] what is the scale of sad people?", "[PAD] what is evaluated on the scale of sad people?", "[PAD] [PAD] what is assessed on the sad persons scale?", "[PAD] [PAD] what is evaluated on the sad persons scale?", "[PAD] what is assessed on the scale of sad faces?", "[PAD] [PAD] what is rated with the sad face scale?", "[PAD] what is assessed with the grieving person scale?", "[PAD] [PAD] what is rated on the sads scale?", "[PAD] [PAD] what is evaluated using the sad persons scale?", "[PAD] [PAD] what is rated on the sad persons scale?", "[PAD] what is evaluated on the size of sad persons?", "[PAD] [PAD] what is assessed with the sad persons scale?", "[PAD] [PAD] [PAD] [PAD] what is the sad persons scale?", "[PAD] [PAD] [PAD] what does the sad persons scale assess?", "[PAD] [PAD] what is valued with the sad persons scale?", "[PAD] what do you rate on the scrapped persons scale?", "[PAD] [PAD] what is assessed on the sad people scale?", "[PAD] [PAD] what is considered with the sad persons scale?", "[PAD] what do you rate on the sad persons scale?", "[PAD] what is assessed on the scale of sads?", "[PAD] [PAD] what is assessed with the scale sad face?", "[PAD] [PAD] what is rated by the sad persons scale?", "[PAD] what is evaluated with the trist persons scale?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is sad persons rated?", "[PAD] [PAD] what is assessed by the sad persons scale?", "[PAD] [PAD] [PAD] what is rated by the sadness scale?", "[PAD] [PAD] what is evaluated with the sad people scale?", "[PAD] what is evaluated by the level of sad persons?", "[PAD] what is an assessment with the sad persons scale?", "[PAD] what is evaluated with the people of peace scale?", "what is assessed on the scale \"self person\"?", "[PAD] [PAD] [PAD] what is measured by sad persons scale?", "[PAD] what is being evaluated with the sad persons rating?", "[PAD] [PAD] what is evaluated with the sad persons scale?", "[PAD] what is being evaluated with the sad persons scale?", "[PAD] [PAD] [PAD] what is the scale of sad people?", "[PAD] what is evaluated on the scale of sad people?", "[PAD] [PAD] what is assessed on the sad persons scale?", "[PAD] [PAD] what is evaluated on the sad persons scale?", "[PAD] what is assessed on the scale of sad faces?", "[PAD] [PAD] what is rated with the sad face scale?", "[PAD] what is assessed with the grieving person scale?", "[PAD] [PAD] what is rated on the sads scale?", "[PAD] [PAD] what is evaluated using the sad persons scale?", "[PAD] [PAD] what is rated on the sad persons scale?", "[PAD] what is evaluated on the size of sad persons?", "[PAD] [PAD] what is assessed with the sad persons scale?", "[PAD] [PAD] [PAD] [PAD] what is the sad persons scale?", "[PAD] [PAD] [PAD] what does the sad persons scale assess?", "[PAD] [PAD] what is valued with the sad persons scale?", "[PAD] what do you rate on the scrapped persons scale?", "[PAD] [PAD] what is assessed on the sad people scale?", "[PAD] [PAD] what is considered with the sad persons scale?", "[PAD] what do you rate on the sad persons scale?", "[PAD] what is assessed on the scale of sads?", "[PAD] [PAD] what is assessed with the scale sad face?", "[PAD] [PAD] what is rated by the sad persons scale?", "[PAD] what is evaluated with the trist persons scale?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is sad persons rated?", "[PAD] [PAD] what is assessed by the sad persons scale?", "[PAD] [PAD] [PAD] what is rated by the sadness scale?", "[PAD] [PAD] what is evaluated with the sad people scale?", "[PAD] what is evaluated by the level of sad persons?", "[PAD] what is an assessment with the sad persons scale?", "[PAD] what is evaluated with the people of peace scale?", "what is assessed on the scale \"self person\"?", "[PAD] [PAD] [PAD] what is measured by sad persons scale?", "[PAD] what is being evaluated with the sad persons rating?", "[PAD] [PAD] what is evaluated with the sad persons scale?", "[PAD] what is being evaluated with the sad persons scale?", "[PAD] [PAD] [PAD] what is the scale of sad people?", "[PAD] what is evaluated on the scale of sad people?", "[PAD] [PAD] what is assessed on the sad persons scale?", "[PAD] [PAD] what is evaluated on the sad persons scale?", "[PAD] what is assessed on the scale of sad faces?", "[PAD] [PAD] what is rated with the sad face scale?", "[PAD] what is assessed with the grieving person scale?", "[PAD] [PAD] what is rated on the sads scale?", "[PAD] [PAD] what is evaluated using the sad persons scale?", "[PAD] [PAD] what is rated on the sad persons scale?", "[PAD] what is evaluated on the size of sad persons?", "[PAD] [PAD] what is assessed with the sad persons scale?", "[PAD] [PAD] [PAD] [PAD] what is the sad persons scale?", "[PAD] [PAD] [PAD] what does the sad persons scale assess?", "[PAD] [PAD] what is valued with the sad persons scale?", "[PAD] what do you rate on the scrapped persons scale?", "[PAD] [PAD] what is assessed on the sad people scale?", "[PAD] [PAD] what is considered with the sad persons scale?", "[PAD] what do you rate on the sad persons scale?", "[PAD] what is assessed on the scale of sads?", "[PAD] [PAD] what is assessed with the scale sad face?", "[PAD] [PAD] what is rated by the sad persons scale?", "[PAD] what is evaluated with the trist persons scale?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is sad persons rated?", "[PAD] [PAD] what is assessed by the sad persons scale?", "[PAD] [PAD] [PAD] what is rated by the sadness scale?", "[PAD] [PAD] what is evaluated with the sad people scale?", "[PAD] what is evaluated by the level of sad persons?", "[PAD] what is an assessment with the sad persons scale?", "[PAD] what is evaluated with the people of peace scale?", "what is assessed on the scale \"self person\"?", "[PAD] [PAD] [PAD] what is measured by sad persons scale?", "[PAD] what is being evaluated with the sad persons rating?", "[PAD] [PAD] what is evaluated with the sad persons scale?", "[PAD] what is being evaluated with the sad persons scale?", "[PAD] [PAD] [PAD] what is the scale of sad people?", "[PAD] what is evaluated on the scale of sad people?", "[PAD] [PAD] what is assessed on the sad persons scale?", "[PAD] [PAD] what is evaluated on the sad persons scale?", "[PAD] what is assessed on the scale of sad faces?", "[PAD] [PAD] what is rated with the sad face scale?", "[PAD] what is assessed with the grieving person scale?", "[PAD] [PAD] what is rated on the sads scale?", "[PAD] [PAD] what is evaluated using the sad persons scale?", "[PAD] [PAD] what is rated on the sad persons scale?", "[PAD] what is evaluated on the size of sad persons?", "[PAD] [PAD] what is assessed with the sad persons scale?", "[PAD] [PAD] [PAD] [PAD] what is the sad persons scale?", "[PAD] [PAD] [PAD] what does the sad persons scale assess?", "[PAD] [PAD] what is valued with the sad persons scale?", "[PAD] what do you rate on the scrapped persons scale?", "[PAD] [PAD] what is assessed on the sad people scale?", "[PAD] [PAD] what is considered with the sad persons scale?", "[PAD] what do you rate on the sad persons scale?", "[PAD] what is assessed on the scale of sads?", "[PAD] [PAD] what is assessed with the scale sad face?", "[PAD] [PAD] what is rated by the sad persons scale?", "[PAD] what is evaluated with the trist persons scale?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is sad persons rated?", "[PAD] [PAD] what is assessed by the sad persons scale?", "[PAD] [PAD] [PAD] what is rated by the sadness scale?", "[PAD] [PAD] what is evaluated with the sad people scale?", "[PAD] what is evaluated by the level of sad persons?", "[PAD] what is an assessment with the sad persons scale?", "[PAD] what is evaluated with the people of peace scale?", "what is assessed on the scale \"self person\"?", "[PAD] [PAD] [PAD] what is measured by sad persons scale?", "[PAD] what is being evaluated with the sad persons rating?", "[PAD] [PAD] what is evaluated with the sad persons scale?", "[PAD] what is being evaluated with the sad persons scale?", "[PAD] [PAD] [PAD] what is the scale of sad people?", "[PAD] what is evaluated on the scale of sad people?", "[PAD] [PAD] what is assessed on the sad persons scale?", "[PAD] [PAD] what is evaluated on the sad persons scale?", "[PAD] what is assessed on the scale of sad faces?", "[PAD] [PAD] what is rated with the sad face scale?", "[PAD] what is assessed with the grieving person scale?", "[PAD] [PAD] what is rated on the sads scale?", "[PAD] [PAD] what is evaluated using the sad persons scale?", "[PAD] [PAD] what is rated on the sad persons scale?", "[PAD] what is evaluated on the size of sad persons?", "[PAD] [PAD] what is assessed with the sad persons scale?", "[PAD] [PAD] [PAD] [PAD] what is the sad persons scale?", "[PAD] [PAD] [PAD] what does the sad persons scale assess?", "[PAD] [PAD] what is valued with the sad persons scale?", "[PAD] what do you rate on the scrapped persons scale?", "[PAD] [PAD] what is assessed on the sad people scale?", "[PAD] [PAD] what is considered with the sad persons scale?", "[PAD] what do you rate on the sad persons scale?", "[PAD] what is assessed on the scale of sads?", "[PAD] [PAD] what is assessed with the scale sad face?", "[PAD] [PAD] what is rated by the sad persons scale?", "[PAD] what is evaluated with the trist persons scale?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is sad persons rated?", "[PAD] [PAD] what is assessed by the sad persons scale?", "[PAD] [PAD] [PAD] what is rated by the sadness scale?", "[PAD] [PAD] what is evaluated with the sad people scale?", "[PAD] what is evaluated by the level of sad persons?", "[PAD] what is an assessment with the sad persons scale?", "[PAD] what is evaluated with the people of peace scale?", "what is assessed on the scale \"self person\"?", "[PAD] [PAD] [PAD] what is measured by sad persons scale?", "[PAD] what is being evaluated with the sad persons rating?", "[PAD] [PAD] what is evaluated with the sad persons scale?", "[PAD] what is being evaluated with the sad persons scale?", "[PAD] [PAD] [PAD] what is the scale of sad people?", "[PAD] what is evaluated on the scale of sad people?", "[PAD] [PAD] what is assessed on the sad persons scale?", "[PAD] [PAD] what is evaluated on the sad persons scale?", "[PAD] what is assessed on the scale of sad faces?", "[PAD] [PAD] what is rated with the sad face scale?", "[PAD] what is assessed with the grieving person scale?", "[PAD] [PAD] what is rated on the sads scale?", "[PAD] [PAD] what is evaluated using the sad persons scale?", "[PAD] [PAD] what is rated on the sad persons scale?", "[PAD] what is evaluated on the size of sad persons?", "[PAD] [PAD] what is assessed with the sad persons scale?", "[PAD] [PAD] [PAD] [PAD] what is the sad persons scale?", "[PAD] [PAD] [PAD] what does the sad persons scale assess?", "[PAD] [PAD] what is valued with the sad persons scale?", "[PAD] what do you rate on the scrapped persons scale?", "[PAD] [PAD] what is assessed on the sad people scale?", "[PAD] [PAD] what is considered with the sad persons scale?", "[PAD] what do you rate on the sad persons scale?", "[PAD] what is assessed on the scale of sads?", "[PAD] [PAD] what is assessed with the scale sad face?", "[PAD] [PAD] what is rated by the sad persons scale?", "[PAD] what is evaluated with the trist persons scale?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is sad persons rated?", "[PAD] [PAD] what is assessed by the sad persons scale?", "[PAD] [PAD] [PAD] what is rated by the sadness scale?", "[PAD] [PAD] what is evaluated with the sad people scale?", "[PAD] what is evaluated by the level of sad persons?", "[PAD] what is an assessment with the sad persons scale?", "[PAD] what is evaluated with the people of peace scale?", "what is assessed on the scale \"self person\"?", "[PAD] [PAD] [PAD] what is measured by sad persons scale?", "[PAD] what is being evaluated with the sad persons rating?", "[PAD] what is etarfolatide used for?", "[PAD] [PAD] what is etarfolate used for?", "what is etharpholatide used for?", "[PAD] [PAD] [PAD] what is etafolate used for?", "what is the use of etarfolatide?", "[PAD] what is the use of transferflatide?", "[PAD] [PAD] what is atrapolide used for?", "[PAD] [PAD] what is atorfoltide used for?", "[PAD] [PAD] [PAD] what is ether folate used for?", "[PAD] what is etalphortide used for?", "[PAD] what is ettarpolatide used for?", "what is etharfolatide used for?", "[PAD] [PAD] [PAD] is etarfolatide used?", "[PAD] [PAD] what is atarfolate used for?", "[PAD] [PAD] [PAD] what is etharfolate for?", "[PAD] [PAD] why is etarfolatide used?", "[PAD] what is ether folatide used for?", "[PAD] what is etarfolatide used for?", "[PAD] [PAD] what is etarfolate used for?", "what is etharpholatide used for?", "[PAD] [PAD] [PAD] what is etafolate used for?", "what is the use of etarfolatide?", "[PAD] what is the use of transferflatide?", "[PAD] [PAD] what is atrapolide used for?", "[PAD] [PAD] what is atorfoltide used for?", "[PAD] [PAD] [PAD] what is ether folate used for?", "[PAD] what is etalphortide used for?", "[PAD] what is ettarpolatide used for?", "what is etharfolatide used for?", "[PAD] [PAD] [PAD] is etarfolatide used?", "[PAD] [PAD] what is atarfolate used for?", "[PAD] [PAD] [PAD] what is etharfolate for?", "[PAD] [PAD] why is etarfolatide used?", "[PAD] what is ether folatide used for?", "[PAD] [PAD] [PAD] which disease can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awaji criteria?", "which disease can be classified within the criteria of al-awaji?", "[PAD] which disease can be classified according to avaji's criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified according to awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified according to awaji criteria?", "[PAD] what disease can be classified according to awaji's criteria?", "[PAD] [PAD] [PAD] which diseases can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to awaji criteria?", "[PAD] [PAD] what diseases can be classified according to the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified in the awaji criteria?", "[PAD] [PAD] what disease can be classified with awaji's criteria?", "[PAD] what disease can be classified according to awaji\u2019s criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to avaj criteria?", "[PAD] [PAD] [PAD] what disease can be classified using the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] which disease can be included in the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified by the awaji criteria?", "[PAD] [PAD] which diseases can be classified according to the awachi standard?", "[PAD] [PAD] [PAD] [PAD] what diseases can be classified by awaji criteria?", "[PAD] [PAD] which disease can be classified according to the avaji criteria?", "[PAD] [PAD] [PAD] [PAD] which diseases can be classified with awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by phonological criteria?", "[PAD] [PAD] [PAD] which disease can be classified using the awaji criteria?", "[PAD] [PAD] what disease can be classified according to the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awai criteria?", "[PAD] [PAD] [PAD] [PAD] what disease can be classified by a drop criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease can be classified with sound quality?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified with awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awaji criteria?", "which disease can be classified within the criteria of al-awaji?", "[PAD] which disease can be classified according to avaji's criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified according to awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified according to awaji criteria?", "[PAD] what disease can be classified according to awaji's criteria?", "[PAD] [PAD] [PAD] which diseases can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to awaji criteria?", "[PAD] [PAD] what diseases can be classified according to the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified in the awaji criteria?", "[PAD] [PAD] what disease can be classified with awaji's criteria?", "[PAD] what disease can be classified according to awaji\u2019s criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to avaj criteria?", "[PAD] [PAD] [PAD] what disease can be classified using the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] which disease can be included in the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified by the awaji criteria?", "[PAD] [PAD] which diseases can be classified according to the awachi standard?", "[PAD] [PAD] [PAD] [PAD] what diseases can be classified by awaji criteria?", "[PAD] [PAD] which disease can be classified according to the avaji criteria?", "[PAD] [PAD] [PAD] [PAD] which diseases can be classified with awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by phonological criteria?", "[PAD] [PAD] [PAD] which disease can be classified using the awaji criteria?", "[PAD] [PAD] what disease can be classified according to the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awai criteria?", "[PAD] [PAD] [PAD] [PAD] what disease can be classified by a drop criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease can be classified with sound quality?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified with awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awaji criteria?", "which disease can be classified within the criteria of al-awaji?", "[PAD] which disease can be classified according to avaji's criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified according to awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified according to awaji criteria?", "[PAD] what disease can be classified according to awaji's criteria?", "[PAD] [PAD] [PAD] which diseases can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to awaji criteria?", "[PAD] [PAD] what diseases can be classified according to the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified in the awaji criteria?", "[PAD] [PAD] what disease can be classified with awaji's criteria?", "[PAD] what disease can be classified according to awaji\u2019s criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to avaj criteria?", "[PAD] [PAD] [PAD] what disease can be classified using the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] which disease can be included in the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified by the awaji criteria?", "[PAD] [PAD] which diseases can be classified according to the awachi standard?", "[PAD] [PAD] [PAD] [PAD] what diseases can be classified by awaji criteria?", "[PAD] [PAD] which disease can be classified according to the avaji criteria?", "[PAD] [PAD] [PAD] [PAD] which diseases can be classified with awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by phonological criteria?", "[PAD] [PAD] [PAD] which disease can be classified using the awaji criteria?", "[PAD] [PAD] what disease can be classified according to the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awai criteria?", "[PAD] [PAD] [PAD] [PAD] what disease can be classified by a drop criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease can be classified with sound quality?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified with awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awaji criteria?", "which disease can be classified within the criteria of al-awaji?", "[PAD] which disease can be classified according to avaji's criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified according to awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified according to awaji criteria?", "[PAD] what disease can be classified according to awaji's criteria?", "[PAD] [PAD] [PAD] which diseases can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to awaji criteria?", "[PAD] [PAD] what diseases can be classified according to the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified in the awaji criteria?", "[PAD] [PAD] what disease can be classified with awaji's criteria?", "[PAD] what disease can be classified according to awaji\u2019s criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to avaj criteria?", "[PAD] [PAD] [PAD] what disease can be classified using the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] which disease can be included in the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified by the awaji criteria?", "[PAD] [PAD] which diseases can be classified according to the awachi standard?", "[PAD] [PAD] [PAD] [PAD] what diseases can be classified by awaji criteria?", "[PAD] [PAD] which disease can be classified according to the avaji criteria?", "[PAD] [PAD] [PAD] [PAD] which diseases can be classified with awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by phonological criteria?", "[PAD] [PAD] [PAD] which disease can be classified using the awaji criteria?", "[PAD] [PAD] what disease can be classified according to the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awai criteria?", "[PAD] [PAD] [PAD] [PAD] what disease can be classified by a drop criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease can be classified with sound quality?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified with awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awaji criteria?", "which disease can be classified within the criteria of al-awaji?", "[PAD] which disease can be classified according to avaji's criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified according to awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified according to awaji criteria?", "[PAD] what disease can be classified according to awaji's criteria?", "[PAD] [PAD] [PAD] which diseases can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to awaji criteria?", "[PAD] [PAD] what diseases can be classified according to the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified in the awaji criteria?", "[PAD] [PAD] what disease can be classified with awaji's criteria?", "[PAD] what disease can be classified according to awaji\u2019s criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to avaj criteria?", "[PAD] [PAD] [PAD] what disease can be classified using the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] which disease can be included in the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified by the awaji criteria?", "[PAD] [PAD] which diseases can be classified according to the awachi standard?", "[PAD] [PAD] [PAD] [PAD] what diseases can be classified by awaji criteria?", "[PAD] [PAD] which disease can be classified according to the avaji criteria?", "[PAD] [PAD] [PAD] [PAD] which diseases can be classified with awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by phonological criteria?", "[PAD] [PAD] [PAD] which disease can be classified using the awaji criteria?", "[PAD] [PAD] what disease can be classified according to the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awai criteria?", "[PAD] [PAD] [PAD] [PAD] what disease can be classified by a drop criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease can be classified with sound quality?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified with awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awaji criteria?", "which disease can be classified within the criteria of al-awaji?", "[PAD] which disease can be classified according to avaji's criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified according to awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified according to awaji criteria?", "[PAD] what disease can be classified according to awaji's criteria?", "[PAD] [PAD] [PAD] which diseases can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to awaji criteria?", "[PAD] [PAD] what diseases can be classified according to the awaji criteria?", "[PAD] [PAD] [PAD] which disease can be classified in the awaji criteria?", "[PAD] [PAD] what disease can be classified with awaji's criteria?", "[PAD] what disease can be classified according to awaji\u2019s criteria?", "[PAD] [PAD] [PAD] which disease can be classified according to avaj criteria?", "[PAD] [PAD] [PAD] what disease can be classified using the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criterion?", "[PAD] [PAD] [PAD] which disease can be included in the awaji criteria?", "[PAD] [PAD] [PAD] what disease can be classified by the awaji criteria?", "[PAD] [PAD] [PAD] what diseases can be classified by the awaji criteria?", "[PAD] [PAD] which diseases can be classified according to the awachi standard?", "[PAD] [PAD] [PAD] [PAD] what diseases can be classified by awaji criteria?", "[PAD] [PAD] which disease can be classified according to the avaji criteria?", "[PAD] [PAD] [PAD] [PAD] which diseases can be classified with awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified by phonological criteria?", "[PAD] [PAD] [PAD] which disease can be classified using the awaji criteria?", "[PAD] [PAD] what disease can be classified according to the awaji criteria?", "[PAD] [PAD] which disease can be classified according to the awai criteria?", "[PAD] [PAD] [PAD] [PAD] what disease can be classified by a drop criteria?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease can be classified with sound quality?", "[PAD] [PAD] [PAD] what diseases can be classified with the awaji criteria?", "[PAD] [PAD] [PAD] [PAD] which disease can be classified with awaji criteria?", "[PAD] [PAD] what is the normal function p53?", "[PAD] what is the normal function of p53?", "[PAD] [PAD] [PAD] what is normal p53 function?", "what is the normal function of the p53?", "[PAD] [PAD] what is the standard p53 function?", "[PAD] [PAD] what is a standard function p53?", "[PAD] [PAD] [PAD] what is normal function p53?", "[PAD] [PAD] what is the normal p53 function?", "[PAD] [PAD] [PAD] what is p53 normal function?", "[PAD] [PAD] what is the standard f53 function?", "[PAD] [PAD] what is the 3d tomography imaging technique for diagnosis of  eye disease?", "[PAD] what is the 3d tomography imaging technique for the diagnosis of eye disease?", "[PAD] what is the 3d tomography imaging technique for diagnosing eye diseases?", "[PAD] [PAD] what is the 3d tomography technique for diagnosing eye diseases?", "[PAD] [PAD] [PAD] what is the technique of 3d tomography diagnosis of eye diseases?", "what is the technique of 3d tomography imaging for the diagnosis of eye diseases?", "[PAD] what is the technique of 3d tomography imaging to diagnose eye disease?", "[PAD] what is the method of 3d tomography for the diagnosis of eye diseases?", "[PAD] what is the technique of 3d tomography for diagnosing eye diseases?", "[PAD] [PAD] what is 3d tomographic imaging technology used to diagnose eye diseases?", "what is the imaging technique of 3d tomography for the diagnosis of eye diseases?", "[PAD] what is the 3d tomography imaging technique for diagnosing eye disease?", "[PAD] [PAD] what is the technique of 3d tomography to diagnose eye diseases?", "[PAD] [PAD] what is 3d tomography imaging technology for diagnosing ocular diseases?", "[PAD] what is the technique of 3d tomography for the diagnosis of eye disease?", "[PAD] [PAD] what is 3d tomography imaging technique for diagnosing eye disease?", "[PAD] [PAD] [PAD] [PAD] what are 3d tomography techniques to diagnose eye disease?", "what is a three-dimensional tomography imaging technique for diagnosing eye diseases?", "[PAD] [PAD] [PAD] what is 3d tomography imaging technique for diagnosis of eye diseases?", "[PAD] [PAD] [PAD] what is 3d tomography imaging technique to diagnose eye diseases?", "[PAD] [PAD] [PAD] what is the 3d ct scan technique for diagnosing eye diseases?", "[PAD] what are the 3d tomographic imaging techniques for the diagnosis of eye diseases?", "[PAD] [PAD] [PAD] what is 3d tomography imaging techniques for diagnosis of eye diseases?", "[PAD] [PAD] [PAD] [PAD] what is 3d tomography for diagnosing eye diseases?", "[PAD] [PAD] what are 3d tomography imaging techniques for the diagnosis of eye diseases?", "what is the technique of three-dimensional tomography imaging to diagnose eye disease?", "[PAD] what is the 3d tomography imaging technique in the diagnosis of eye diseases?", "[PAD] [PAD] [PAD] [PAD] what is the 3d imaging technique for diagnosing eye disease?", "[PAD] [PAD] what is a 3d tomography method for diagnosing eye diseases?", "what is the technique of imaging 3d tomography for the diagnosis of eye diseases?", "[PAD] [PAD] what is the technique of 3d tomography to diagnose eye disease?", "[PAD] what is the 3d tomography imaging technique for the diagnosis of eye diseases?", "[PAD] [PAD] je! what is the 3d diagnostic technique for the diagnosis of eye disease?", "[PAD] [PAD] what is the 3d tomography technique for the diagnosis of eye disease?", "[PAD] [PAD] what is the technique of 3d x-ray imaging in ophthalmic diagnosis?", "[PAD] what is the technology of 3d tomography for the diagnosis of eye diseases?", "[PAD] [PAD] [PAD] [PAD] what is 3d tomography technology to diagnose eye diseases?", "[PAD] [PAD] what is the 3d tomography imaging technique for diagnosis of eye disease?", "what part of the body is affected by meniere's disease?", "which part of the body is affected by meniere's disease?", "what parts of the body are affected by meniere's disease?", "[PAD] which part of the body does meniere's disease affect?", "what part of the body is affected by meni\u00e8re's disease?", "what part of the body is affected by m\u00e9ni\u00e8re's disease?", "[PAD] [PAD] [PAD] [PAD] what part of the body is affected by paper disease?", "[PAD] [PAD] which body part is affected by meniere's disease?", "which parts of the body are affected by meniere's disease?", "what parts of the body are affected by meniere\u2019s disease?", "[PAD] [PAD] [PAD] which part of the body is affected by munir disease?", "what part of the body is affected in meniere's disease?", "what part of the body is affected by meniere's disease?", "which part of the body is affected by meniere's disease?", "what parts of the body are affected by meniere's disease?", "[PAD] which part of the body does meniere's disease affect?", "what part of the body is affected by meni\u00e8re's disease?", "what part of the body is affected by m\u00e9ni\u00e8re's disease?", "[PAD] [PAD] [PAD] [PAD] what part of the body is affected by paper disease?", "[PAD] [PAD] which body part is affected by meniere's disease?", "which parts of the body are affected by meniere's disease?", "what parts of the body are affected by meniere\u2019s disease?", "[PAD] [PAD] [PAD] which part of the body is affected by munir disease?", "what part of the body is affected in meniere's disease?", "what part of the body is affected by meniere's disease?", "which part of the body is affected by meniere's disease?", "what parts of the body are affected by meniere's disease?", "[PAD] which part of the body does meniere's disease affect?", "what part of the body is affected by meni\u00e8re's disease?", "what part of the body is affected by m\u00e9ni\u00e8re's disease?", "[PAD] [PAD] [PAD] [PAD] what part of the body is affected by paper disease?", "[PAD] [PAD] which body part is affected by meniere's disease?", "which parts of the body are affected by meniere's disease?", "what parts of the body are affected by meniere\u2019s disease?", "[PAD] [PAD] [PAD] which part of the body is affected by munir disease?", "what part of the body is affected in meniere's disease?", "[PAD] [PAD] [PAD] rv3-bb vaccine is used for prevention of which viral infection?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent which virus infection?", "[PAD] [PAD] [PAD] [PAD] for which viral infection is the rv3-bb vaccine used?", "[PAD] [PAD] [PAD] the rv3-bb vaccine is used to prevent any viral infection?", "[PAD] [PAD] [PAD] [PAD] which rv3-bb vaccine is used to prevent viral infection?", "[PAD] [PAD] [PAD] which viral infection is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] what rv3-bb vaccine is used to prevent viral infections?", "[PAD] [PAD] [PAD] [PAD] which viral infection is rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] is the rv3-bb vaccine used to prevent which viral infection?", "[PAD] [PAD] [PAD] is the rv3-bb vaccine used to prevent any viral infection?", "[PAD] [PAD] [PAD] [PAD] [PAD] which viral infections are rv3-bb used to prevent?", "[PAD] [PAD] [PAD] the rv3-bb vaccine is used to prevent which viral infection?", "[PAD] [PAD] [PAD] [PAD] what virus infection is rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] what viral infection is the rv3-bb vaccine used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] which viral infection is used to prevent rv3-bb?", "[PAD] the rv3-bb vaccine is used for the prevention of which viral infection?", "[PAD] [PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent viral infection?", "[PAD] [PAD] [PAD] which rv3-bb vaccine is used to prevent which viral infection?", "[PAD] [PAD] [PAD] [PAD] what viral infections are used to prevent rv3-bb vaccine?", "[PAD] [PAD] [PAD] [PAD] [PAD] rv3-bb vaccine used to prevent some viral infection?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent any viral infection?", "[PAD] [PAD] [PAD] [PAD] [PAD] is rv3-bb vaccine used to prevent viral infection?", "[PAD] [PAD] rv3-bb vaccine is used for the prevention of which viral infection?", "[PAD] [PAD] [PAD] what viral infections is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] which viral rv3-bb vaccine is used to prevent infection?", "[PAD] [PAD] [PAD] what is the rv3-bb vaccine used to prevent viral infections?", "[PAD] [PAD] [PAD] [PAD] which rv3-bb vaccine is used to prevent viral infections?", "[PAD] [PAD] [PAD] [PAD] to prevent what viral infection is used with rv3-bb?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent which viral infection?", "[PAD] [PAD] [PAD] what viral infection is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent which viral infections?", "[PAD] [PAD] [PAD] [PAD] [PAD] which viral infection is rv3-bb used to prevent?", "[PAD] [PAD] [PAD] [PAD] what virus is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] [PAD] rv3-bb vaccine used to prevent which virus infection?", "the rv3-bb vaccine is used to prevent infection with what type of virus?", "[PAD] [PAD] [PAD] [PAD] which viral infection is the rv3-bb vaccine used for?", "[PAD] [PAD] [PAD] which virus infection is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] rv3-bb vaccine is used for prevention of what viral infection?", "[PAD] [PAD] [PAD] rv3-bb vaccine is used for prevention of which viral infection?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent which virus infection?", "[PAD] [PAD] [PAD] [PAD] for which viral infection is the rv3-bb vaccine used?", "[PAD] [PAD] [PAD] the rv3-bb vaccine is used to prevent any viral infection?", "[PAD] [PAD] [PAD] [PAD] which rv3-bb vaccine is used to prevent viral infection?", "[PAD] [PAD] [PAD] which viral infection is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] what rv3-bb vaccine is used to prevent viral infections?", "[PAD] [PAD] [PAD] [PAD] which viral infection is rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] is the rv3-bb vaccine used to prevent which viral infection?", "[PAD] [PAD] [PAD] is the rv3-bb vaccine used to prevent any viral infection?", "[PAD] [PAD] [PAD] [PAD] [PAD] which viral infections are rv3-bb used to prevent?", "[PAD] [PAD] [PAD] the rv3-bb vaccine is used to prevent which viral infection?", "[PAD] [PAD] [PAD] [PAD] what virus infection is rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] what viral infection is the rv3-bb vaccine used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] which viral infection is used to prevent rv3-bb?", "[PAD] the rv3-bb vaccine is used for the prevention of which viral infection?", "[PAD] [PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent viral infection?", "[PAD] [PAD] [PAD] which rv3-bb vaccine is used to prevent which viral infection?", "[PAD] [PAD] [PAD] [PAD] what viral infections are used to prevent rv3-bb vaccine?", "[PAD] [PAD] [PAD] [PAD] [PAD] rv3-bb vaccine used to prevent some viral infection?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent any viral infection?", "[PAD] [PAD] [PAD] [PAD] [PAD] is rv3-bb vaccine used to prevent viral infection?", "[PAD] [PAD] rv3-bb vaccine is used for the prevention of which viral infection?", "[PAD] [PAD] [PAD] what viral infections is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] which viral rv3-bb vaccine is used to prevent infection?", "[PAD] [PAD] [PAD] what is the rv3-bb vaccine used to prevent viral infections?", "[PAD] [PAD] [PAD] [PAD] which rv3-bb vaccine is used to prevent viral infections?", "[PAD] [PAD] [PAD] [PAD] to prevent what viral infection is used with rv3-bb?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent which viral infection?", "[PAD] [PAD] [PAD] what viral infection is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent which viral infections?", "[PAD] [PAD] [PAD] [PAD] [PAD] which viral infection is rv3-bb used to prevent?", "[PAD] [PAD] [PAD] [PAD] what virus is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] [PAD] rv3-bb vaccine used to prevent which virus infection?", "the rv3-bb vaccine is used to prevent infection with what type of virus?", "[PAD] [PAD] [PAD] [PAD] which viral infection is the rv3-bb vaccine used for?", "[PAD] [PAD] [PAD] which virus infection is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] rv3-bb vaccine is used for prevention of what viral infection?", "[PAD] [PAD] [PAD] rv3-bb vaccine is used for prevention of which viral infection?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent which virus infection?", "[PAD] [PAD] [PAD] [PAD] for which viral infection is the rv3-bb vaccine used?", "[PAD] [PAD] [PAD] the rv3-bb vaccine is used to prevent any viral infection?", "[PAD] [PAD] [PAD] [PAD] which rv3-bb vaccine is used to prevent viral infection?", "[PAD] [PAD] [PAD] which viral infection is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] what rv3-bb vaccine is used to prevent viral infections?", "[PAD] [PAD] [PAD] [PAD] which viral infection is rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] is the rv3-bb vaccine used to prevent which viral infection?", "[PAD] [PAD] [PAD] is the rv3-bb vaccine used to prevent any viral infection?", "[PAD] [PAD] [PAD] [PAD] [PAD] which viral infections are rv3-bb used to prevent?", "[PAD] [PAD] [PAD] the rv3-bb vaccine is used to prevent which viral infection?", "[PAD] [PAD] [PAD] [PAD] what virus infection is rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] what viral infection is the rv3-bb vaccine used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] which viral infection is used to prevent rv3-bb?", "[PAD] the rv3-bb vaccine is used for the prevention of which viral infection?", "[PAD] [PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent viral infection?", "[PAD] [PAD] [PAD] which rv3-bb vaccine is used to prevent which viral infection?", "[PAD] [PAD] [PAD] [PAD] what viral infections are used to prevent rv3-bb vaccine?", "[PAD] [PAD] [PAD] [PAD] [PAD] rv3-bb vaccine used to prevent some viral infection?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent any viral infection?", "[PAD] [PAD] [PAD] [PAD] [PAD] is rv3-bb vaccine used to prevent viral infection?", "[PAD] [PAD] rv3-bb vaccine is used for the prevention of which viral infection?", "[PAD] [PAD] [PAD] what viral infections is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] which viral rv3-bb vaccine is used to prevent infection?", "[PAD] [PAD] [PAD] what is the rv3-bb vaccine used to prevent viral infections?", "[PAD] [PAD] [PAD] [PAD] which rv3-bb vaccine is used to prevent viral infections?", "[PAD] [PAD] [PAD] [PAD] to prevent what viral infection is used with rv3-bb?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent which viral infection?", "[PAD] [PAD] [PAD] what viral infection is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] rv3-bb vaccine is used to prevent which viral infections?", "[PAD] [PAD] [PAD] [PAD] [PAD] which viral infection is rv3-bb used to prevent?", "[PAD] [PAD] [PAD] [PAD] what virus is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] [PAD] [PAD] rv3-bb vaccine used to prevent which virus infection?", "the rv3-bb vaccine is used to prevent infection with what type of virus?", "[PAD] [PAD] [PAD] [PAD] which viral infection is the rv3-bb vaccine used for?", "[PAD] [PAD] [PAD] which virus infection is the rv3-bb vaccine used to prevent?", "[PAD] [PAD] [PAD] rv3-bb vaccine is used for prevention of what viral infection?", "[PAD] which molecule is inhibited by larotrectinib?", "[PAD] [PAD] [PAD] which molecule does larotrectinib inhibit?", "[PAD] [PAD] [PAD] which molecule inhibits larotectinib?", "[PAD] [PAD] [PAD] which molecule larotrectinib inhibits?", "[PAD] [PAD] [PAD] what molecule does larotrectinib block?", "which molecule is inhibited by larotrecretinib?", "[PAD] which molecule is inhibited by lorotrectinib?", "[PAD] [PAD] which molecule is blocked by larotrectinib?", "[PAD] which molecules are inhibited by larotrectinib?", "[PAD] which molecule is inhibited by lalotrectinib?", "[PAD] [PAD] [PAD] what molecules does larotrectinib inhibit?", "[PAD] [PAD] which molecule is inhibited by larotretinib?", "[PAD] [PAD] [PAD] [PAD] which molecule does larotretinib inhibit?", "[PAD] what molecule is inhibited by larotrectinib?", "[PAD] [PAD] [PAD] which molecule inhibits larotrectinib?", "[PAD] what molecules are inhibited by larotrectinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] larotrectinib inhibit which molecule", "[PAD] [PAD] [PAD] which molecule inhibits luterotactinib?", "[PAD] which molecule is inhibited by larotractinib?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] sweat chloride testing is used  for which disease?", "[PAD] [PAD] for what disease is sweat chloride testing used?", "[PAD] sweat chloride test for which disease is it used?", "[PAD] for what disease is the sweat chloride test used?", "[PAD] for which disease is the chloride sweat test used?", "[PAD] [PAD] sweat chloride test is used for what disease?", "for what diseases is the study of sweat chloride used?", "[PAD] for which disease is the sweat chloride test used?", "[PAD] for which disease is a sweat chloride test used?", "[PAD] what disease is the sweat chloride test used for?", "[PAD] [PAD] what disease is sweat chloride testing used for?", "[PAD] [PAD] what disease is sweat chloride test used for?", "[PAD] [PAD] for what disease is sweat chloride test used?", "[PAD] [PAD] sweat chloride testing is used for what disease?", "[PAD] the sweat chloride test is used for what disease?", "[PAD] [PAD] in which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride test is used for which disease?", "[PAD] [PAD] for which diseases are sweat chloride tests used?", "[PAD] for what disease is a sweat chloride test used?", "[PAD] [PAD] what disease is used in sweating chloride test?", "[PAD] [PAD] which illness is the sweat test used for?", "[PAD] what diseases is the sweat chloride test used for?", "what disease is the sweat chloride test used to treat?", "[PAD] [PAD] sweat chloride test is used for which diseases?", "[PAD] [PAD] for which disease is sweat chloride testing used?", "[PAD] [PAD] sweat chloride testing is used for which disease?", "[PAD] the sweat chloride test is used for which disease?", "in what diseases is the definition of sweat chloride used?", "[PAD] [PAD] what is the dosage of sweat chloride?", "[PAD] [PAD] [PAD] [PAD] sweat chloride testing for what disease?", "[PAD] [PAD] sweet chloride testing is used for which disease?", "[PAD] [PAD] which disease is used for sweat chloride test?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk of dominant medically actionable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk of developing a dominant medical condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk of the dominant disease of medical action?", "[PAD] [PAD] [PAD] [PAD] what percentage of individuals are at risk of developing a medically treatable dominant disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals who are at risk for predominant medical conditions?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk for a dominant medical condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk of major medical illness?", "[PAD] [PAD] [PAD] what percentage of individuals are at risk for a dominant disease that is subject to medical treatment?", "[PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk of the dominant medical action of the disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk for a dominant medical condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what percentage of individuals are at risk for a major medically actionable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what percentage of people are at risk for a dominant medically effective disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk for a dominant medically susceptible disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk for predominant medical actionable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk for a dominant medically useful disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk of a dominant medical condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what percentage of individuals are at risk of predominantly medically actionable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk for a dominant medical function?", "[PAD] [PAD] [PAD] what is the percentage of individuals at risk of a dominant disease giving rise to medical action?", "[PAD] [PAD] [PAD] what is the percentage of people at risk of developing a dominant disease susceptible to medical action?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what percentage of individuals are at risk for a dominant medically effective disease?", "[PAD] [PAD] [PAD] what is the percentage of people at risk of having a dominant medically treatable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk of a predominantly medically active disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what percentage of people are at risk for dominant diseases who can take medical action?", "[PAD] [PAD] [PAD] [PAD] [PAD] what percentage of people are at risk for a dominant disease with a medical claim?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk for effective medically actionable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what percentage of individuals are at risk for a dominant, medically applicable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk for a predominant medical condition?", "[PAD] [PAD] what percentage of individuals are at risk for the dominant disease that can be followed up medically?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk of medically operable dominant disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what percentage of individuals at risk of dominant disease is medically pursued?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk of predominant medically viable illness?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the proportion of individuals at risk for the dominant medically viable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk of a predominantly medically affected disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk of a dominant medically illness?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what percentage of individuals are at risk of a predominantly medically active disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what percentage of individuals are at risk of getting a medically treatable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk of medically operable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk for predominantly medically treatable disease?", "[PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk for a major medically treatable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk of the dominant medically performed disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk for dominant medically actionable disease?", "what is the percentage of individuals who are at risk for a dominant disease that can be treated medically?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk for a dominant disease requiring medical intervention?", "[PAD] [PAD] [PAD] what percentage of individuals are at risk of a dominant disease that is susceptible to medical activities?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk for a dominant medically viable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk of predominant health disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what percentage of people are at risk of developing a medical condition?", "[PAD] [PAD] [PAD] [PAD] what is the proportion of individuals at risk of developing a predominantly medically active disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk of disease with outstanding medical outcomes?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk of medically treatable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what percentage of people are at risk for a dominant medical disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk of predominantly medically viable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what percentage of individuals are at risk for a medically treatable dominant disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of individuals at risk of medically actionable disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the percentage of people at risk of dominant medical actionable disease?", "[PAD] [PAD] [PAD] when did delafloxacin receive its first approval in the usa for acute bacterial skin and skin structure infections?", "[PAD] [PAD] [PAD] [PAD] when did delafloxacin receive its first approval in the us for acute bacterial skin and skin structure infections?", "[PAD] [PAD] [PAD] [PAD] when did delafloxacin get its first us approval for acute bacterial infections of the skin and skin structure?", "[PAD] when was delafloxacin first approved in the usa for the treatment of acute bacterial skin infections and skin structure infections?", "[PAD] [PAD] when was delafloxacin first approved in the united states for acute bacterial infections of the skin's skin structure?", "[PAD] [PAD] [PAD] [PAD] [PAD] when was delafloxacin first approved in the united states for acute bacterial skin and skin structure infections?", "[PAD] [PAD] when was delafloxacin first approved in the united states for the treatment of acute bacterial skin infections and skin structures?", "[PAD] when did delafloxacin receive its first approval in the united states for acute bacterial infections of the skin and skin structure?", "[PAD] [PAD] when did delafloxacin receive its first approval in the us for acute bacterial infections of the skin and skin structure?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] when was delafloxacin first approved in the us for acute bacterial skin and skin structure infections?", "[PAD] [PAD] [PAD] [PAD] [PAD] when was delafloxacin first approved in the united states for acute bacterial skin infections and skin structures?", "[PAD] [PAD] when did delafloxacin get its first approval in the us for acute bacterial infections of the skin and skin structures?", "[PAD] [PAD] [PAD] when did delafloxacin receive its first approval in the united states for acute bacterial skin and skin structure infections?", "[PAD] [PAD] [PAD] when did delafloxacin receive its first approval in the usa for chronic bacterial skin and skin structure infections?", "[PAD] [PAD] [PAD] when was delafloxacin first approved in the united states for the treatment of acute bacterial skin and skin infections?", "[PAD] [PAD] when did delafloxacin first receive approval in the united states for acute bacterial infections of the skin and skin structures?", "[PAD] when did delafloxacin receive its first u.s. approval for acute bacterial infections of the skin and skin structure?", "[PAD] when was delafloxacin first approved in the u.s. for acute bacterial infections of the skin and skin structure?", "[PAD] [PAD] [PAD] [PAD] [PAD] when did delafloxacin first receive approval in the us for acute bacterial skin and skin structure infections?", "[PAD] [PAD] [PAD] [PAD] [PAD] when did delafloxacin first receive us approval for acute bacterial infections of the skin and skin structure?", "[PAD] [PAD] [PAD] [PAD] [PAD] when was delafloxacin first approved in the united states for acute bacterial skin infections and skin structure?", "[PAD] [PAD] [PAD] when did delafloxacin receive its first approval in the united states for acute skin and bacterial skin skin infections?", "[PAD] [PAD] [PAD] when did delafloxacin get its first approval in the united states for acute bacterial skin and skin structure infections?", "[PAD] [PAD] [PAD] when was delafloxacin first approved in the u.s. for acute bacterial skin and skin structure infections?", "[PAD] [PAD] [PAD] [PAD] when was delafloxacin first approved in the united states for acute bacterial skin infections and dermatitis?", "[PAD] [PAD] when did delafloxacin receive its first approval in the us for acute bacterial infections of the skin and skin structures?", "[PAD] [PAD] [PAD] when did delafloxacin first get its approval in the us for acute bacterial infections of skin and skin structures?", "[PAD] [PAD] [PAD] when did delafloxacin receive its first approval in the united states for acute bacterial skin and skin texture infections?", "[PAD] [PAD] [PAD] [PAD] [PAD] when was delafloxacin first approved in the united states for acute bacterial skin and cutaneous structural infections?", "[PAD] [PAD] [PAD] when was delafloxacin first approved for acute bacterial infections of the skin and skin structure in the united states?", "[PAD] [PAD] [PAD] when was delafloxacin first approved in the united states for acute bacterial infections of the skin and skin structure?", "[PAD] [PAD] [PAD] when did delafloxacin receive its first approval in the united states for acute bacterial skin infections and skin structures?", "[PAD] when did delafloxacin first receive its approval in the united states for acute bacterial infections of the skin and skin structure?", "[PAD] when was the first confirmation of dalafloxacin in the united states for acute bacterial infections of the skin and skin structure?", "[PAD] [PAD] [PAD] [PAD] when was delafloxacin first approved in the us for acute bacterial infections of the skin and skin structures?", "[PAD] [PAD] [PAD] [PAD] when was delafloxacin first approved in the us for acute bacterial infections of the skin and skin structure?", "[PAD] [PAD] when was delafloxacin first approved in the us for the treatment of acute bacterial skin and subcutaneous tissue infections?", "[PAD] when did delafloxacin get its first approval in the united states for acute bacterial infections of the skin and skin structures?", "[PAD] when did delafloxacin receive its first approval in the united states for acute bacterial infections of the skin and skin structures?", "[PAD] [PAD] when did delafloxacin first receive its approval in the us for acute bacterial infections of the skin and skin structure?", "[PAD] [PAD] [PAD] [PAD] when did delafloxacin receive its first approval in the united states for bacterial skin infections and skin structure?", "[PAD] [PAD] [PAD] [PAD] when did delafloxacin get its first approval in the us for acute bacterial skin and skin structure infections?", "when did delafloxacin receive its first approval in the united states for the treatment of acute bacterial skin infections and skin structures?", "[PAD] [PAD] [PAD] [PAD] [PAD] when did delfloxacin first get approved in the united states for acute bacterial skin and skin structure infections?", "[PAD] [PAD] [PAD] when was delafloxacin first approved in the usa for acute bacterial infections on the skin and skin structure?", "[PAD] [PAD] [PAD] [PAD] when did delfloxacin receive its first approval in the usa for acute bacterial skin and skin structure infections?", "[PAD] which enzyme is inhibited by a drug lorlatinib?", "[PAD] [PAD] what is the enzyme that loratinib inhibits?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme inhibits lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme does lorlatinib inhibit?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme is lorlatinib inhibiting?", "[PAD] [PAD] [PAD] which enzyme inhibits the drug lorlatinib?", "[PAD] [PAD] [PAD] which enzyme is inhibited by lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzymes does lorlatinib inhibit?", "[PAD] [PAD] [PAD] [PAD] which enzyme is lorlatinib inhibited?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme is lorlatinib blocking?", "[PAD] which enzyme is inhibited by the drug lorlatinib?", "which enzyme is inhibited by a medicine called lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme inhibits lorlatinib?", "[PAD] what enzymes are inhibited by the drug lorlatinib?", "[PAD] which enzyme is inhibited by the drug lorratinib?", "[PAD] which enzyme is inhibited by a lorlatinib drug?", "[PAD] [PAD] which enzyme is blocked by the drug lorlatinib?", "[PAD] what enzymes are inhibited by the drug loratinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme does lorlatinib inhibit?", "[PAD] what enzyme is inhibited by a lorlatinib drug?", "[PAD] which enzyme has been blocked by the drug lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] lorlatinib inhibits which enzyme?", "[PAD] which enzyme is inhibited by a drug lorlatinib?", "[PAD] [PAD] what is the enzyme that loratinib inhibits?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme inhibits lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme does lorlatinib inhibit?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme is lorlatinib inhibiting?", "[PAD] [PAD] [PAD] which enzyme inhibits the drug lorlatinib?", "[PAD] [PAD] [PAD] which enzyme is inhibited by lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzymes does lorlatinib inhibit?", "[PAD] [PAD] [PAD] [PAD] which enzyme is lorlatinib inhibited?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme is lorlatinib blocking?", "[PAD] which enzyme is inhibited by the drug lorlatinib?", "which enzyme is inhibited by a medicine called lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme inhibits lorlatinib?", "[PAD] what enzymes are inhibited by the drug lorlatinib?", "[PAD] which enzyme is inhibited by the drug lorratinib?", "[PAD] which enzyme is inhibited by a lorlatinib drug?", "[PAD] [PAD] which enzyme is blocked by the drug lorlatinib?", "[PAD] what enzymes are inhibited by the drug loratinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme does lorlatinib inhibit?", "[PAD] what enzyme is inhibited by a lorlatinib drug?", "[PAD] which enzyme has been blocked by the drug lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] lorlatinib inhibits which enzyme?", "[PAD] which enzyme is inhibited by a drug lorlatinib?", "[PAD] [PAD] what is the enzyme that loratinib inhibits?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme inhibits lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme does lorlatinib inhibit?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme is lorlatinib inhibiting?", "[PAD] [PAD] [PAD] which enzyme inhibits the drug lorlatinib?", "[PAD] [PAD] [PAD] which enzyme is inhibited by lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzymes does lorlatinib inhibit?", "[PAD] [PAD] [PAD] [PAD] which enzyme is lorlatinib inhibited?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme is lorlatinib blocking?", "[PAD] which enzyme is inhibited by the drug lorlatinib?", "which enzyme is inhibited by a medicine called lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme inhibits lorlatinib?", "[PAD] what enzymes are inhibited by the drug lorlatinib?", "[PAD] which enzyme is inhibited by the drug lorratinib?", "[PAD] which enzyme is inhibited by a lorlatinib drug?", "[PAD] [PAD] which enzyme is blocked by the drug lorlatinib?", "[PAD] what enzymes are inhibited by the drug loratinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme does lorlatinib inhibit?", "[PAD] what enzyme is inhibited by a lorlatinib drug?", "[PAD] which enzyme has been blocked by the drug lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] lorlatinib inhibits which enzyme?", "[PAD] which enzyme is inhibited by a drug lorlatinib?", "[PAD] [PAD] what is the enzyme that loratinib inhibits?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme inhibits lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme does lorlatinib inhibit?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzyme is lorlatinib inhibiting?", "[PAD] [PAD] [PAD] which enzyme inhibits the drug lorlatinib?", "[PAD] [PAD] [PAD] which enzyme is inhibited by lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] which enzymes does lorlatinib inhibit?", "[PAD] [PAD] [PAD] [PAD] which enzyme is lorlatinib inhibited?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme is lorlatinib blocking?", "[PAD] which enzyme is inhibited by the drug lorlatinib?", "which enzyme is inhibited by a medicine called lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme inhibits lorlatinib?", "[PAD] what enzymes are inhibited by the drug lorlatinib?", "[PAD] which enzyme is inhibited by the drug lorratinib?", "[PAD] which enzyme is inhibited by a lorlatinib drug?", "[PAD] [PAD] which enzyme is blocked by the drug lorlatinib?", "[PAD] what enzymes are inhibited by the drug loratinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] what enzyme does lorlatinib inhibit?", "[PAD] what enzyme is inhibited by a lorlatinib drug?", "[PAD] which enzyme has been blocked by the drug lorlatinib?", "[PAD] [PAD] [PAD] [PAD] [PAD] lorlatinib inhibits which enzyme?", "cerliponase alfa is apprived for treatment of which disease?", "[PAD] cerliponase alfa is approved for the treatment of which disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] [PAD] for what disease is cerliponase alpha accepted?", "[PAD] [PAD] [PAD] [PAD] cerliponase alpha is used to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the treatment for zerliponase alpha?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha permitted?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which disease is cerliponase alfa approved?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha allowed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha approved?", "[PAD] [PAD] [PAD] cerliponase alfa is approved to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alpacerliponase used for?", "[PAD] cerliponase alfa is approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which diseases is serliponase alfa approved?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of this disease?", "[PAD] [PAD] [PAD] for which disease is ceriponase alpha approved for treatment?", "[PAD] [PAD] cerliponaz alpha is approved for the treatment of the disease?", "[PAD] [PAD] [PAD] seraliponase alpha approved for the treatment of any disease?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa suitable for?", "[PAD] cerliponase alfa is approved for the treatment of any disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of what disease?", "[PAD] [PAD] which diseases are approved for the treatment of seriponase alpha?", "[PAD] [PAD] [PAD] [PAD] what diseases is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] which disease is cerliponase alfa used to treat?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is cerliponase alfa used for?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which diseases?", "[PAD] [PAD] [PAD] which disease is allowed to treat alpha serliponase alpha?", "[PAD] cerliponase alfa is authorized for the treatment of which diseases?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is cerliponase alpha permitted for?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what treatment?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa prescribed for?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha intended for?", "[PAD] [PAD] [PAD] [PAD] cerliponese alfa is used to treat which disease?", "[PAD] [PAD] [PAD] cerliponase alfa is used to treat what disease?", "[PAD] [PAD] [PAD] cerliponase alfa is approved for treating which disease?", "[PAD] [PAD] [PAD] serliponase alpha is approved for treatment of which disease?", "cerliponase alfa is apprived for treatment of which disease?", "[PAD] cerliponase alfa is approved for the treatment of which disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] [PAD] for what disease is cerliponase alpha accepted?", "[PAD] [PAD] [PAD] [PAD] cerliponase alpha is used to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the treatment for zerliponase alpha?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha permitted?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which disease is cerliponase alfa approved?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha allowed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha approved?", "[PAD] [PAD] [PAD] cerliponase alfa is approved to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alpacerliponase used for?", "[PAD] cerliponase alfa is approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which diseases is serliponase alfa approved?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of this disease?", "[PAD] [PAD] [PAD] for which disease is ceriponase alpha approved for treatment?", "[PAD] [PAD] cerliponaz alpha is approved for the treatment of the disease?", "[PAD] [PAD] [PAD] seraliponase alpha approved for the treatment of any disease?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa suitable for?", "[PAD] cerliponase alfa is approved for the treatment of any disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of what disease?", "[PAD] [PAD] which diseases are approved for the treatment of seriponase alpha?", "[PAD] [PAD] [PAD] [PAD] what diseases is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] which disease is cerliponase alfa used to treat?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is cerliponase alfa used for?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which diseases?", "[PAD] [PAD] [PAD] which disease is allowed to treat alpha serliponase alpha?", "[PAD] cerliponase alfa is authorized for the treatment of which diseases?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is cerliponase alpha permitted for?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what treatment?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa prescribed for?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha intended for?", "[PAD] [PAD] [PAD] [PAD] cerliponese alfa is used to treat which disease?", "[PAD] [PAD] [PAD] cerliponase alfa is used to treat what disease?", "[PAD] [PAD] [PAD] cerliponase alfa is approved for treating which disease?", "[PAD] [PAD] [PAD] serliponase alpha is approved for treatment of which disease?", "cerliponase alfa is apprived for treatment of which disease?", "[PAD] cerliponase alfa is approved for the treatment of which disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] [PAD] for what disease is cerliponase alpha accepted?", "[PAD] [PAD] [PAD] [PAD] cerliponase alpha is used to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the treatment for zerliponase alpha?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha permitted?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which disease is cerliponase alfa approved?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha allowed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha approved?", "[PAD] [PAD] [PAD] cerliponase alfa is approved to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alpacerliponase used for?", "[PAD] cerliponase alfa is approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which diseases is serliponase alfa approved?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of this disease?", "[PAD] [PAD] [PAD] for which disease is ceriponase alpha approved for treatment?", "[PAD] [PAD] cerliponaz alpha is approved for the treatment of the disease?", "[PAD] [PAD] [PAD] seraliponase alpha approved for the treatment of any disease?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa suitable for?", "[PAD] cerliponase alfa is approved for the treatment of any disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of what disease?", "[PAD] [PAD] which diseases are approved for the treatment of seriponase alpha?", "[PAD] [PAD] [PAD] [PAD] what diseases is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] which disease is cerliponase alfa used to treat?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is cerliponase alfa used for?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which diseases?", "[PAD] [PAD] [PAD] which disease is allowed to treat alpha serliponase alpha?", "[PAD] cerliponase alfa is authorized for the treatment of which diseases?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is cerliponase alpha permitted for?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what treatment?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa prescribed for?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha intended for?", "[PAD] [PAD] [PAD] [PAD] cerliponese alfa is used to treat which disease?", "[PAD] [PAD] [PAD] cerliponase alfa is used to treat what disease?", "[PAD] [PAD] [PAD] cerliponase alfa is approved for treating which disease?", "[PAD] [PAD] [PAD] serliponase alpha is approved for treatment of which disease?", "cerliponase alfa is apprived for treatment of which disease?", "[PAD] cerliponase alfa is approved for the treatment of which disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] [PAD] for what disease is cerliponase alpha accepted?", "[PAD] [PAD] [PAD] [PAD] cerliponase alpha is used to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the treatment for zerliponase alpha?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha permitted?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which disease is cerliponase alfa approved?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha allowed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha approved?", "[PAD] [PAD] [PAD] cerliponase alfa is approved to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alpacerliponase used for?", "[PAD] cerliponase alfa is approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which diseases is serliponase alfa approved?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of this disease?", "[PAD] [PAD] [PAD] for which disease is ceriponase alpha approved for treatment?", "[PAD] [PAD] cerliponaz alpha is approved for the treatment of the disease?", "[PAD] [PAD] [PAD] seraliponase alpha approved for the treatment of any disease?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa suitable for?", "[PAD] cerliponase alfa is approved for the treatment of any disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of what disease?", "[PAD] [PAD] which diseases are approved for the treatment of seriponase alpha?", "[PAD] [PAD] [PAD] [PAD] what diseases is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] which disease is cerliponase alfa used to treat?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is cerliponase alfa used for?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which diseases?", "[PAD] [PAD] [PAD] which disease is allowed to treat alpha serliponase alpha?", "[PAD] cerliponase alfa is authorized for the treatment of which diseases?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is cerliponase alpha permitted for?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what treatment?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa prescribed for?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha intended for?", "[PAD] [PAD] [PAD] [PAD] cerliponese alfa is used to treat which disease?", "[PAD] [PAD] [PAD] cerliponase alfa is used to treat what disease?", "[PAD] [PAD] [PAD] cerliponase alfa is approved for treating which disease?", "[PAD] [PAD] [PAD] serliponase alpha is approved for treatment of which disease?", "cerliponase alfa is apprived for treatment of which disease?", "[PAD] cerliponase alfa is approved for the treatment of which disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] [PAD] for what disease is cerliponase alpha accepted?", "[PAD] [PAD] [PAD] [PAD] cerliponase alpha is used to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the treatment for zerliponase alpha?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha permitted?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which disease is cerliponase alfa approved?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha allowed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha approved?", "[PAD] [PAD] [PAD] cerliponase alfa is approved to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alpacerliponase used for?", "[PAD] cerliponase alfa is approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which diseases is serliponase alfa approved?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of this disease?", "[PAD] [PAD] [PAD] for which disease is ceriponase alpha approved for treatment?", "[PAD] [PAD] cerliponaz alpha is approved for the treatment of the disease?", "[PAD] [PAD] [PAD] seraliponase alpha approved for the treatment of any disease?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa suitable for?", "[PAD] cerliponase alfa is approved for the treatment of any disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of what disease?", "[PAD] [PAD] which diseases are approved for the treatment of seriponase alpha?", "[PAD] [PAD] [PAD] [PAD] what diseases is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] which disease is cerliponase alfa used to treat?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is cerliponase alfa used for?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which diseases?", "[PAD] [PAD] [PAD] which disease is allowed to treat alpha serliponase alpha?", "[PAD] cerliponase alfa is authorized for the treatment of which diseases?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is cerliponase alpha permitted for?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what treatment?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa prescribed for?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha intended for?", "[PAD] [PAD] [PAD] [PAD] cerliponese alfa is used to treat which disease?", "[PAD] [PAD] [PAD] cerliponase alfa is used to treat what disease?", "[PAD] [PAD] [PAD] cerliponase alfa is approved for treating which disease?", "[PAD] [PAD] [PAD] serliponase alpha is approved for treatment of which disease?", "cerliponase alfa is apprived for treatment of which disease?", "[PAD] cerliponase alfa is approved for the treatment of which disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] [PAD] for what disease is cerliponase alpha accepted?", "[PAD] [PAD] [PAD] [PAD] cerliponase alpha is used to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the treatment for zerliponase alpha?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha permitted?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which disease is cerliponase alfa approved?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha allowed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha approved?", "[PAD] [PAD] [PAD] cerliponase alfa is approved to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alpacerliponase used for?", "[PAD] cerliponase alfa is approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which diseases is serliponase alfa approved?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of this disease?", "[PAD] [PAD] [PAD] for which disease is ceriponase alpha approved for treatment?", "[PAD] [PAD] cerliponaz alpha is approved for the treatment of the disease?", "[PAD] [PAD] [PAD] seraliponase alpha approved for the treatment of any disease?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa suitable for?", "[PAD] cerliponase alfa is approved for the treatment of any disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of what disease?", "[PAD] [PAD] which diseases are approved for the treatment of seriponase alpha?", "[PAD] [PAD] [PAD] [PAD] what diseases is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] which disease is cerliponase alfa used to treat?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is cerliponase alfa used for?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which diseases?", "[PAD] [PAD] [PAD] which disease is allowed to treat alpha serliponase alpha?", "[PAD] cerliponase alfa is authorized for the treatment of which diseases?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is cerliponase alpha permitted for?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what treatment?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa prescribed for?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha intended for?", "[PAD] [PAD] [PAD] [PAD] cerliponese alfa is used to treat which disease?", "[PAD] [PAD] [PAD] cerliponase alfa is used to treat what disease?", "[PAD] [PAD] [PAD] cerliponase alfa is approved for treating which disease?", "[PAD] [PAD] [PAD] serliponase alpha is approved for treatment of which disease?", "cerliponase alfa is apprived for treatment of which disease?", "[PAD] cerliponase alfa is approved for the treatment of which disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] [PAD] for what disease is cerliponase alpha accepted?", "[PAD] [PAD] [PAD] [PAD] cerliponase alpha is used to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the treatment for zerliponase alpha?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha permitted?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which disease is cerliponase alfa approved?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha allowed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha approved?", "[PAD] [PAD] [PAD] cerliponase alfa is approved to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alpacerliponase used for?", "[PAD] cerliponase alfa is approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which diseases is serliponase alfa approved?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of this disease?", "[PAD] [PAD] [PAD] for which disease is ceriponase alpha approved for treatment?", "[PAD] [PAD] cerliponaz alpha is approved for the treatment of the disease?", "[PAD] [PAD] [PAD] seraliponase alpha approved for the treatment of any disease?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa suitable for?", "[PAD] cerliponase alfa is approved for the treatment of any disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of what disease?", "[PAD] [PAD] which diseases are approved for the treatment of seriponase alpha?", "[PAD] [PAD] [PAD] [PAD] what diseases is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] which disease is cerliponase alfa used to treat?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is cerliponase alfa used for?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which diseases?", "[PAD] [PAD] [PAD] which disease is allowed to treat alpha serliponase alpha?", "[PAD] cerliponase alfa is authorized for the treatment of which diseases?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is cerliponase alpha permitted for?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what treatment?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa prescribed for?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha intended for?", "[PAD] [PAD] [PAD] [PAD] cerliponese alfa is used to treat which disease?", "[PAD] [PAD] [PAD] cerliponase alfa is used to treat what disease?", "[PAD] [PAD] [PAD] cerliponase alfa is approved for treating which disease?", "[PAD] [PAD] [PAD] serliponase alpha is approved for treatment of which disease?", "cerliponase alfa is apprived for treatment of which disease?", "[PAD] cerliponase alfa is approved for the treatment of which disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which disease?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] [PAD] for what disease is cerliponase alpha accepted?", "[PAD] [PAD] [PAD] [PAD] cerliponase alpha is used to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the treatment for zerliponase alpha?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha permitted?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which disease is cerliponase alfa approved?", "[PAD] [PAD] for the treatment of which disease is cerliponase alpha allowed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha approved?", "[PAD] [PAD] [PAD] cerliponase alfa is approved to treat what disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is alpacerliponase used for?", "[PAD] cerliponase alfa is approved for the treatment of what disease?", "[PAD] [PAD] [PAD] [PAD] for which diseases is serliponase alfa approved?", "[PAD] [PAD] is cerliponase alpha approved for the treatment of this disease?", "[PAD] [PAD] [PAD] for which disease is ceriponase alpha approved for treatment?", "[PAD] [PAD] cerliponaz alpha is approved for the treatment of the disease?", "[PAD] [PAD] [PAD] seraliponase alpha approved for the treatment of any disease?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] [PAD] which disease is cerliponase alfa suitable for?", "[PAD] cerliponase alfa is approved for the treatment of any disease?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of what disease?", "[PAD] [PAD] which diseases are approved for the treatment of seriponase alpha?", "[PAD] [PAD] [PAD] [PAD] what diseases is cerliponase alfa approved for?", "[PAD] [PAD] [PAD] which disease is cerliponase alfa used to treat?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is cerliponase alfa used for?", "[PAD] [PAD] cerliponase alpha is approved for the treatment of which diseases?", "[PAD] [PAD] [PAD] which disease is allowed to treat alpha serliponase alpha?", "[PAD] cerliponase alfa is authorized for the treatment of which diseases?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what condition?", "[PAD] [PAD] [PAD] [PAD] [PAD] what disease is cerliponase alpha permitted for?", "[PAD] [PAD] [PAD] [PAD] cerliponase alfa is approved for what treatment?", "[PAD] [PAD] [PAD] [PAD] what disease is cerliponase alfa prescribed for?", "[PAD] [PAD] [PAD] [PAD] [PAD] which disease is cerliponase alpha intended for?", "[PAD] [PAD] [PAD] [PAD] cerliponese alfa is used to treat which disease?", "[PAD] [PAD] [PAD] cerliponase alfa is used to treat what disease?", "[PAD] [PAD] [PAD] cerliponase alfa is approved for treating which disease?", "[PAD] [PAD] [PAD] serliponase alpha is approved for treatment of which disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] [PAD] [PAD] which enzyme is deficient in wolman disease?", "[PAD] what is the deficient enzyme in wollmann disease?", "[PAD] what enzyme is deficient in volman's disease?", "what enzyme deficiency is observed in wolman's disease?", "what is the enzyme deficiency in wolman's disease?", "[PAD] which enzyme is deficient in wolman's disease?", "[PAD] which enzyme is deficient in volman's disease?", "[PAD] which enzyme is lacking in wolman's disease?", "[PAD] which enzyme is missing in wolman's disease?", "[PAD] what enzyme is missing in wolman's disease?", "[PAD] which enzyme is deficient in walman's disease?", "[PAD] [PAD] [PAD] which enzyme is missing in wolman disease?", "[PAD] what enzymes are missing in wolman's disease?", "[PAD] what enzyme is missing in wellman's disease?", "[PAD] what enzyme is lacking in wolman's disease?", "which enzyme is deficient in wollman's disease?", "[PAD] which enzyme is missing from volman's disease?", "[PAD] [PAD] [PAD] what enzyme is missing in wolman disease?", "[PAD] which enzyme is deficient in wellman's disease?", "which enzyme deficiency is observed in wolman's disease?", "[PAD] which enzyme is missing in volman's disease?", "[PAD] [PAD] [PAD] what enzyme is deficient in wolman disease?", "[PAD] deficiency of which enzyme in wolman's disease?", "[PAD] which enzyme is deficient in woolman's disease?", "[PAD] [PAD] [PAD] wolman disease is deficient in which enzyme?", "[PAD] which enzyme is defective in wolman's disease?", "[PAD] what enzyme is deficient in wallman's disease?", "[PAD] what is the exoproteome?", "[PAD] what is the exoproteoma?", "[PAD] what is an exoproteoma?", "[PAD] what is an exoproteome?", "[PAD] what is an exoproteom?", "[PAD] [PAD] what is exoproteom?", "[PAD] what is the epiproteome?", "[PAD] what is an exoprotein?", "[PAD] what is an exoproteus?", "[PAD] [PAD] [PAD] [PAD] what is an exterior?", "[PAD] what is the exoprotome?", "[PAD] what is exo proteome?", "[PAD] [PAD] what are exoproteoms?", "[PAD] what is an exoproteum?", "[PAD] [PAD] what is exoproteome?", "what is the exoprutome?", "[PAD] which receptor is targeted by erenumab?", "[PAD] what receptors does erinumab target?", "[PAD] [PAD] [PAD] which receptor targets erenabab?", "[PAD] [PAD] which receptor does erenumab target?", "[PAD] what is the target of erenumab?", "[PAD] which receptor is targeted to erenumab?", "[PAD] which receptor is directed by erenumab?", "[PAD] what receptor is erenumab targeted at?", "[PAD] [PAD] [PAD] which receptor targets erenumab?", "[PAD] [PAD] which receptors does erenumab target?", "[PAD] which receptor is directed at erenumab?", "[PAD] [PAD] what receptor does erenumab target?", "[PAD] [PAD] which erenumab receptors are targeted?", "[PAD] [PAD] which receptor is erenumab targeting?", "[PAD] which receptor is erenumab targeted at?", "[PAD] which receptors are targeted by elenumab?", "[PAD] [PAD] what receptors does erenumab target?", "[PAD] to which receptor is erenumab targeted?", "[PAD] which receptors is targeted by erenumab?", "which receptor is the target of erenumab?", "[PAD] [PAD] which receptor is erenumab targeted?", "[PAD] what receptor does erenumab act on?", "[PAD] which recipient is targeted by erenumab?", "[PAD] which receptors are targeted by erenumab?", "[PAD] which receptor is affected by erenumab?", "[PAD] [PAD] [PAD] erenumab targets which receptor?", "[PAD] which receptor is targeted by erenumab?", "[PAD] what receptors does erinumab target?", "[PAD] [PAD] [PAD] which receptor targets erenabab?", "[PAD] [PAD] which receptor does erenumab target?", "[PAD] what is the target of erenumab?", "[PAD] which receptor is targeted to erenumab?", "[PAD] which receptor is directed by erenumab?", "[PAD] what receptor is erenumab targeted at?", "[PAD] [PAD] [PAD] which receptor targets erenumab?", "[PAD] [PAD] which receptors does erenumab target?", "[PAD] which receptor is directed at erenumab?", "[PAD] [PAD] what receptor does erenumab target?", "[PAD] [PAD] which erenumab receptors are targeted?", "[PAD] [PAD] which receptor is erenumab targeting?", "[PAD] which receptor is erenumab targeted at?", "[PAD] which receptors are targeted by elenumab?", "[PAD] [PAD] what receptors does erenumab target?", "[PAD] to which receptor is erenumab targeted?", "[PAD] which receptors is targeted by erenumab?", "which receptor is the target of erenumab?", "[PAD] [PAD] which receptor is erenumab targeted?", "[PAD] what receptor does erenumab act on?", "[PAD] which recipient is targeted by erenumab?", "[PAD] which receptors are targeted by erenumab?", "[PAD] which receptor is affected by erenumab?", "[PAD] [PAD] [PAD] erenumab targets which receptor?", "[PAD] which receptor is targeted by erenumab?", "[PAD] what receptors does erinumab target?", "[PAD] [PAD] [PAD] which receptor targets erenabab?", "[PAD] [PAD] which receptor does erenumab target?", "[PAD] what is the target of erenumab?", "[PAD] which receptor is targeted to erenumab?", "[PAD] which receptor is directed by erenumab?", "[PAD] what receptor is erenumab targeted at?", "[PAD] [PAD] [PAD] which receptor targets erenumab?", "[PAD] [PAD] which receptors does erenumab target?", "[PAD] which receptor is directed at erenumab?", "[PAD] [PAD] what receptor does erenumab target?", "[PAD] [PAD] which erenumab receptors are targeted?", "[PAD] [PAD] which receptor is erenumab targeting?", "[PAD] which receptor is erenumab targeted at?", "[PAD] which receptors are targeted by elenumab?", "[PAD] [PAD] what receptors does erenumab target?", "[PAD] to which receptor is erenumab targeted?", "[PAD] which receptors is targeted by erenumab?", "which receptor is the target of erenumab?", "[PAD] [PAD] which receptor is erenumab targeted?", "[PAD] what receptor does erenumab act on?", "[PAD] which recipient is targeted by erenumab?", "[PAD] which receptors are targeted by erenumab?", "[PAD] which receptor is affected by erenumab?", "[PAD] [PAD] [PAD] erenumab targets which receptor?", "[PAD] which receptor is targeted by erenumab?", "[PAD] what receptors does erinumab target?", "[PAD] [PAD] [PAD] which receptor targets erenabab?", "[PAD] [PAD] which receptor does erenumab target?", "[PAD] what is the target of erenumab?", "[PAD] which receptor is targeted to erenumab?", "[PAD] which receptor is directed by erenumab?", "[PAD] what receptor is erenumab targeted at?", "[PAD] [PAD] [PAD] which receptor targets erenumab?", "[PAD] [PAD] which receptors does erenumab target?", "[PAD] which receptor is directed at erenumab?", "[PAD] [PAD] what receptor does erenumab target?", "[PAD] [PAD] which erenumab receptors are targeted?", "[PAD] [PAD] which receptor is erenumab targeting?", "[PAD] which receptor is erenumab targeted at?", "[PAD] which receptors are targeted by elenumab?", "[PAD] [PAD] what receptors does erenumab target?", "[PAD] to which receptor is erenumab targeted?", "[PAD] which receptors is targeted by erenumab?", "which receptor is the target of erenumab?", "[PAD] [PAD] which receptor is erenumab targeted?", "[PAD] what receptor does erenumab act on?", "[PAD] which recipient is targeted by erenumab?", "[PAD] which receptors are targeted by erenumab?", "[PAD] which receptor is affected by erenumab?", "[PAD] [PAD] [PAD] erenumab targets which receptor?", "[PAD] which receptor is targeted by erenumab?", "[PAD] what receptors does erinumab target?", "[PAD] [PAD] [PAD] which receptor targets erenabab?", "[PAD] [PAD] which receptor does erenumab target?", "[PAD] what is the target of erenumab?", "[PAD] which receptor is targeted to erenumab?", "[PAD] which receptor is directed by erenumab?", "[PAD] what receptor is erenumab targeted at?", "[PAD] [PAD] [PAD] which receptor targets erenumab?", "[PAD] [PAD] which receptors does erenumab target?", "[PAD] which receptor is directed at erenumab?", "[PAD] [PAD] what receptor does erenumab target?", "[PAD] [PAD] which erenumab receptors are targeted?", "[PAD] [PAD] which receptor is erenumab targeting?", "[PAD] which receptor is erenumab targeted at?", "[PAD] which receptors are targeted by elenumab?", "[PAD] [PAD] what receptors does erenumab target?", "[PAD] to which receptor is erenumab targeted?", "[PAD] which receptors is targeted by erenumab?", "which receptor is the target of erenumab?", "[PAD] [PAD] which receptor is erenumab targeted?", "[PAD] what receptor does erenumab act on?", "[PAD] which recipient is targeted by erenumab?", "[PAD] which receptors are targeted by erenumab?", "[PAD] which receptor is affected by erenumab?", "[PAD] [PAD] [PAD] erenumab targets which receptor?", "[PAD] which receptor is targeted by erenumab?", "[PAD] what receptors does erinumab target?", "[PAD] [PAD] [PAD] which receptor targets erenabab?", "[PAD] [PAD] which receptor does erenumab target?", "[PAD] what is the target of erenumab?", "[PAD] which receptor is targeted to erenumab?", "[PAD] which receptor is directed by erenumab?", "[PAD] what receptor is erenumab targeted at?", "[PAD] [PAD] [PAD] which receptor targets erenumab?", "[PAD] [PAD] which receptors does erenumab target?", "[PAD] which receptor is directed at erenumab?", "[PAD] [PAD] what receptor does erenumab target?", "[PAD] [PAD] which erenumab receptors are targeted?", "[PAD] [PAD] which receptor is erenumab targeting?", "[PAD] which receptor is erenumab targeted at?", "[PAD] which receptors are targeted by elenumab?", "[PAD] [PAD] what receptors does erenumab target?", "[PAD] to which receptor is erenumab targeted?", "[PAD] which receptors is targeted by erenumab?", "which receptor is the target of erenumab?", "[PAD] [PAD] which receptor is erenumab targeted?", "[PAD] what receptor does erenumab act on?", "[PAD] which recipient is targeted by erenumab?", "[PAD] which receptors are targeted by erenumab?", "[PAD] which receptor is affected by erenumab?", "[PAD] [PAD] [PAD] erenumab targets which receptor?", "[PAD] which receptor is targeted by erenumab?", "[PAD] what receptors does erinumab target?", "[PAD] [PAD] [PAD] which receptor targets erenabab?", "[PAD] [PAD] which receptor does erenumab target?", "[PAD] what is the target of erenumab?", "[PAD] which receptor is targeted to erenumab?", "[PAD] which receptor is directed by erenumab?", "[PAD] what receptor is erenumab targeted at?", "[PAD] [PAD] [PAD] which receptor targets erenumab?", "[PAD] [PAD] which receptors does erenumab target?", "[PAD] which receptor is directed at erenumab?", "[PAD] [PAD] what receptor does erenumab target?", "[PAD] [PAD] which erenumab receptors are targeted?", "[PAD] [PAD] which receptor is erenumab targeting?", "[PAD] which receptor is erenumab targeted at?", "[PAD] which receptors are targeted by elenumab?", "[PAD] [PAD] what receptors does erenumab target?", "[PAD] to which receptor is erenumab targeted?", "[PAD] which receptors is targeted by erenumab?", "which receptor is the target of erenumab?", "[PAD] [PAD] which receptor is erenumab targeted?", "[PAD] what receptor does erenumab act on?", "[PAD] which recipient is targeted by erenumab?", "[PAD] which receptors are targeted by erenumab?", "[PAD] which receptor is affected by erenumab?", "[PAD] [PAD] [PAD] erenumab targets which receptor?", "[PAD] what type of drug is apixaban?", "[PAD] what kind of drug is apixaban?", "[PAD] what kind of medicine is apixaban?", "[PAD] what type of medicine is apixaban?", "[PAD] what is the type of apixaban?", "[PAD] [PAD] [PAD] [PAD] what is apixaban?", "[PAD] [PAD] what is the drug apixaban?", "what is the type of apixaban medicine?", "[PAD] [PAD] [PAD] what drug is apixaban?", "[PAD] [PAD] what the chromsomal location of the gene that is deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene hidden in potocki-shaffer syndrome?", "what is the chromosomal locus of the gene that is deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potok-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potokki-schaffer syndrome?", "[PAD] what is the chromosomal location of the gene that is deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal location of a gene deleted in potocki-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosome location of the gene that was deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the missing gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the cross-position of the gene deleted in potocki-schaffer syndrome?", "[PAD] what is the chromomal location of the gene that is removed in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the crosomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromsomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potock-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene deleted in potocki-shaffer's syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potocki-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene that was deleted during potoc-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal position of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where are chromsomal genes deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schafer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome site of the gene destroyed in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene destroyed in potocki-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene that is eliminated in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in photoki-schaffer syndrome?", "[PAD] [PAD] what is the location of the gene chromosomes that are deleted in potocki-schafer syndrome?", "[PAD] [PAD] [PAD] what is the location of the chromosomes of a gene deleted in potock-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potoki-schaefer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the deleted gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] where is the chromosomal site of the deleted gene in scotch scotch syndrome?", "[PAD] what is the chromosomal location of the gene that was deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal localization of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosome area of the gene that has been erased in potocki-shaffer syndrome?", "[PAD] [PAD] the chromosome location of the deleted gene in the disease. what is a potocki-shaffer?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potochi schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal position of the deleted gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] why was the chromomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what the chromsomal location of the gene that is deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene hidden in potocki-shaffer syndrome?", "what is the chromosomal locus of the gene that is deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potok-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potokki-schaffer syndrome?", "[PAD] what is the chromosomal location of the gene that is deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal location of a gene deleted in potocki-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosome location of the gene that was deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the missing gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the cross-position of the gene deleted in potocki-schaffer syndrome?", "[PAD] what is the chromomal location of the gene that is removed in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the crosomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromsomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potock-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene deleted in potocki-shaffer's syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potocki-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene that was deleted during potoc-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal position of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where are chromsomal genes deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schafer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome site of the gene destroyed in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene destroyed in potocki-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene that is eliminated in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in photoki-schaffer syndrome?", "[PAD] [PAD] what is the location of the gene chromosomes that are deleted in potocki-schafer syndrome?", "[PAD] [PAD] [PAD] what is the location of the chromosomes of a gene deleted in potock-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potoki-schaefer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the deleted gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] where is the chromosomal site of the deleted gene in scotch scotch syndrome?", "[PAD] what is the chromosomal location of the gene that was deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal localization of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosome area of the gene that has been erased in potocki-shaffer syndrome?", "[PAD] [PAD] the chromosome location of the deleted gene in the disease. what is a potocki-shaffer?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potochi schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal position of the deleted gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] why was the chromomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what the chromsomal location of the gene that is deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene hidden in potocki-shaffer syndrome?", "what is the chromosomal locus of the gene that is deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potok-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potokki-schaffer syndrome?", "[PAD] what is the chromosomal location of the gene that is deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal location of a gene deleted in potocki-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosome location of the gene that was deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the missing gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the cross-position of the gene deleted in potocki-schaffer syndrome?", "[PAD] what is the chromomal location of the gene that is removed in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the crosomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromsomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potock-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene deleted in potocki-shaffer's syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potocki-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene that was deleted during potoc-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal position of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where are chromsomal genes deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schafer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome site of the gene destroyed in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene destroyed in potocki-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene that is eliminated in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in photoki-schaffer syndrome?", "[PAD] [PAD] what is the location of the gene chromosomes that are deleted in potocki-schafer syndrome?", "[PAD] [PAD] [PAD] what is the location of the chromosomes of a gene deleted in potock-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potoki-schaefer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the deleted gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] where is the chromosomal site of the deleted gene in scotch scotch syndrome?", "[PAD] what is the chromosomal location of the gene that was deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal localization of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosome area of the gene that has been erased in potocki-shaffer syndrome?", "[PAD] [PAD] the chromosome location of the deleted gene in the disease. what is a potocki-shaffer?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potochi schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal position of the deleted gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] why was the chromomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what the chromsomal location of the gene that is deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene hidden in potocki-shaffer syndrome?", "what is the chromosomal locus of the gene that is deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potok-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potokki-schaffer syndrome?", "[PAD] what is the chromosomal location of the gene that is deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal location of a gene deleted in potocki-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosome location of the gene that was deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the missing gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the cross-position of the gene deleted in potocki-schaffer syndrome?", "[PAD] what is the chromomal location of the gene that is removed in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the crosomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromsomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potock-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene deleted in potocki-shaffer's syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potocki-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene that was deleted during potoc-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal position of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where are chromsomal genes deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schafer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome site of the gene destroyed in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene destroyed in potocki-shaffer syndrome?", "[PAD] what is the chromosomal location of the gene that is eliminated in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in photoki-schaffer syndrome?", "[PAD] [PAD] what is the location of the gene chromosomes that are deleted in potocki-schafer syndrome?", "[PAD] [PAD] [PAD] what is the location of the chromosomes of a gene deleted in potock-shaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potoki-schaefer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the deleted gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] where is the chromosomal site of the deleted gene in scotch scotch syndrome?", "[PAD] what is the chromosomal location of the gene that was deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosomal localization of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the chromosome location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] what is the chromosome area of the gene that has been erased in potocki-shaffer syndrome?", "[PAD] [PAD] the chromosome location of the deleted gene in the disease. what is a potocki-shaffer?", "[PAD] [PAD] [PAD] what is the chromosomal location of the gene deleted in potocki-schaffer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal location of the deleted gene in potochi schaefer syndrome?", "[PAD] [PAD] [PAD] what is the chromosomal position of the deleted gene in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] why was the chromomal location of the gene deleted in potocki-shaffer syndrome?", "[PAD] [PAD] [PAD] where is fatty acid binding protein 2 expressed?", "[PAD] where is the fatty acid-binding protein 2 expressed?", "[PAD] [PAD] where is the fatty acid binding protein 2 expressed?", "[PAD] where is the protein that binds fatty acid 2 expressed?", "[PAD] [PAD] where is the fatty acid binding protein 2 indicated?", "where is protein 2, which binds fatty acids, found?", "[PAD] [PAD] [PAD] [PAD] where is protein 2 fatty acid expressed?", "[PAD] [PAD] [PAD] where is protein 2 binding to fatty acids?", "[PAD] [PAD] [PAD] where is fatty acid 2 binding protein expressed?", "[PAD] [PAD] where is the 2 fatty acid binding protein expressed?", "[PAD] [PAD] where is fatty acid-binding protein 2 expressed?", "[PAD] [PAD] [PAD] where does fatty acid binding protein 2 work?", "[PAD] [PAD] [PAD] [PAD] where is fatty acid binding protein 2?", "[PAD] [PAD] where is protein 2 expressed for fatty acid binding?", "[PAD] [PAD] where is the protein 2 that binds fatty acids?", "[PAD] [PAD] where is the protein 2 binding fatty acid shown?", "[PAD] [PAD] where is the protein binding to fatty acids 2?", "[PAD] where is the protein 2 that binds fatty acids expressed?", "[PAD] where is the expression of fatty acid binding protein 2?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] losigamone can be used for treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat any disease?", "[PAD] [PAD] [PAD] [PAD] for which disease can losigamon be used?", "[PAD] [PAD] can losigamone be used to treat which disease?", "[PAD] [PAD] [PAD] which disease can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat any disease?", "[PAD] [PAD] what diseases can losigamone be used to treat?", "for the treatment of which disease can be used lozygamon?", "[PAD] [PAD] [PAD] lozigamon can be used to treat which disease?", "[PAD] [PAD] [PAD] what diseases can losigamon be used to treat?", "[PAD] [PAD] [PAD] losigamon can be used to treat which diseases?", "[PAD] [PAD] what diseases can be used to treat losigamone?", "[PAD] [PAD] [PAD] what disease can losigamone be used for?", "[PAD] [PAD] [PAD] for which diseases can losigamone be used?", "losigamone can be used for the treatment of what disease?", "losigamone can be used for the treatment of which disease?", "[PAD] [PAD] can losigamone be used to treat this disease?", "[PAD] [PAD] losigamone can be used to treat which disease?", "[PAD] [PAD] losigamone can be used to treat any disease?", "[PAD] [PAD] [PAD] can losigamone be used to treat illness?", "[PAD] [PAD] can lucigmon be used to treat any disease?", "[PAD] [PAD] [PAD] what diseases can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is losigamone used for?", "[PAD] [PAD] losigamone can be used to treat what disease?", "[PAD] [PAD] [PAD] which diseases can roshigamon be used to treat?", "[PAD] [PAD] [PAD] [PAD] what diseases can rosigamon be used for?", "[PAD] [PAD] [PAD] for which disease can lozigamone be used?", "losigamone can be used for the treatment of which diseases?", "[PAD] [PAD] [PAD] can losigamon be used to treat any disease?", "[PAD] [PAD] [PAD] which disease can be used to treat losigamon?", "[PAD] [PAD] which disease can be used to treat losigammon?", "[PAD] [PAD] [PAD] [PAD] what disease can be treated with losigamon?", "[PAD] [PAD] what disease can be used to treat losigamone?", "[PAD] [PAD] [PAD] what treatment can losigamone be used for?", "[PAD] [PAD] [PAD] [PAD] what diseases can losigamon be used for?", "[PAD] losigamon can be used in the treatment of which disease?", "[PAD] [PAD] lucigamon can be used to treat which disease?", "[PAD] [PAD] losigamone can be used for treating which disease?", "can losigamone be used for the treatment of any disease?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat any specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is a human monoclonal antibody to treat what type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat specific types of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab, a humanized monoclonal antibody?", "[PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which type of asthma?", "[PAD] reslizumab is a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody to treat?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody that treats a specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody for the treatment of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat what type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of any particular type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of any specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat specific types of asthma?", "[PAD] [PAD] reslizumab is a man-made monoclonal antibody to treat any particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat certain types of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanised monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody for?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody to treat a specific type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a monoclonal antibody humanized to treat certain types of asthma?", "[PAD] [PAD] reslizumab is a human monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] is reslizumab a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is one of the human antibodies to treat which specific asthma?", "reslizumab is a human-characterized monoclonal antibody for the treatment of a specific type of asthma.", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat any specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is a human monoclonal antibody to treat what type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat specific types of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab, a humanized monoclonal antibody?", "[PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which type of asthma?", "[PAD] reslizumab is a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody to treat?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody that treats a specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody for the treatment of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat what type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of any particular type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of any specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat specific types of asthma?", "[PAD] [PAD] reslizumab is a man-made monoclonal antibody to treat any particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat certain types of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanised monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody for?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody to treat a specific type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a monoclonal antibody humanized to treat certain types of asthma?", "[PAD] [PAD] reslizumab is a human monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] is reslizumab a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is one of the human antibodies to treat which specific asthma?", "reslizumab is a human-characterized monoclonal antibody for the treatment of a specific type of asthma.", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat any specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is a human monoclonal antibody to treat what type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat specific types of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab, a humanized monoclonal antibody?", "[PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which type of asthma?", "[PAD] reslizumab is a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody to treat?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody that treats a specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody for the treatment of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat what type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of any particular type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of any specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat specific types of asthma?", "[PAD] [PAD] reslizumab is a man-made monoclonal antibody to treat any particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat certain types of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanised monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody for?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody to treat a specific type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a monoclonal antibody humanized to treat certain types of asthma?", "[PAD] [PAD] reslizumab is a human monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] is reslizumab a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is one of the human antibodies to treat which specific asthma?", "reslizumab is a human-characterized monoclonal antibody for the treatment of a specific type of asthma.", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat any specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is a human monoclonal antibody to treat what type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat specific types of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab, a humanized monoclonal antibody?", "[PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which type of asthma?", "[PAD] reslizumab is a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody to treat?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody that treats a specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody for the treatment of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat what type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of any particular type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of any specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat specific types of asthma?", "[PAD] [PAD] reslizumab is a man-made monoclonal antibody to treat any particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat certain types of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanised monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody for?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody to treat a specific type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a monoclonal antibody humanized to treat certain types of asthma?", "[PAD] [PAD] reslizumab is a human monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] is reslizumab a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is one of the human antibodies to treat which specific asthma?", "reslizumab is a human-characterized monoclonal antibody for the treatment of a specific type of asthma.", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat any specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is a human monoclonal antibody to treat what type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat specific types of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab, a humanized monoclonal antibody?", "[PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which type of asthma?", "[PAD] reslizumab is a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody to treat?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody that treats a specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody for the treatment of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat what type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of any particular type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of any specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat specific types of asthma?", "[PAD] [PAD] reslizumab is a man-made monoclonal antibody to treat any particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat certain types of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanised monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody for?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody to treat a specific type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a monoclonal antibody humanized to treat certain types of asthma?", "[PAD] [PAD] reslizumab is a human monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] is reslizumab a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is one of the human antibodies to treat which specific asthma?", "reslizumab is a human-characterized monoclonal antibody for the treatment of a specific type of asthma.", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat any specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is a human monoclonal antibody to treat what type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat specific types of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab, a humanized monoclonal antibody?", "[PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which type of asthma?", "[PAD] reslizumab is a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody to treat?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody that treats a specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody for the treatment of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat what type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of any particular type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of any specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat specific types of asthma?", "[PAD] [PAD] reslizumab is a man-made monoclonal antibody to treat any particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat certain types of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanised monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody for?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody to treat a specific type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a monoclonal antibody humanized to treat certain types of asthma?", "[PAD] [PAD] reslizumab is a human monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] is reslizumab a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is one of the human antibodies to treat which specific asthma?", "reslizumab is a human-characterized monoclonal antibody for the treatment of a specific type of asthma.", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat any specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is a human monoclonal antibody to treat what type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat specific types of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab, a humanized monoclonal antibody?", "[PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which type of asthma?", "[PAD] reslizumab is a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody to treat?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody that treats a specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody for the treatment of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat what type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of any particular type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of any specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat specific types of asthma?", "[PAD] [PAD] reslizumab is a man-made monoclonal antibody to treat any particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat certain types of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanised monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody for?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody to treat a specific type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a monoclonal antibody humanized to treat certain types of asthma?", "[PAD] [PAD] reslizumab is a human monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] is reslizumab a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is one of the human antibodies to treat which specific asthma?", "reslizumab is a human-characterized monoclonal antibody for the treatment of a specific type of asthma.", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat any specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is a human monoclonal antibody to treat what type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat specific types of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of which specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab, a humanized monoclonal antibody?", "[PAD] [PAD] reslizumab is a humanized monoclonal antibody for the treatment of which type of asthma?", "[PAD] reslizumab is a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody to treat?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody that treats a specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat what particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody for the treatment of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat what type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of any particular type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of any specific type of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody used to treat specific types of asthma?", "[PAD] [PAD] reslizumab is a man-made monoclonal antibody to treat any particular type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat certain types of asthma?", "[PAD] [PAD] [PAD] reslizumab is a humanised monoclonal antibody to treat which specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody?", "[PAD] [PAD] [PAD] [PAD] what specific type of asthma is reslizumab a humanized monoclonal antibody for?", "[PAD] [PAD] [PAD] is reslizumab a humanized monoclonal antibody to treat a specific type of asthma?", "[PAD] is reslizumab a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] reslizumab is a monoclonal antibody humanized to treat certain types of asthma?", "[PAD] [PAD] reslizumab is a human monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] reslizumab is a humanized monoclonal antibody for the treatment of a specific type of asthma?", "[PAD] is reslizumab a humanised monoclonal antibody for the treatment of what specific type of asthma?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] reslizumab is one of the human antibodies to treat which specific asthma?", "reslizumab is a human-characterized monoclonal antibody for the treatment of a specific type of asthma.", "[PAD] [PAD] [PAD] [PAD] reslizumab is a humanized monoclonal antibody to treat which type of asthma?", "[PAD] [PAD] [PAD] what is the function of the transcriptional co-activator p300?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the function of p300 transcript activator?", "[PAD] [PAD] [PAD] what is the function of the p300 transcriptional co-activator?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the function of p300 transcriptional activator?", "[PAD] [PAD] [PAD] what is the function of the transcription co-activator p300?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the function of the p300 transcription activator?", "[PAD] [PAD] [PAD] what is the function of the p300 transcription co-activator?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the function of the p300 transcriptional coactivator?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the function of transcriptional coactivator p300?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the function of the p300 transcription coactivator?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the function of the transcriptional coactivator p300?", "[PAD] [PAD] [PAD] [PAD] what is the function of transcriptional co-activator p300?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the role of the transcription coactivator p300?", "[PAD] [PAD] [PAD] [PAD] what is the function of transcription co-activator p300?", "[PAD] [PAD] [PAD] what is the transcription function of the p300 co-activator?", "[PAD] [PAD] [PAD] what is the role of the transcript co-operator p300?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the role of the p300 transcription activator?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the function of the p300 transcription syntax?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the function of the transcription coactivator p300?", "[PAD] what is the function of the co -driver of the p300 transcript?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the transcription function of p300 activator?", "[PAD] [PAD] [PAD] [PAD] what is the function of p300 transcription co-activator?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the function of the participant transcriptional p300?", "what is the function of the p300 decoding co-actuator?", "[PAD] [PAD] [PAD] [PAD] [PAD] what is the function of transactive activator p300?", "[PAD] [PAD] [PAD] [PAD] what is the function of p300 transcriptional co-activator?", "[PAD] [PAD] [PAD] what is the function of the p300 transcription co-stimulator?", "from where is gamabufotalin (gbt) isolated?", "where is gamabufotalin (gbt) isolated from?", "[PAD] where is gamabufotalin (gbt) isolated?", "[PAD] [PAD] where is gammabutalin (gbt) isolated from?", "[PAD] where is gamamufotalin (gbt) isolated?", "[PAD] where is gamabufotaline (gbt) isolated?", "[PAD] where is homobufotalin (gbt) secreted?", "[PAD] where is gamma bufotalin (gbt) isolated from?", "what is gamabufotalin (gbt) isolated from?", "where is gamabufotaline (gbt) isolated from?", "[PAD] [PAD] where is gammabutophthalene (gbt) isolated from?", "[PAD] where is gambufotalin (gbt) isolated from?", "[PAD] [PAD] where is gamabopotlin (gbt) isolated?", "[PAD] [PAD] [PAD] where is gamma-buffalo (gbt) isolated from?", "where is gamabu fotalin (gbt) separated from?", "[PAD] where is gamabuportalin (gbt) isolated?", "[PAD] [PAD] where does gammabutophthalene (gbt) come from?", "[PAD] where is gammabufotalin (gbt) isolated from?", "[PAD] [PAD] where is gammabufotalin (gbt) isolated?", "from where is gamabufotalin (gbt) isolated?", "where is gamabufotalin (gbt) isolated from?", "[PAD] where is gamabufotalin (gbt) isolated?", "[PAD] [PAD] where is gammabutalin (gbt) isolated from?", "[PAD] where is gamamufotalin (gbt) isolated?", "[PAD] where is gamabufotaline (gbt) isolated?", "[PAD] where is homobufotalin (gbt) secreted?", "[PAD] where is gamma bufotalin (gbt) isolated from?", "what is gamabufotalin (gbt) isolated from?", "where is gamabufotaline (gbt) isolated from?", "[PAD] [PAD] where is gammabutophthalene (gbt) isolated from?", "[PAD] where is gambufotalin (gbt) isolated from?", "[PAD] [PAD] where is gamabopotlin (gbt) isolated?", "[PAD] [PAD] [PAD] where is gamma-buffalo (gbt) isolated from?", "where is gamabu fotalin (gbt) separated from?", "[PAD] where is gamabuportalin (gbt) isolated?", "[PAD] [PAD] where does gammabutophthalene (gbt) come from?", "[PAD] where is gammabufotalin (gbt) isolated from?", "[PAD] [PAD] where is gammabufotalin (gbt) isolated?", "from where is gamabufotalin (gbt) isolated?", "where is gamabufotalin (gbt) isolated from?", "[PAD] where is gamabufotalin (gbt) isolated?", "[PAD] [PAD] where is gammabutalin (gbt) isolated from?", "[PAD] where is gamamufotalin (gbt) isolated?", "[PAD] where is gamabufotaline (gbt) isolated?", "[PAD] where is homobufotalin (gbt) secreted?", "[PAD] where is gamma bufotalin (gbt) isolated from?", "what is gamabufotalin (gbt) isolated from?", "where is gamabufotaline (gbt) isolated from?", "[PAD] [PAD] where is gammabutophthalene (gbt) isolated from?", "[PAD] where is gambufotalin (gbt) isolated from?", "[PAD] [PAD] where is gamabopotlin (gbt) isolated?", "[PAD] [PAD] [PAD] where is gamma-buffalo (gbt) isolated from?", "where is gamabu fotalin (gbt) separated from?", "[PAD] where is gamabuportalin (gbt) isolated?", "[PAD] [PAD] where does gammabutophthalene (gbt) come from?", "[PAD] where is gammabufotalin (gbt) isolated from?", "[PAD] [PAD] where is gammabufotalin (gbt) isolated?", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in what biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydrototate dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] human dehydrogenase dihydrororotate is a target drug and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroergotase dehydrogenase is a drug target and participates in the biosynthesis pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target \u0587 involved in the biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotat dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and what biosynthetic pathway is involved", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is the target of drugs and is involved in which pathway of biosynthesis", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target of the drug and is involved in any biosynthetic pathway", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target of the drug and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in a biosynthetic pathway", "human dihydroorotate dehydrogenase is the target of the drug and is involved in a number of pathways of biosynthesis", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is the target of the drug and is involved in some biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in which biosynthesis pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in any biosynthetic pathway", "[PAD] [PAD] human dihydroorotate dehydrogenase is a target of the drug and is involved in the biosynthetic pathway.", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and participates in the biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotic dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in biosynthetic pathways", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dehydrogenate dehydrogenase is a drug target and is involved in some biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and which biosynthetic pathway is involved in", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] the target of human dihydroorotate dehydrogenase and the biosynthetic process involved", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydrorotate dehydrogenase is a drug target and is involved in any biogenesis process", "[PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in what biosynthetic pathway?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dehydrogenase dehydrogenase is a target drug and is involved in what biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which biosynthetic pathway is human dihydroorotic acid dehydrogenase a drug target?", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in certain biosynthetic pathways", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and is involved in a biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and is involved in any biosynthetic pathway.", "[PAD] [PAD] [PAD] [PAD] human dehydrogenase dehydrogenase is a drug target and in what biosynthetic pathway it plays a role", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in the biosynthetic process", "[PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in which biosynthetic pathway?", "[PAD] [PAD] human dihydroorotate dehydrogenase is the target of the drug and is involved in some pathways of biosynthesis", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is the target of the drug and is involved in what biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is targeted by drugs and is involved in what biological process", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in biosynthesis pathways.", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and in which biosynthetic pathway is it involved?", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target of drugs and is involved in which pathway of biosynthesis", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroroate dehydrogenase is a drug target and contains a biosynthetic pathway.", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in the biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and relates to which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dehydrorotate dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in what biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydrototate dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] human dehydrogenase dihydrororotate is a target drug and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroergotase dehydrogenase is a drug target and participates in the biosynthesis pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target \u0587 involved in the biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotat dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and what biosynthetic pathway is involved", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is the target of drugs and is involved in which pathway of biosynthesis", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target of the drug and is involved in any biosynthetic pathway", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target of the drug and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in a biosynthetic pathway", "human dihydroorotate dehydrogenase is the target of the drug and is involved in a number of pathways of biosynthesis", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is the target of the drug and is involved in some biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in which biosynthesis pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in any biosynthetic pathway", "[PAD] [PAD] human dihydroorotate dehydrogenase is a target of the drug and is involved in the biosynthetic pathway.", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and participates in the biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotic dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in biosynthetic pathways", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dehydrogenate dehydrogenase is a drug target and is involved in some biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and which biosynthetic pathway is involved in", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] the target of human dihydroorotate dehydrogenase and the biosynthetic process involved", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydrorotate dehydrogenase is a drug target and is involved in any biogenesis process", "[PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in what biosynthetic pathway?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dehydrogenase dehydrogenase is a target drug and is involved in what biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which biosynthetic pathway is human dihydroorotic acid dehydrogenase a drug target?", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in certain biosynthetic pathways", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and is involved in a biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and is involved in any biosynthetic pathway.", "[PAD] [PAD] [PAD] [PAD] human dehydrogenase dehydrogenase is a drug target and in what biosynthetic pathway it plays a role", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in the biosynthetic process", "[PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in which biosynthetic pathway?", "[PAD] [PAD] human dihydroorotate dehydrogenase is the target of the drug and is involved in some pathways of biosynthesis", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is the target of the drug and is involved in what biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is targeted by drugs and is involved in what biological process", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in biosynthesis pathways.", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and in which biosynthetic pathway is it involved?", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target of drugs and is involved in which pathway of biosynthesis", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroroate dehydrogenase is a drug target and contains a biosynthetic pathway.", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in the biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and relates to which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dehydrorotate dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in what biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydrototate dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] human dehydrogenase dihydrororotate is a target drug and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroergotase dehydrogenase is a drug target and participates in the biosynthesis pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target \u0587 involved in the biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotat dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and what biosynthetic pathway is involved", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is the target of drugs and is involved in which pathway of biosynthesis", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target of the drug and is involved in any biosynthetic pathway", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target of the drug and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in a biosynthetic pathway", "human dihydroorotate dehydrogenase is the target of the drug and is involved in a number of pathways of biosynthesis", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is the target of the drug and is involved in some biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in which biosynthesis pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in any biosynthetic pathway", "[PAD] [PAD] human dihydroorotate dehydrogenase is a target of the drug and is involved in the biosynthetic pathway.", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and participates in the biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotic dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in biosynthetic pathways", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dehydrogenate dehydrogenase is a drug target and is involved in some biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and which biosynthetic pathway is involved in", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] the target of human dihydroorotate dehydrogenase and the biosynthetic process involved", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydrorotate dehydrogenase is a drug target and is involved in any biogenesis process", "[PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in what biosynthetic pathway?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dehydrogenase dehydrogenase is a target drug and is involved in what biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] which biosynthetic pathway is human dihydroorotic acid dehydrogenase a drug target?", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in certain biosynthetic pathways", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and is involved in a biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target drug and is involved in any biosynthetic pathway.", "[PAD] [PAD] [PAD] [PAD] human dehydrogenase dehydrogenase is a drug target and in what biosynthetic pathway it plays a role", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in the biosynthetic process", "[PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in which biosynthetic pathway?", "[PAD] [PAD] human dihydroorotate dehydrogenase is the target of the drug and is involved in some pathways of biosynthesis", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is the target of the drug and is involved in what biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is targeted by drugs and is involved in what biological process", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in biosynthesis pathways.", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and in which biosynthetic pathway is it involved?", "[PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a target of drugs and is involved in which pathway of biosynthesis", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroroate dehydrogenase is a drug target and contains a biosynthetic pathway.", "[PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and is involved in the biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dihydroorotate dehydrogenase is a drug target and relates to which biosynthetic pathway", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] human dehydrorotate dehydrogenase is a drug target and is involved in which biosynthetic pathway", "[PAD] [PAD] what is the cause of krabbe disease?", "[PAD] [PAD] [PAD] [PAD] what causes crabbe's disease?", "what is the cause of krabbe's illness?", "[PAD] [PAD] [PAD] what is the cause of krabe disease?", "[PAD] what is the cause of krabe's disease?", "what is the cause of krabbe's disease?", "[PAD] [PAD] [PAD] what causes krabbe's disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] what causes krabbe disease?", "[PAD] [PAD] [PAD] [PAD] what is the cause of crab disease?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what causes crab disease?", "[PAD] [PAD] [PAD] [PAD] what causes krabe's disease?", "[PAD] [PAD] what is the cause of krabbes disease?", "[PAD] what is the cause of crabbe's disease?", "[PAD] [PAD] [PAD] [PAD] what causes kirby's disease?", "what is a exposome?", "what is an exposome?", "[PAD] [PAD] what is an exposure?", "[PAD] what's the offer?", "[PAD] [PAD] what is a discovery?", "[PAD] [PAD] what is an exposition?", "[PAD] [PAD] [PAD] what is exposure?", "[PAD] what is exposom?", "[PAD] [PAD] what is an exhibit?", "[PAD] [PAD] [PAD] what is disclosure?", "what is an exosome?", "[PAD] [PAD] [PAD] what is exposition?", "[PAD] what is exposome?", "[PAD] [PAD] what is an exhibition?", "[PAD] is an exposome?", "[PAD] what is an expos?", "what is an exposom?", "[PAD] [PAD] what is a revelation?", "[PAD] [PAD] [PAD] what is predicted using surfy?", "[PAD] [PAD] [PAD] what is predicted with surfy?", "[PAD] [PAD] [PAD] what to expect with surfy?", "[PAD] [PAD] [PAD] what is predicted by surfy?", "[PAD] [PAD] [PAD] what is planned using surfy?", "what is predicted with the help of surfy?", "[PAD] [PAD] [PAD] what to predict with surfy?", "[PAD] [PAD] [PAD] what is anticipated using surfy?", "[PAD] [PAD] [PAD] what is expected using surfy?", "[PAD] [PAD] [PAD] what is provided using surfy?", "[PAD] [PAD] [PAD] what is expected through surfy?", "[PAD] [PAD] [PAD] what to expect from surfy?", "[PAD] [PAD] [PAD] what to predict using surfy?", "[PAD] [PAD] [PAD] what is expected using surpy?", "[PAD] [PAD] what is predicted when using surfy?", "[PAD] [PAD] what are the predictions using surfy?", "[PAD] [PAD] [PAD] what is anticipated using surfi?", "[PAD] what is envisaged using surfy?", "[PAD] [PAD] what is predicted to use surfy?", "[PAD] [PAD] [PAD] what is provided by surfy?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] salivary cortisol is a biomarker for what disease/syndrome/condition?", "[PAD] [PAD] saliva cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for which disease/syndrome/condition?", "[PAD] [PAD] [PAD] which disease (syndrome) is biomarkers of salivary cortisol?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] what is the biomarker of salivary cortisol?", "[PAD] cortisol in saliva is a biomarker of which disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker for what disease / syndrome / condition?", "[PAD] salivary cortisol is a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] what disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] what disease / syndrome / condition is the biomarker of salivary cortisol?", "[PAD] [PAD] [PAD] which disease / syndrome / disease biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of what disease / syndrome / condition?", "[PAD] [PAD] [PAD] what disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker for what disease / syndrome / condition?", "[PAD] [PAD] brock cortisol is a biological marker for which disease / syndrome / condition?", "[PAD] for which disease/syndrome/condition is salivary cortisol a biomarker?", "[PAD] salivary cortisol is a biomarker for any disease / syndrome / condition?", "[PAD] cortisol salivary is a biomarker for which disease / syndrome / condition?", "[PAD] what kind of disease / syndrome / condition biomarker is salivary cortisol?", "[PAD] is salivary cortisol a biomarker of any disease / syndrome / condition?", "[PAD] cortisol in saliva is a biomarker for which disease / syndrome / condition?", "[PAD] [PAD] cortisol saliva is a biomarker of the disease / syndrome / condition?", "[PAD] [PAD] saliv cortisol is a biomarker for which disease / syndrome / condition?", "cortisol saliva is a biomarker for what disease/syndrome/symptom?", "[PAD] is cortisol in saliva a biomarker of which disease / syndrome / condition?", "[PAD] [PAD] salvary cortisol is a biomarker for which disease / syndrome / condition?", "salivary cortisol is a biomarker for what diseases / syndromes / conditions?", "[PAD] where, in the body, would the cobb-stainsby excision arthroplasty be performed?", "[PAD] [PAD] where, in the body, would the cobb-stainsby excision perform arthroplasty?", "[PAD] [PAD] [PAD] [PAD] where in the body would cobb-stainsby excision arthroplasty be performed?", "[PAD] [PAD] [PAD] where on the body will cobb-stainsby circumcision arthroplasty be performed?", "[PAD] [PAD] [PAD] [PAD] where was cobb-stainsby's excision arthroplasty to be performed?", "[PAD] [PAD] [PAD] [PAD] where will cobb-stainsby excision arthroplasty be performed on the body?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where in the body will cobb-steinsby excising be performed?", "[PAD] [PAD] [PAD] where in the body will cobb-stainsby excisional arthroplasty be performed?", "[PAD] [PAD] [PAD] where on the body is the cobb-stainsby resection arthroplasty performed?", "[PAD] where, in the body, would cobb-stainsby excisional arthroplasty be performed?", "[PAD] [PAD] [PAD] [PAD] [PAD] where in the body would cobb-stainsby excision arthroplasty perform?", "where, in the body, would the cobb-stainsby excisional arthroplasty be performed?", "[PAD] [PAD] [PAD] [PAD] [PAD] where in the body is cobb-stainsby excision arthroplasty performed?", "[PAD] [PAD] where, in the body, will cobb-stainsby excision arthroplasty be performed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] in what body would cobb-stainsby surgery be performed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where in the body would cobb-stainsby excision replacement surgery be performed?", "[PAD] [PAD] [PAD] where in the body would cobb-stainsby cleavage arthroplasty be performed?", "[PAD] [PAD] where, in the body, should cobb-stainsby excision arthroplasty be performed?", "[PAD] [PAD] where in the body would the cobb-stainsby excisional arthroplasty be performed?", "[PAD] [PAD] [PAD] where in the body would cobb-stainsby resection arthroplasty be performed?", "[PAD] [PAD] [PAD] [PAD] where, in the body, should cobb-stainsby atroplasts be performed?", "[PAD] [PAD] [PAD] [PAD] where, in the body, will a cob-stainsby resection be performed?", "[PAD] [PAD] [PAD] [PAD] where in the body will cobb-stainsby excision arthroplasty be performed?", "[PAD] [PAD] [PAD] [PAD] where in the body would i perform cobb-stainsby dissection arthroplasty?", "[PAD] [PAD] [PAD] [PAD] [PAD] where, in the body, would the cobb-stainsby carving operation be performed?", "[PAD] where, in the body, will cobb-stainsby excisional arthroplasty be performed?", "[PAD] where, in the body, would the cobb-stainsby excision arthroplasty take place?", "[PAD] [PAD] [PAD] where in the body is cobb stain's bee resection arthroplasty performed?", "[PAD] [PAD] [PAD] [PAD] where in the body is cobb-stainsby resection arthroplasty performed?", "[PAD] [PAD] [PAD] [PAD] where in the body would cob-stintsby excision endoprosthesis be performed?", "[PAD] [PAD] [PAD] [PAD] where in the body would cobb-stainsby excise arthroplasty be performed?", "[PAD] [PAD] [PAD] [PAD] where, in the body, is cobb-stainsby cutting arthroplasty performed?", "[PAD] [PAD] [PAD] [PAD] where is cobb-stainsby resection arthroplasty performed on the body?", "[PAD] [PAD] [PAD] where in the body would cobb-stainsby excisional arthroplasty be performed?", "[PAD] [PAD] where in the body will the cobb-stainsby excisional arthroplasty be performed?", "[PAD] [PAD] where, in the body, would cobb-stainsby excision arthroplasty be performed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where in the body would cobb-stainsby excuse arthroplasty?", "[PAD] [PAD] [PAD] where on the body would the cobb-stainsby excision arthroplasty be performed?", "[PAD] where would the cobb-stainby amputation arthroplasty be performed, in the body?", "[PAD] [PAD] [PAD] [PAD] [PAD] where in the body would the cobb-stainsby excision prosthesis be performed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] will perform joint replacement surgery cobb stainsby where in the body?", "[PAD] [PAD] [PAD] [PAD] where in the body will cobb-stainsby excising endoprosthesis be performed?", "[PAD] in the body, where will kobe stansby's excise arthroplasty be performed?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] in the body, where is cobb-stainsby arthroplasty performed?", "[PAD] [PAD] where, in the body, would the cobb-stainsby fracture arthroplasty be performed?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] where in the body, is ghrelin secreted?", "[PAD] [PAD] where in the body is ghrelin secreted?", "[PAD] [PAD] where is ghrelin secreted in the body?", "[PAD] where is ghrelin excreted in the body?", "[PAD] [PAD] [PAD] where does ghrelin flow into the body?", "[PAD] [PAD] [PAD] where in the body is ghrelin released?", "[PAD] [PAD] where is ghrelin secreted from the body?", "[PAD] where in the body is ghrelin excreted?", "[PAD] [PAD] where in the body, is ghrelin stored?", "[PAD] [PAD] [PAD] in which body is ghrelin secreted?", "[PAD] [PAD] where does ghrelin secrete from the body?", "in which part of the body is ghrelin secreted?", "[PAD] [PAD] [PAD] where in the body does ghrelin release?", "[PAD] [PAD] where in the body does ghrelin radiate?", "[PAD] where in the body, is ghrelin a secret?", "[PAD] [PAD] where is the ghrelin hidden in the body?", "[PAD] [PAD] [PAD] where in the body is released ghrelin?", "[PAD] [PAD] [PAD] [PAD] [PAD] [PAD] where does the body come from?", "[PAD] where in the body, is grilin secreted?", "[PAD] what is resistin?", "[PAD] [PAD] what is resistance?", "what is a resistor?", "[PAD] [PAD] what is resisting?", "what is registin?", "[PAD] [PAD] what is resist?", "[PAD] what is resistin?", "[PAD] [PAD] what is resistance?", "what is a resistor?", "[PAD] [PAD] what is resisting?", "what is registin?", "[PAD] [PAD] what is resist?", "[PAD] what is resistin?", "[PAD] [PAD] what is resistance?", "what is a resistor?", "[PAD] [PAD] what is resisting?", "what is registin?", "[PAD] [PAD] what is resist?", "[PAD] what is resistin?", "[PAD] [PAD] what is resistance?", "what is a resistor?", "[PAD] [PAD] what is resisting?", "what is registin?", "[PAD] [PAD] what is resist?"], "title": ["5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c34ad63da8336e21a000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58962286df2b9174000007", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c58b99586df2b9174000012", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c588efb86df2b9174000004", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c581e1507647bbc4b00001c", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c73ad367c78d69471000099", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c536b857e3cb0e23100001c", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c73ad027c78d6947100008d", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c7161f47c78d69471000066", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c61d278e842deac67000005", "5c5f1f371a4c55d80b00001a", "5c5f1f371a4c55d80b00001a", "5c5f1f371a4c55d80b00001a", "5c5f1f371a4c55d80b00001a", "5c5f1f371a4c55d80b00001a", "5c5f1f371a4c55d80b00001a", "5c5f1f371a4c55d80b00001a", "5c5f1f371a4c55d80b00001a", "5c5f1f371a4c55d80b00001a", "5c5f1f371a4c55d80b00001a", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5249077e3cb0e23100000b", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c5310c37e3cb0e231000010", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e05f37c78d69471000049", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e0f537c78d6947100004a", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c6e16eb7c78d6947100004e", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c51fe8907ef653866000007", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c0117fd133db5eb7800002a", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c72ade07c78d69471000070", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c6b810e7c78d6947100002e", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c72f6b17c78d6947100007f", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c8cd26a0101eac870000003", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c73acef7c78d69471000088", "5c920f13ecadf2e73f000010", "5c920f13ecadf2e73f000010", "5c920f13ecadf2e73f000010", "5c920f13ecadf2e73f000010", "5c920f13ecadf2e73f000010", "5c920f13ecadf2e73f000010", "5c920f13ecadf2e73f000010", "5c920f13ecadf2e73f000010", "5c920f13ecadf2e73f000010", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c72b7277c78d69471000073", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c8d15cf0101eac870000009", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5c73acec7c78d69471000086", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5ca0bf00ecadf2e73f000045", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c990241ecadf2e73f00002d", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5c9904eaecadf2e73f00002e", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5cb0856decadf2e73f000058", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5c9efde8ecadf2e73f000039", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0d647ecadf2e73f000059", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5cb0e4a6ecadf2e73f00005b", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9fb428ecadf2e73f000041", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5c9ff25eecadf2e73f000043", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5caa06d0ecadf2e73f000056", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006", "5c840782617e120c34000006"], "new_id": ["0_0", "0_1", "0_2", "0_3", "0_4", "0_5", "0_6", "0_7", "0_8", "0_9", "0_10", "0_11", "0_12", "0_13", "0_14", "0_15", "0_16", "0_17", "0_18", "0_19", "0_20", "0_21", "0_22", "0_23", "0_24", "0_25", "0_26", "0_27", "0_28", "0_29", "0_30", "0_31", "0_32", "1_0", "1_1", "1_2", "1_3", "1_4", "1_5", "1_6", "1_7", "1_8", "1_9", "1_10", "1_11", "1_12", "1_13", "1_14", "1_15", "1_16", "1_17", "1_18", "1_19", "1_20", "1_21", "1_22", "1_23", "1_24", "1_25", "1_26", "1_27", "1_28", "1_29", "1_30", "1_31", "1_32", "1_33", "2_0", "2_1", "2_2", "2_3", "2_4", "2_5", "2_6", "2_7", "2_8", "2_9", "2_10", "2_11", "2_12", "2_13", "2_14", "2_15", "2_16", "2_17", "2_18", "2_19", "2_20", "2_21", "2_22", "2_23", "2_24", "2_25", "2_26", "2_27", "2_28", "2_29", "2_30", "2_31", "2_32", "2_33", "3_0", "3_1", "3_2", "3_3", "3_4", "3_5", "3_6", "3_7", "3_8", "3_9", "3_10", "3_11", "3_12", "3_13", "3_14", "3_15", "3_16", "3_17", "3_18", "3_19", "3_20", "3_21", "3_22", "3_23", "3_24", "3_25", "3_26", "3_27", "3_28", "3_29", "3_30", "3_31", "3_32", "3_33", "4_0", "4_1", "4_2", "4_3", "4_4", "4_5", "4_6", "4_7", "4_8", "4_9", "4_10", "4_11", "4_12", "4_13", "4_14", "4_15", "4_16", "4_17", "4_18", "4_19", "4_20", "4_21", "4_22", "4_23", "4_24", "4_25", "4_26", "4_27", "4_28", "4_29", "4_30", "4_31", "4_32", "4_33", "5_0", "5_1", "5_2", "5_3", "5_4", "5_5", "5_6", "5_7", "5_8", "5_9", "5_10", "5_11", "5_12", "5_13", "5_14", "5_15", "5_16", "5_17", "5_18", "5_19", "5_20", "5_21", "5_22", "5_23", "5_24", "5_25", "5_26", "5_27", "5_28", "5_29", "5_30", "5_31", "5_32", "5_33", "5_34", "5_35", "5_36", "5_37", "6_0", "6_1", "6_2", "6_3", "6_4", "6_5", "6_6", "6_7", "6_8", "6_9", "6_10", "6_11", "6_12", "6_13", "6_14", "6_15", "6_16", "6_17", "6_18", "6_19", "6_20", "6_21", "6_22", "6_23", "6_24", "6_25", "6_26", "6_27", "6_28", "6_29", "6_30", "6_31", "6_32", "6_33", "6_34", "6_35", "6_36", "6_37", "7_0", "7_1", "7_2", "7_3", "7_4", "8_0", "8_1", "8_2", "8_3", "8_4", "9_0", "9_1", "9_2", "9_3", "9_4", "10_0", "10_1", "10_2", "10_3", "10_4", "10_5", "10_6", "10_7", "10_8", "10_9", "10_10", "10_11", "10_12", "10_13", "10_14", "10_15", "10_16", "10_17", "10_18", "10_19", "10_20", "10_21", "10_22", "10_23", "10_24", "10_25", "10_26", "10_27", "10_28", "10_29", "10_30", "10_31", "10_32", "10_33", "10_34", "10_35", "10_36", "10_37", "10_38", "10_39", "10_40", "10_41", "10_42", "11_0", "11_1", "11_2", "11_3", "11_4", "11_5", "11_6", "11_7", "11_8", "11_9", "11_10", "11_11", "11_12", "11_13", "11_14", "11_15", "11_16", "11_17", "11_18", "11_19", "11_20", "12_0", "12_1", "12_2", "12_3", "12_4", "12_5", "12_6", "12_7", "12_8", "12_9", "12_10", "12_11", "12_12", "12_13", "12_14", "12_15", "12_16", "12_17", "12_18", "12_19", "12_20", "13_0", "13_1", "13_2", "13_3", "13_4", "13_5", "13_6", "13_7", "13_8", "13_9", "13_10", "13_11", "13_12", "13_13", "13_14", "13_15", "13_16", "13_17", "13_18", "13_19", "13_20", "14_0", "14_1", "14_2", "14_3", "14_4", "14_5", "14_6", "14_7", "14_8", "14_9", "14_10", "14_11", "14_12", "14_13", "14_14", "14_15", "14_16", "14_17", "14_18", "14_19", "14_20", "15_0", "15_1", "15_2", "15_3", "15_4", "15_5", "15_6", "15_7", "15_8", "15_9", "15_10", "15_11", "15_12", "15_13", "15_14", "15_15", "15_16", "15_17", "15_18", "15_19", "15_20", "16_0", "16_1", "16_2", "16_3", "16_4", "16_5", "16_6", "16_7", "16_8", "16_9", "16_10", "16_11", "16_12", "16_13", "16_14", "16_15", "16_16", "16_17", "16_18", "16_19", "16_20", "17_0", "17_1", "17_2", "17_3", "17_4", "17_5", "17_6", "17_7", "17_8", "17_9", "17_10", "17_11", "17_12", "17_13", "17_14", "17_15", "17_16", "17_17", "17_18", "17_19", "17_20", "18_0", "18_1", "18_2", "18_3", "18_4", "18_5", "18_6", "18_7", "18_8", "18_9", "18_10", "18_11", "18_12", "18_13", "18_14", "18_15", "18_16", "18_17", "18_18", "18_19", "18_20", "19_0", "19_1", "19_2", "19_3", "19_4", "19_5", "19_6", "19_7", "19_8", "19_9", "19_10", "19_11", "19_12", "19_13", "19_14", "19_15", "19_16", "19_17", "19_18", "19_19", "19_20", "20_0", "20_1", "20_2", "20_3", "20_4", "20_5", "20_6", "20_7", "20_8", "20_9", "20_10", "20_11", "20_12", "20_13", "20_14", "20_15", "20_16", "20_17", "20_18", "20_19", "20_20", "21_0", "21_1", "21_2", "21_3", "21_4", "21_5", "21_6", "21_7", "21_8", "21_9", "21_10", "21_11", "21_12", "21_13", "21_14", "21_15", "21_16", "21_17", "21_18", "21_19", "21_20", "22_0", "22_1", "22_2", "22_3", "22_4", "22_5", "22_6", "22_7", "22_8", "22_9", "22_10", "22_11", "22_12", "22_13", "22_14", "22_15", "22_16", "22_17", "22_18", "22_19", "22_20", "23_0", "23_1", "23_2", "23_3", "23_4", "23_5", "23_6", "23_7", "23_8", "23_9", "23_10", "23_11", "23_12", "23_13", "23_14", "23_15", "23_16", "23_17", "23_18", "23_19", "23_20", "24_0", "24_1", "24_2", "24_3", "24_4", "24_5", "24_6", "24_7", "24_8", "24_9", "24_10", "24_11", "24_12", "24_13", "24_14", "24_15", "24_16", "24_17", "24_18", "24_19", "24_20", "25_0", "25_1", "25_2", "25_3", "25_4", "25_5", "25_6", "25_7", "25_8", "25_9", "25_10", "25_11", "25_12", "25_13", "25_14", "25_15", "25_16", "25_17", "25_18", "25_19", "25_20", "26_0", "26_1", "26_2", "26_3", "26_4", "26_5", "26_6", "26_7", "26_8", "26_9", "26_10", "26_11", "26_12", "26_13", "26_14", "26_15", "26_16", "26_17", "26_18", "26_19", "26_20", "27_0", "27_1", "27_2", "27_3", "27_4", "27_5", "27_6", "27_7", "27_8", "27_9", "27_10", "27_11", "27_12", "27_13", "27_14", "27_15", "27_16", "27_17", "27_18", "27_19", "27_20", "28_0", "28_1", "28_2", "28_3", "28_4", "28_5", "28_6", "28_7", "28_8", "28_9", "28_10", "28_11", "28_12", "28_13", "28_14", "28_15", "28_16", "28_17", "28_18", "28_19", "28_20", "29_0", "29_1", "29_2", "29_3", "29_4", "29_5", "29_6", "29_7", "29_8", "29_9", "29_10", "29_11", "29_12", "29_13", "29_14", "29_15", "29_16", "29_17", "29_18", "29_19", "29_20", "30_0", "30_1", "30_2", "30_3", "30_4", "30_5", "30_6", "30_7", "30_8", "30_9", "30_10", "30_11", "30_12", "30_13", "30_14", "30_15", "30_16", "30_17", "30_18", "30_19", "30_20", "31_0", "31_1", "31_2", "31_3", "31_4", "31_5", "31_6", "31_7", "31_8", "31_9", "31_10", "31_11", "31_12", "31_13", "31_14", "31_15", "31_16", "31_17", "31_18", "31_19", "31_20", "32_0", "32_1", "32_2", "32_3", "32_4", "32_5", "32_6", "32_7", "32_8", "32_9", "32_10", "32_11", "32_12", "32_13", "32_14", "32_15", "32_16", "32_17", "32_18", "32_19", "32_20", "33_0", "33_1", "33_2", "33_3", "33_4", "33_5", "33_6", "33_7", "33_8", "33_9", "33_10", "33_11", "33_12", "33_13", "33_14", "33_15", "33_16", "33_17", "33_18", "33_19", "33_20", "34_0", "34_1", "34_2", "34_3", "34_4", "34_5", "34_6", "34_7", "34_8", "34_9", "34_10", "34_11", "34_12", "34_13", "34_14", "34_15", "34_16", "34_17", "34_18", "34_19", "34_20", "34_21", "34_22", "34_23", "34_24", "34_25", "34_26", "34_27", "34_28", "34_29", "34_30", "34_31", "34_32", "34_33", "34_34", "35_0", "35_1", "35_2", "35_3", "35_4", "35_5", "35_6", "35_7", "35_8", "35_9", "35_10", "35_11", "35_12", "35_13", "35_14", "35_15", "35_16", "35_17", "35_18", "35_19", "35_20", "35_21", "35_22", "35_23", "35_24", "35_25", "35_26", "35_27", "35_28", "35_29", "35_30", "35_31", "35_32", "35_33", "35_34", "36_0", "36_1", "36_2", "36_3", "36_4", "36_5", "36_6", "36_7", "36_8", "36_9", "36_10", "36_11", "36_12", "36_13", "36_14", "36_15", "36_16", "36_17", "36_18", "36_19", "36_20", "36_21", "36_22", "36_23", "36_24", "36_25", "36_26", "36_27", "36_28", "36_29", "36_30", "36_31", "36_32", "36_33", "36_34", "37_0", "37_1", "37_2", "37_3", "37_4", "37_5", "37_6", "37_7", "37_8", "37_9", "37_10", "37_11", "37_12", "37_13", "37_14", "37_15", "37_16", "37_17", "37_18", "37_19", "37_20", "37_21", "37_22", "37_23", "37_24", "37_25", "37_26", "37_27", "37_28", "37_29", "37_30", "37_31", "37_32", "37_33", "37_34", "38_0", "38_1", "38_2", "38_3", "38_4", "38_5", "38_6", "38_7", "38_8", "38_9", "38_10", "38_11", "38_12", "38_13", "38_14", "38_15", "38_16", "38_17", "38_18", "38_19", "38_20", "38_21", "38_22", "38_23", "38_24", "38_25", "38_26", "38_27", "38_28", "38_29", "38_30", "38_31", "38_32", "38_33", "38_34", "39_0", "39_1", "39_2", "39_3", "39_4", "39_5", "39_6", "39_7", "39_8", "39_9", "39_10", "39_11", "39_12", "39_13", "39_14", "39_15", "39_16", "39_17", "39_18", "39_19", "39_20", "39_21", "39_22", "39_23", "39_24", "39_25", "39_26", "39_27", "39_28", "39_29", "39_30", "39_31", "39_32", "39_33", "39_34", "40_0", "40_1", "40_2", "40_3", "40_4", "40_5", "40_6", "40_7", "40_8", "40_9", "40_10", "40_11", "40_12", "40_13", "40_14", "40_15", "40_16", "41_0", "41_1", "41_2", "41_3", "41_4", "41_5", "41_6", "41_7", "41_8", "41_9", "41_10", "41_11", "41_12", "41_13", "41_14", "41_15", "41_16", "42_0", "42_1", "42_2", "42_3", "42_4", "42_5", "42_6", "42_7", "42_8", "42_9", "42_10", "42_11", "42_12", "42_13", "42_14", "42_15", "42_16", "42_17", "42_18", "42_19", "42_20", "42_21", "42_22", "42_23", "42_24", "42_25", "42_26", "42_27", "42_28", "42_29", "42_30", "42_31", "42_32", "42_33", "43_0", "43_1", "43_2", "43_3", "43_4", "43_5", "43_6", "43_7", "43_8", "43_9", "43_10", "43_11", "43_12", "43_13", "43_14", "43_15", "43_16", "43_17", "43_18", "43_19", "43_20", "43_21", "43_22", "43_23", "43_24", "43_25", "43_26", "43_27", "43_28", "43_29", "43_30", "43_31", "43_32", "43_33", "44_0", "44_1", "44_2", "44_3", "44_4", "44_5", "44_6", "44_7", "44_8", "44_9", "44_10", "44_11", "44_12", "44_13", "44_14", "44_15", "44_16", "44_17", "44_18", "44_19", "44_20", "44_21", "44_22", "44_23", "44_24", "44_25", "44_26", "44_27", "44_28", "44_29", "44_30", "44_31", "44_32", "44_33", "45_0", "45_1", "45_2", "45_3", "45_4", "45_5", "45_6", "45_7", "45_8", "45_9", "45_10", "45_11", "45_12", "45_13", "45_14", "45_15", "45_16", "45_17", "45_18", "45_19", "45_20", "45_21", "45_22", "45_23", "45_24", "45_25", "45_26", "45_27", "45_28", "45_29", "45_30", "45_31", "45_32", "45_33", "46_0", "46_1", "46_2", "46_3", "46_4", "46_5", "46_6", "46_7", "46_8", "46_9", "46_10", "46_11", "46_12", "46_13", "46_14", "46_15", "46_16", "46_17", "46_18", "46_19", "46_20", "46_21", "46_22", "46_23", "46_24", "46_25", "46_26", "46_27", "46_28", "46_29", "46_30", "46_31", "46_32", "46_33", "47_0", "47_1", "47_2", "47_3", "47_4", "47_5", "47_6", "47_7", "47_8", "47_9", "47_10", "47_11", "47_12", "47_13", "47_14", "47_15", "47_16", "47_17", "47_18", "47_19", "47_20", "47_21", "47_22", "47_23", "47_24", "47_25", "47_26", "47_27", "47_28", "47_29", "47_30", "47_31", "47_32", "47_33", "48_0", "48_1", "48_2", "48_3", "48_4", "48_5", "48_6", "48_7", "48_8", "48_9", "49_0", "49_1", "49_2", "49_3", "49_4", "49_5", "49_6", "49_7", "49_8", "49_9", "49_10", "49_11", "49_12", "49_13", "49_14", "49_15", "49_16", "49_17", "49_18", "49_19", "49_20", "49_21", "49_22", "49_23", "49_24", "49_25", "49_26", "49_27", "49_28", "49_29", "49_30", "49_31", "49_32", "49_33", "49_34", "49_35", "49_36", "49_37", "50_0", "50_1", "50_2", "50_3", "50_4", "50_5", "50_6", "50_7", "50_8", "50_9", "50_10", "50_11", "51_0", "51_1", "51_2", "51_3", "51_4", "51_5", "51_6", "51_7", "51_8", "51_9", "51_10", "51_11", "52_0", "52_1", "52_2", "52_3", "52_4", "52_5", "52_6", "52_7", "52_8", "52_9", "52_10", "52_11", "53_0", "53_1", "53_2", "53_3", "53_4", "53_5", "53_6", "53_7", "53_8", "53_9", "53_10", "53_11", "53_12", "53_13", "53_14", "53_15", "53_16", "53_17", "53_18", "53_19", "53_20", "53_21", "53_22", "53_23", "53_24", "53_25", "53_26", "53_27", "53_28", "53_29", "53_30", "53_31", "53_32", "53_33", "53_34", "53_35", "53_36", "53_37", "54_0", "54_1", "54_2", "54_3", "54_4", "54_5", "54_6", "54_7", "54_8", "54_9", "54_10", "54_11", "54_12", "54_13", "54_14", "54_15", "54_16", "54_17", "54_18", "54_19", "54_20", "54_21", "54_22", "54_23", "54_24", "54_25", "54_26", "54_27", "54_28", "54_29", "54_30", "54_31", "54_32", "54_33", "54_34", "54_35", "54_36", "54_37", "55_0", "55_1", "55_2", "55_3", "55_4", "55_5", "55_6", "55_7", "55_8", "55_9", "55_10", "55_11", "55_12", "55_13", "55_14", "55_15", "55_16", "55_17", "55_18", "55_19", "55_20", "55_21", "55_22", "55_23", "55_24", "55_25", "55_26", "55_27", "55_28", "55_29", "55_30", "55_31", "55_32", "55_33", "55_34", "55_35", "55_36", "55_37", "56_0", "56_1", "56_2", "56_3", "56_4", "56_5", "56_6", "56_7", "56_8", "56_9", "56_10", "56_11", "56_12", "56_13", "56_14", "56_15", "56_16", "56_17", "56_18", "57_0", "57_1", "57_2", "57_3", "57_4", "57_5", "57_6", "57_7", "57_8", "57_9", "57_10", "57_11", "57_12", "57_13", "57_14", "57_15", "57_16", "57_17", "57_18", "57_19", "57_20", "57_21", "57_22", "57_23", "57_24", "57_25", "57_26", "57_27", "57_28", "57_29", "57_30", "57_31", "58_0", "58_1", "58_2", "58_3", "58_4", "58_5", "58_6", "58_7", "58_8", "58_9", "58_10", "58_11", "58_12", "58_13", "58_14", "58_15", "58_16", "58_17", "58_18", "58_19", "58_20", "58_21", "58_22", "58_23", "58_24", "58_25", "58_26", "58_27", "58_28", "58_29", "58_30", "58_31", "59_0", "59_1", "59_2", "59_3", "59_4", "59_5", "59_6", "59_7", "59_8", "59_9", "59_10", "59_11", "59_12", "59_13", "59_14", "59_15", "59_16", "59_17", "59_18", "59_19", "59_20", "59_21", "59_22", "59_23", "59_24", "59_25", "59_26", "59_27", "59_28", "59_29", "59_30", "59_31", "60_0", "60_1", "60_2", "60_3", "60_4", "60_5", "60_6", "60_7", "60_8", "60_9", "60_10", "60_11", "60_12", "60_13", "60_14", "60_15", "60_16", "60_17", "60_18", "60_19", "60_20", "60_21", "60_22", "60_23", "60_24", "60_25", "60_26", "60_27", "60_28", "60_29", "60_30", "60_31", "61_0", "61_1", "61_2", "61_3", "61_4", "61_5", "61_6", "61_7", "61_8", "61_9", "61_10", "61_11", "61_12", "61_13", "61_14", "61_15", "61_16", "61_17", "61_18", "61_19", "61_20", "61_21", "61_22", "61_23", "61_24", "61_25", "61_26", "61_27", "61_28", "61_29", "61_30", "61_31", "62_0", "62_1", "62_2", "62_3", "62_4", "62_5", "62_6", "62_7", "62_8", "62_9", "62_10", "62_11", "62_12", "62_13", "62_14", "62_15", "62_16", "62_17", "62_18", "62_19", "62_20", "62_21", "62_22", "62_23", "62_24", "62_25", "62_26", "62_27", "62_28", "62_29", "62_30", "62_31", "63_0", "63_1", "63_2", "63_3", "63_4", "63_5", "63_6", "63_7", "63_8", "63_9", "63_10", "63_11", "63_12", "63_13", "63_14", "63_15", "63_16", "63_17", "63_18", "63_19", "63_20", "63_21", "63_22", "63_23", "63_24", "63_25", "63_26", "63_27", "63_28", "63_29", "63_30", "63_31", "64_0", "64_1", "64_2", "64_3", "64_4", "64_5", "64_6", "64_7", "64_8", "64_9", "64_10", "64_11", "64_12", "64_13", "64_14", "64_15", "64_16", "64_17", "64_18", "64_19", "64_20", "64_21", "64_22", "64_23", "64_24", "64_25", "64_26", "64_27", "64_28", "64_29", "64_30", "64_31", "65_0", "65_1", "65_2", "65_3", "65_4", "65_5", "65_6", "65_7", "65_8", "65_9", "65_10", "65_11", "65_12", "65_13", "65_14", "65_15", "65_16", "65_17", "65_18", "65_19", "65_20", "65_21", "65_22", "65_23", "65_24", "65_25", "65_26", "65_27", "65_28", "65_29", "65_30", "65_31", "66_0", "66_1", "66_2", "66_3", "66_4", "66_5", "66_6", "66_7", "66_8", "66_9", "66_10", "66_11", "66_12", "66_13", "66_14", "66_15", "66_16", "66_17", "66_18", "66_19", "66_20", "66_21", "66_22", "66_23", "66_24", "66_25", "66_26", "66_27", "66_28", "66_29", "66_30", "66_31", "67_0", "67_1", "67_2", "67_3", "67_4", "67_5", "67_6", "67_7", "67_8", "67_9", "67_10", "67_11", "67_12", "67_13", "67_14", "67_15", "67_16", "67_17", "67_18", "67_19", "67_20", "67_21", "67_22", "67_23", "67_24", "67_25", "67_26", "67_27", "67_28", "67_29", "67_30", "67_31", "68_0", "68_1", "68_2", "68_3", "68_4", "68_5", "68_6", "68_7", "68_8", "68_9", "68_10", "68_11", "68_12", "68_13", "68_14", "68_15", "68_16", "68_17", "68_18", "68_19", "68_20", "68_21", "68_22", "68_23", "68_24", "68_25", "68_26", "68_27", "68_28", "68_29", "68_30", "68_31", "69_0", "69_1", "69_2", "69_3", "69_4", "69_5", "69_6", "69_7", "69_8", "69_9", "69_10", "69_11", "69_12", "69_13", "69_14", "69_15", "69_16", "69_17", "69_18", "69_19", "69_20", "69_21", "69_22", "69_23", "69_24", "69_25", "69_26", "69_27", "69_28", "69_29", "69_30", "69_31", "70_0", "70_1", "70_2", "70_3", "70_4", "70_5", "70_6", "70_7", "70_8", "70_9", "70_10", "70_11", "70_12", "70_13", "70_14", "70_15", "70_16", "70_17", "70_18", "70_19", "70_20", "70_21", "70_22", "70_23", "70_24", "70_25", "70_26", "70_27", "70_28", "70_29", "70_30", "70_31", "71_0", "71_1", "71_2", "71_3", "71_4", "71_5", "71_6", "71_7", "71_8", "71_9", "71_10", "71_11", "71_12", "71_13", "71_14", "71_15", "71_16", "71_17", "71_18", "71_19", "71_20", "71_21", "71_22", "71_23", "71_24", "71_25", "71_26", "71_27", "71_28", "71_29", "71_30", "71_31", "72_0", "72_1", "72_2", "72_3", "72_4", "72_5", "72_6", "72_7", "72_8", "72_9", "72_10", "72_11", "72_12", "72_13", "72_14", "72_15", "72_16", "72_17", "72_18", "72_19", "72_20", "72_21", "72_22", "72_23", "72_24", "72_25", "72_26", "72_27", "72_28", "72_29", "72_30", "72_31", "72_32", "72_33", "72_34", "72_35", "72_36", "72_37", "72_38", "72_39", "72_40", "72_41", "72_42", "72_43", "72_44", "72_45", "72_46", "72_47", "72_48", "72_49", "72_50", "72_51", "72_52", "72_53", "72_54", "72_55", "73_0", "73_1", "73_2", "73_3", "73_4", "73_5", "73_6", "73_7", "73_8", "73_9", "73_10", "73_11", "73_12", "73_13", "73_14", "73_15", "73_16", "73_17", "73_18", "73_19", "73_20", "73_21", "73_22", "73_23", "73_24", "73_25", "73_26", "73_27", "73_28", "73_29", "73_30", "73_31", "73_32", "73_33", "73_34", "73_35", "73_36", "73_37", "73_38", "73_39", "73_40", "73_41", "73_42", "73_43", "73_44", "73_45", "74_0", "74_1", "74_2", "74_3", "74_4", "74_5", "74_6", "74_7", "74_8", "74_9", "74_10", "74_11", "74_12", "74_13", "74_14", "74_15", "74_16", "74_17", "74_18", "74_19", "74_20", "74_21", "75_0", "75_1", "75_2", "75_3", "75_4", "75_5", "75_6", "75_7", "75_8", "75_9", "75_10", "75_11", "75_12", "75_13", "75_14", "75_15", "75_16", "75_17", "75_18", "75_19", "75_20", "75_21", "76_0", "76_1", "76_2", "76_3", "76_4", "76_5", "76_6", "76_7", "76_8", "76_9", "76_10", "76_11", "76_12", "76_13", "76_14", "76_15", "76_16", "76_17", "76_18", "76_19", "76_20", "76_21", "77_0", "77_1", "77_2", "77_3", "77_4", "77_5", "77_6", "77_7", "77_8", "77_9", "77_10", "77_11", "77_12", "77_13", "77_14", "77_15", "77_16", "77_17", "77_18", "77_19", "77_20", "77_21", "78_0", "78_1", "78_2", "78_3", "78_4", "78_5", "78_6", "78_7", "78_8", "78_9", "78_10", "78_11", "78_12", "78_13", "78_14", "78_15", "78_16", "78_17", "78_18", "78_19", "78_20", "78_21", "78_22", "78_23", "78_24", "78_25", "78_26", "78_27", "78_28", "78_29", "78_30", "78_31", "78_32", "78_33", "78_34", "78_35", "78_36", "78_37", "78_38", "78_39", "79_0", "79_1", "79_2", "79_3", "79_4", "79_5", "79_6", "79_7", "79_8", "79_9", "79_10", "79_11", "79_12", "79_13", "79_14", "79_15", "79_16", "79_17", "79_18", "79_19", "79_20", "79_21", "79_22", "79_23", "79_24", "79_25", "79_26", "79_27", "79_28", "79_29", "79_30", "79_31", "79_32", "79_33", "79_34", "79_35", "79_36", "79_37", "79_38", "79_39", "80_0", "80_1", "80_2", "80_3", "80_4", "80_5", "80_6", "80_7", "80_8", "80_9", "80_10", "80_11", "80_12", "80_13", "80_14", "80_15", "80_16", "80_17", "80_18", "80_19", "80_20", "80_21", "80_22", "80_23", "80_24", "80_25", "80_26", "80_27", "80_28", "80_29", "80_30", "80_31", "80_32", "80_33", "80_34", "80_35", "80_36", "80_37", "80_38", "80_39", "81_0", "81_1", "81_2", "81_3", "81_4", "81_5", "81_6", "81_7", "81_8", "81_9", "81_10", "81_11", "81_12", "81_13", "81_14", "81_15", "81_16", "81_17", "81_18", "81_19", "81_20", "81_21", "81_22", "81_23", "81_24", "81_25", "81_26", "81_27", "81_28", "81_29", "81_30", "81_31", "81_32", "81_33", "81_34", "81_35", "81_36", "81_37", "81_38", "81_39", "82_0", "82_1", "82_2", "82_3", "82_4", "82_5", "82_6", "82_7", "82_8", "82_9", "82_10", "82_11", "82_12", "82_13", "82_14", "82_15", "82_16", "82_17", "82_18", "82_19", "82_20", "82_21", "82_22", "82_23", "82_24", "82_25", "82_26", "82_27", "82_28", "82_29", "82_30", "82_31", "82_32", "82_33", "82_34", "82_35", "82_36", "82_37", "82_38", "82_39", "83_0", "83_1", "83_2", "83_3", "83_4", "83_5", "83_6", "83_7", "83_8", "83_9", "83_10", "83_11", "83_12", "83_13", "83_14", "83_15", "83_16", "83_17", "83_18", "83_19", "83_20", "83_21", "83_22", "83_23", "83_24", "83_25", "83_26", "83_27", "83_28", "83_29", "83_30", "83_31", "83_32", "83_33", "83_34", "83_35", "83_36", "83_37", "83_38", "83_39", "84_0", "84_1", "84_2", "84_3", "84_4", "84_5", "84_6", "84_7", "84_8", "84_9", "84_10", "84_11", "84_12", "84_13", "84_14", "84_15", "84_16", "84_17", "84_18", "84_19", "84_20", "84_21", "84_22", "84_23", "84_24", "84_25", "84_26", "84_27", "84_28", "84_29", "84_30", "84_31", "84_32", "84_33", "84_34", "84_35", "84_36", "84_37", "84_38", "84_39", "85_0", "85_1", "85_2", "85_3", "85_4", "85_5", "85_6", "85_7", "85_8", "85_9", "85_10", "85_11", "85_12", "85_13", "85_14", "85_15", "85_16", "85_17", "85_18", "85_19", "85_20", "85_21", "85_22", "85_23", "85_24", "85_25", "85_26", "85_27", "85_28", "85_29", "85_30", "85_31", "85_32", "85_33", "85_34", "85_35", "85_36", "85_37", "85_38", "85_39", "86_0", "86_1", "86_2", "86_3", "86_4", "86_5", "86_6", "86_7", "86_8", "86_9", "86_10", "86_11", "86_12", "86_13", "86_14", "86_15", "86_16", "86_17", "86_18", "86_19", "86_20", "86_21", "86_22", "86_23", "86_24", "86_25", "86_26", "87_0", "87_1", "87_2", "87_3", "87_4", "87_5", "87_6", "87_7", "87_8", "87_9", "87_10", "87_11", "87_12", "87_13", "87_14", "87_15", "87_16", "87_17", "87_18", "87_19", "87_20", "87_21", "87_22", "87_23", "87_24", "87_25", "87_26", "88_0", "88_1", "88_2", "88_3", "88_4", "88_5", "88_6", "88_7", "88_8", "88_9", "88_10", "88_11", "88_12", "88_13", "88_14", "88_15", "88_16", "88_17", "88_18", "88_19", "88_20", "88_21", "88_22", "88_23", "88_24", "88_25", "88_26", "89_0", "89_1", "89_2", "89_3", "89_4", "89_5", "89_6", "89_7", "89_8", "89_9", "89_10", "89_11", "89_12", "89_13", "89_14", "89_15", "89_16", "89_17", "89_18", "89_19", "89_20", "89_21", "89_22", "89_23", "89_24", "89_25", "89_26", "90_0", "90_1", "90_2", "90_3", "90_4", "90_5", "90_6", "90_7", "90_8", "90_9", "90_10", "90_11", "90_12", "90_13", "90_14", "90_15", "90_16", "90_17", "90_18", "90_19", "90_20", "90_21", "90_22", "90_23", "90_24", "90_25", "90_26", "91_0", "91_1", "91_2", "91_3", "91_4", "91_5", "91_6", "91_7", "91_8", "91_9", "91_10", "91_11", "91_12", "91_13", "91_14", "91_15", "91_16", "91_17", "91_18", "91_19", "91_20", "91_21", "91_22", "91_23", "91_24", "91_25", "91_26", "92_0", "92_1", "92_2", "92_3", "92_4", "92_5", "92_6", "92_7", "92_8", "92_9", "92_10", "92_11", "92_12", "92_13", "92_14", "92_15", "92_16", "92_17", "92_18", "92_19", "92_20", "92_21", "92_22", "92_23", "92_24", "92_25", "92_26", "93_0", "93_1", "93_2", "93_3", "93_4", "93_5", "93_6", "93_7", "93_8", "93_9", "93_10", "93_11", "93_12", "93_13", "93_14", "93_15", "93_16", "93_17", "93_18", "93_19", "93_20", "93_21", "93_22", "93_23", "93_24", "93_25", "93_26", "94_0", "94_1", "94_2", "94_3", "94_4", "94_5", "94_6", "94_7", "94_8", "94_9", "94_10", "94_11", "94_12", "94_13", "94_14", "94_15", "94_16", "94_17", "94_18", "94_19", "94_20", "94_21", "94_22", "94_23", "94_24", "94_25", "94_26", "95_0", "95_1", "95_2", "95_3", "95_4", "95_5", "95_6", "95_7", "95_8", "95_9", "95_10", "95_11", "95_12", "95_13", "95_14", "95_15", "95_16", "95_17", "95_18", "95_19", "95_20", "95_21", "95_22", "95_23", "95_24", "95_25", "95_26", "96_0", "96_1", "96_2", "96_3", "96_4", "96_5", "96_6", "96_7", "96_8", "96_9", "96_10", "96_11", "96_12", "96_13", "96_14", "96_15", "96_16", "96_17", "96_18", "96_19", "96_20", "96_21", "96_22", "96_23", "96_24", "96_25", "96_26", "97_0", "97_1", "97_2", "97_3", "97_4", "97_5", "97_6", "97_7", "97_8", "97_9", "97_10", "97_11", "97_12", "97_13", "97_14", "97_15", "97_16", "97_17", "97_18", "97_19", "97_20", "97_21", "97_22", "97_23", "97_24", "97_25", "97_26", "98_0", "98_1", "98_2", "98_3", "98_4", "98_5", "98_6", "98_7", "98_8", "98_9", "98_10", "98_11", "98_12", "98_13", "98_14", "98_15", "98_16", "98_17", "98_18", "98_19", "98_20", "98_21", "98_22", "98_23", "98_24", "98_25", "98_26", "99_0", "99_1", "99_2", "99_3", "99_4", "99_5", "99_6", "99_7", "99_8", "99_9", "99_10", "99_11", "99_12", "99_13", "99_14", "99_15", "99_16", "99_17", "99_18", "99_19", "99_20", "99_21", "99_22", "99_23", "99_24", "99_25", "99_26", "100_0", "100_1", "100_2", "100_3", "100_4", "100_5", "100_6", "100_7", "100_8", "100_9", "100_10", "100_11", "100_12", "100_13", "100_14", "100_15", "100_16", "100_17", "100_18", "100_19", "100_20", "100_21", "100_22", "100_23", "100_24", "100_25", "100_26", "101_0", "101_1", "101_2", "101_3", "101_4", "101_5", "101_6", "101_7", "101_8", "101_9", "101_10", "101_11", "101_12", "101_13", "101_14", "101_15", "102_0", "102_1", "102_2", "102_3", "102_4", "102_5", "102_6", "102_7", "102_8", "102_9", "102_10", "102_11", "102_12", "102_13", "102_14", "102_15", "102_16", "102_17", "102_18", "102_19", "102_20", "102_21", "102_22", "102_23", "102_24", "102_25", "103_0", "103_1", "103_2", "103_3", "103_4", "103_5", "103_6", "103_7", "103_8", "103_9", "103_10", "103_11", "103_12", "103_13", "103_14", "103_15", "103_16", "103_17", "103_18", "103_19", "103_20", "103_21", "103_22", "103_23", "103_24", "103_25", "104_0", "104_1", "104_2", "104_3", "104_4", "104_5", "104_6", "104_7", "104_8", "104_9", "104_10", "104_11", "104_12", "104_13", "104_14", "104_15", "104_16", "104_17", "104_18", "104_19", "104_20", "104_21", "104_22", "104_23", "104_24", "104_25", "105_0", "105_1", "105_2", "105_3", "105_4", "105_5", "105_6", "105_7", "105_8", "105_9", "105_10", "105_11", "105_12", "105_13", "105_14", "105_15", "105_16", "105_17", "105_18", "105_19", "105_20", "105_21", "105_22", "105_23", "105_24", "105_25", "106_0", "106_1", "106_2", "106_3", "106_4", "106_5", "106_6", "106_7", "106_8", "106_9", "106_10", "106_11", "106_12", "106_13", "106_14", "106_15", "106_16", "106_17", "106_18", "106_19", "106_20", "106_21", "106_22", "106_23", "106_24", "106_25", "107_0", "107_1", "107_2", "107_3", "107_4", "107_5", "107_6", "107_7", "107_8", "107_9", "107_10", "107_11", "107_12", "107_13", "107_14", "107_15", "107_16", "107_17", "107_18", "107_19", "107_20", "107_21", "107_22", "107_23", "107_24", "107_25", "108_0", "108_1", "108_2", "108_3", "108_4", "108_5", "108_6", "108_7", "108_8", "108_9", "108_10", "108_11", "108_12", "108_13", "108_14", "108_15", "108_16", "108_17", "108_18", "108_19", "108_20", "108_21", "108_22", "108_23", "108_24", "108_25", "109_0", "109_1", "109_2", "109_3", "109_4", "109_5", "109_6", "109_7", "109_8", "110_0", "110_1", "110_2", "110_3", "110_4", "110_5", "110_6", "110_7", "110_8", "110_9", "110_10", "110_11", "110_12", "110_13", "110_14", "110_15", "110_16", "110_17", "110_18", "110_19", "110_20", "110_21", "110_22", "110_23", "110_24", "110_25", "110_26", "110_27", "110_28", "110_29", "110_30", "110_31", "110_32", "110_33", "110_34", "110_35", "110_36", "110_37", "110_38", "110_39", "110_40", "111_0", "111_1", "111_2", "111_3", "111_4", "111_5", "111_6", "111_7", "111_8", "111_9", "111_10", "111_11", "111_12", "111_13", "111_14", "111_15", "111_16", "111_17", "111_18", "111_19", "111_20", "111_21", "111_22", "111_23", "111_24", "111_25", "111_26", "111_27", "111_28", "111_29", "111_30", "111_31", "111_32", "111_33", "111_34", "111_35", "111_36", "111_37", "111_38", "111_39", "111_40", "112_0", "112_1", "112_2", "112_3", "112_4", "112_5", "112_6", "112_7", "112_8", "112_9", "112_10", "112_11", "112_12", "112_13", "112_14", "112_15", "112_16", "112_17", "112_18", "112_19", "112_20", "112_21", "112_22", "112_23", "112_24", "112_25", "112_26", "112_27", "112_28", "112_29", "112_30", "112_31", "112_32", "112_33", "112_34", "112_35", "112_36", "112_37", "112_38", "112_39", "112_40", "113_0", "113_1", "113_2", "113_3", "113_4", "113_5", "113_6", "113_7", "113_8", "113_9", "113_10", "113_11", "113_12", "113_13", "113_14", "113_15", "113_16", "113_17", "113_18", "113_19", "113_20", "113_21", "113_22", "113_23", "113_24", "113_25", "113_26", "113_27", "113_28", "113_29", "113_30", "113_31", "113_32", "113_33", "113_34", "113_35", "113_36", "113_37", "113_38", "113_39", "113_40", "114_0", "114_1", "114_2", "114_3", "114_4", "114_5", "114_6", "114_7", "114_8", "114_9", "114_10", "114_11", "114_12", "114_13", "114_14", "114_15", "114_16", "114_17", "114_18", "115_0", "115_1", "115_2", "115_3", "115_4", "115_5", "115_6", "115_7", "115_8", "115_9", "115_10", "115_11", "115_12", "115_13", "115_14", "115_15", "115_16", "115_17", "115_18", "115_19", "115_20", "115_21", "115_22", "115_23", "115_24", "115_25", "115_26", "115_27", "115_28", "115_29", "115_30", "115_31", "115_32", "115_33", "115_34", "115_35", "115_36", "115_37", "115_38", "116_0", "116_1", "116_2", "116_3", "116_4", "116_5", "116_6", "116_7", "116_8", "116_9", "116_10", "116_11", "116_12", "116_13", "116_14", "116_15", "116_16", "116_17", "116_18", "116_19", "116_20", "116_21", "116_22", "116_23", "116_24", "116_25", "116_26", "116_27", "116_28", "116_29", "116_30", "116_31", "116_32", "116_33", "116_34", "116_35", "116_36", "116_37", "116_38", "117_0", "117_1", "117_2", "117_3", "117_4", "117_5", "117_6", "117_7", "117_8", "117_9", "117_10", "117_11", "117_12", "117_13", "117_14", "117_15", "117_16", "117_17", "117_18", "117_19", "117_20", "117_21", "117_22", "117_23", "117_24", "117_25", "117_26", "117_27", "117_28", "117_29", "117_30", "117_31", "117_32", "117_33", "117_34", "117_35", "117_36", "117_37", "117_38", "118_0", "118_1", "118_2", "118_3", "118_4", "118_5", "118_6", "118_7", "118_8", "118_9", "118_10", "118_11", "118_12", "118_13", "118_14", "118_15", "118_16", "118_17", "118_18", "118_19", "118_20", "118_21", "118_22", "118_23", "118_24", "118_25", "118_26", "118_27", "118_28", "118_29", "118_30", "118_31", "118_32", "118_33", "118_34", "118_35", "118_36", "118_37", "118_38", "119_0", "119_1", "119_2", "119_3", "119_4", "119_5", "119_6", "119_7", "119_8", "119_9", "119_10", "119_11", "119_12", "119_13", "119_14", "119_15", "119_16", "119_17", "119_18", "119_19", "119_20", "119_21", "119_22", "119_23", "119_24", "119_25", "119_26", "119_27", "119_28", "119_29", "119_30", "119_31", "119_32", "119_33", "119_34", "119_35", "119_36", "119_37", "119_38", "120_0", "120_1", "120_2", "120_3", "120_4", "120_5", "120_6", "120_7", "120_8", "120_9", "120_10", "120_11", "120_12", "120_13", "120_14", "120_15", "120_16", "120_17", "120_18", "120_19", "120_20", "120_21", "120_22", "120_23", "120_24", "120_25", "120_26", "120_27", "120_28", "120_29", "120_30", "120_31", "120_32", "120_33", "120_34", "120_35", "120_36", "120_37", "120_38", "121_0", "121_1", "121_2", "121_3", "121_4", "121_5", "121_6", "121_7", "121_8", "121_9", "121_10", "121_11", "121_12", "121_13", "121_14", "121_15", "121_16", "121_17", "121_18", "121_19", "121_20", "121_21", "121_22", "121_23", "121_24", "121_25", "121_26", "121_27", "121_28", "121_29", "121_30", "121_31", "121_32", "121_33", "121_34", "121_35", "121_36", "121_37", "121_38", "122_0", "122_1", "122_2", "122_3", "122_4", "122_5", "122_6", "122_7", "122_8", "122_9", "122_10", "122_11", "122_12", "122_13", "122_14", "122_15", "122_16", "122_17", "122_18", "122_19", "122_20", "122_21", "122_22", "122_23", "122_24", "122_25", "122_26", "122_27", "122_28", "122_29", "122_30", "122_31", "122_32", "122_33", "122_34", "122_35", "122_36", "122_37", "122_38", "123_0", "123_1", "123_2", "123_3", "123_4", "123_5", "123_6", "123_7", "123_8", "123_9", "123_10", "123_11", "123_12", "123_13", "123_14", "123_15", "123_16", "123_17", "123_18", "123_19", "123_20", "123_21", "123_22", "123_23", "123_24", "123_25", "123_26", "123_27", "123_28", "123_29", "123_30", "123_31", "123_32", "123_33", "123_34", "123_35", "123_36", "123_37", "123_38", "124_0", "124_1", "124_2", "124_3", "124_4", "124_5", "124_6", "124_7", "124_8", "124_9", "124_10", "124_11", "124_12", "124_13", "124_14", "124_15", "124_16", "124_17", "124_18", "124_19", "124_20", "124_21", "124_22", "124_23", "124_24", "124_25", "124_26", "124_27", "124_28", "124_29", "124_30", "124_31", "124_32", "124_33", "124_34", "124_35", "124_36", "124_37", "124_38", "125_0", "125_1", "125_2", "125_3", "125_4", "125_5", "125_6", "125_7", "125_8", "125_9", "125_10", "125_11", "125_12", "125_13", "125_14", "125_15", "125_16", "125_17", "125_18", "125_19", "125_20", "125_21", "125_22", "125_23", "125_24", "125_25", "125_26", "125_27", "125_28", "125_29", "125_30", "125_31", "125_32", "125_33", "125_34", "125_35", "125_36", "125_37", "125_38", "126_0", "126_1", "126_2", "126_3", "126_4", "126_5", "126_6", "126_7", "126_8", "126_9", "126_10", "126_11", "126_12", "126_13", "126_14", "126_15", "126_16", "126_17", "126_18", "126_19", "126_20", "126_21", "126_22", "126_23", "126_24", "126_25", "126_26", "126_27", "126_28", "126_29", "126_30", "126_31", "126_32", "126_33", "126_34", "126_35", "126_36", "126_37", "126_38", "127_0", "127_1", "127_2", "127_3", "127_4", "127_5", "127_6", "127_7", "127_8", "127_9", "127_10", "127_11", "127_12", "127_13", "127_14", "127_15", "127_16", "127_17", "127_18", "127_19", "127_20", "127_21", "127_22", "127_23", "127_24", "127_25", "127_26", "127_27", "127_28", "127_29", "127_30", "127_31", "127_32", "127_33", "127_34", "127_35", "127_36", "127_37", "127_38", "128_0", "128_1", "128_2", "128_3", "128_4", "128_5", "128_6", "128_7", "128_8", "128_9", "128_10", "128_11", "128_12", "128_13", "128_14", "128_15", "128_16", "128_17", "128_18", "128_19", "128_20", "128_21", "128_22", "128_23", "128_24", "128_25", "128_26", "128_27", "128_28", "128_29", "128_30", "128_31", "128_32", "128_33", "128_34", "128_35", "128_36", "128_37", "128_38", "129_0", "129_1", "129_2", "129_3", "129_4", "129_5", "129_6", "129_7", "129_8", "129_9", "129_10", "129_11", "129_12", "129_13", "129_14", "129_15", "129_16", "129_17", "129_18", "129_19", "129_20", "129_21", "129_22", "129_23", "129_24", "129_25", "129_26", "129_27", "129_28", "129_29", "129_30", "129_31", "129_32", "129_33", "129_34", "129_35", "129_36", "129_37", "129_38", "130_0", "130_1", "130_2", "130_3", "130_4", "130_5", "130_6", "130_7", "130_8", "130_9", "130_10", "130_11", "130_12", "130_13", "130_14", "130_15", "130_16", "130_17", "130_18", "130_19", "130_20", "130_21", "130_22", "130_23", "130_24", "130_25", "130_26", "130_27", "130_28", "130_29", "130_30", "130_31", "130_32", "130_33", "130_34", "130_35", "130_36", "130_37", "130_38", "131_0", "131_1", "131_2", "131_3", "131_4", "131_5", "131_6", "131_7", "131_8", "131_9", "131_10", "131_11", "131_12", "131_13", "131_14", "131_15", "131_16", "131_17", "131_18", "131_19", "131_20", "131_21", "131_22", "131_23", "131_24", "131_25", "131_26", "131_27", "131_28", "131_29", "131_30", "131_31", "131_32", "131_33", "131_34", "131_35", "131_36", "131_37", "131_38", "132_0", "132_1", "132_2", "132_3", "132_4", "132_5", "132_6", "132_7", "132_8", "132_9", "132_10", "132_11", "132_12", "132_13", "132_14", "132_15", "132_16", "132_17", "132_18", "132_19", "132_20", "132_21", "132_22", "132_23", "132_24", "132_25", "132_26", "132_27", "132_28", "132_29", "132_30", "132_31", "132_32", "132_33", "132_34", "132_35", "132_36", "132_37", "132_38", "133_0", "133_1", "133_2", "133_3", "133_4", "133_5", "133_6", "133_7", "133_8", "133_9", "133_10", "133_11", "133_12", "133_13", "133_14", "133_15", "133_16", "133_17", "133_18", "133_19", "133_20", "133_21", "133_22", "133_23", "133_24", "133_25", "133_26", "133_27", "133_28", "133_29", "133_30", "133_31", "133_32", "133_33", "133_34", "133_35", "133_36", "133_37", "133_38", "134_0", "134_1", "134_2", "134_3", "134_4", "134_5", "134_6", "134_7", "134_8", "134_9", "134_10", "134_11", "134_12", "134_13", "134_14", "134_15", "134_16", "134_17", "134_18", "134_19", "134_20", "134_21", "134_22", "134_23", "134_24", "134_25", "134_26", "134_27", "134_28", "134_29", "134_30", "134_31", "134_32", "134_33", "134_34", "134_35", "134_36", "134_37", "134_38", "135_0", "135_1", "135_2", "135_3", "135_4", "135_5", "135_6", "135_7", "135_8", "135_9", "135_10", "135_11", "135_12", "135_13", "135_14", "135_15", "135_16", "135_17", "135_18", "135_19", "135_20", "135_21", "135_22", "135_23", "135_24", "135_25", "135_26", "135_27", "135_28", "135_29", "135_30", "135_31", "135_32", "135_33", "135_34", "135_35", "135_36", "135_37", "135_38", "136_0", "136_1", "136_2", "136_3", "136_4", "136_5", "136_6", "136_7", "136_8", "136_9", "136_10", "136_11", "136_12", "136_13", "136_14", "136_15", "136_16", "136_17", "136_18", "136_19", "136_20", "136_21", "136_22", "136_23", "136_24", "136_25", "136_26", "136_27", "136_28", "136_29", "136_30", "136_31", "136_32", "136_33", "136_34", "136_35", "136_36", "136_37", "136_38", "137_0", "137_1", "137_2", "137_3", "137_4", "137_5", "137_6", "137_7", "137_8", "137_9", "137_10", "137_11", "137_12", "137_13", "137_14", "137_15", "137_16", "137_17", "137_18", "137_19", "137_20", "137_21", "137_22", "137_23", "137_24", "137_25", "137_26", "137_27", "137_28", "137_29", "137_30", "137_31", "137_32", "137_33", "137_34", "137_35", "137_36", "137_37", "137_38", "138_0", "138_1", "138_2", "138_3", "138_4", "138_5", "138_6", "138_7", "138_8", "138_9", "138_10", "138_11", "138_12", "138_13", "138_14", "138_15", "138_16", "138_17", "138_18", "138_19", "138_20", "138_21", "138_22", "138_23", "138_24", "138_25", "138_26", "138_27", "138_28", "138_29", "138_30", "138_31", "138_32", "138_33", "138_34", "138_35", "138_36", "138_37", "138_38", "139_0", "139_1", "139_2", "139_3", "139_4", "139_5", "139_6", "139_7", "139_8", "139_9", "139_10", "139_11", "139_12", "139_13", "139_14", "139_15", "139_16", "139_17", "139_18", "139_19", "139_20", "139_21", "139_22", "139_23", "139_24", "139_25", "139_26", "139_27", "139_28", "139_29", "139_30", "139_31", "139_32", "139_33", "139_34", "139_35", "139_36", "139_37", "139_38", "140_0", "140_1", "140_2", "140_3", "140_4", "140_5", "140_6", "140_7", "140_8", "140_9", "140_10", "140_11", "140_12", "140_13", "140_14", "140_15", "140_16", "140_17", "140_18", "140_19", "140_20", "140_21", "140_22", "140_23", "140_24", "140_25", "140_26", "140_27", "140_28", "140_29", "140_30", "140_31", "140_32", "140_33", "140_34", "140_35", "140_36", "140_37", "140_38", "141_0", "141_1", "141_2", "141_3", "141_4", "141_5", "141_6", "141_7", "141_8", "141_9", "141_10", "141_11", "141_12", "141_13", "141_14", "141_15", "141_16", "141_17", "141_18", "141_19", "141_20", "141_21", "141_22", "141_23", "141_24", "141_25", "141_26", "141_27", "141_28", "141_29", "141_30", "141_31", "141_32", "141_33", "141_34", "141_35", "141_36", "141_37", "141_38", "142_0", "142_1", "142_2", "142_3", "142_4", "142_5", "142_6", "142_7", "142_8", "142_9", "142_10", "142_11", "142_12", "142_13", "142_14", "142_15", "142_16", "142_17", "142_18", "142_19", "142_20", "142_21", "142_22", "142_23", "142_24", "142_25", "142_26", "142_27", "142_28", "142_29", "142_30", "142_31", "142_32", "142_33", "142_34", "142_35", "142_36", "142_37", "142_38", "143_0", "143_1", "143_2", "143_3", "143_4", "143_5", "143_6", "143_7", "143_8", "143_9", "143_10", "143_11", "143_12", "143_13", "143_14", "143_15", "143_16", "143_17", "143_18", "143_19", "143_20", "143_21", "143_22", "143_23", "143_24", "143_25", "143_26", "143_27", "143_28", "143_29", "143_30", "143_31", "143_32", "144_0", "144_1", "144_2", "144_3", "144_4", "144_5", "144_6", "144_7", "144_8", "144_9", "144_10", "144_11", "144_12", "144_13", "144_14", "144_15", "144_16", "144_17", "144_18", "144_19", "144_20", "144_21", "144_22", "144_23", "144_24", "144_25", "144_26", "144_27", "144_28", "144_29", "144_30", "144_31", "144_32", "145_0", "145_1", "145_2", "145_3", "145_4", "145_5", "145_6", "145_7", "145_8", "145_9", "145_10", "145_11", "145_12", "145_13", "145_14", "145_15", "145_16", "145_17", "145_18", "145_19", "145_20", "145_21", "145_22", "145_23", "145_24", "145_25", "145_26", "145_27", "145_28", "145_29", "145_30", "145_31", "145_32", "146_0", "146_1", "146_2", "146_3", "146_4", "146_5", "146_6", "146_7", "146_8", "146_9", "146_10", "146_11", "146_12", "146_13", "146_14", "146_15", "146_16", "146_17", "146_18", "146_19", "146_20", "146_21", "146_22", "146_23", "146_24", "146_25", "146_26", "146_27", "146_28", "146_29", "146_30", "146_31", "146_32", "147_0", "147_1", "147_2", "147_3", "147_4", "147_5", "147_6", "147_7", "147_8", "147_9", "147_10", "147_11", "147_12", "147_13", "147_14", "147_15", "147_16", "147_17", "147_18", "147_19", "147_20", "147_21", "147_22", "147_23", "147_24", "147_25", "147_26", "147_27", "147_28", "147_29", "147_30", "147_31", "147_32", "148_0", "148_1", "148_2", "148_3", "148_4", "148_5", "148_6", "148_7", "148_8", "148_9", "148_10", "148_11", "148_12", "148_13", "148_14", "148_15", "148_16", "148_17", "148_18", "148_19", "148_20", "148_21", "148_22", "148_23", "148_24", "148_25", "148_26", "148_27", "148_28", "148_29", "148_30", "148_31", "148_32", "149_0", "149_1", "149_2", "149_3", "149_4", "149_5", "149_6", "149_7", "149_8", "149_9", "149_10", "149_11", "149_12", "149_13", "149_14", "149_15", "149_16", "149_17", "149_18", "149_19", "149_20", "149_21", "149_22", "149_23", "149_24", "149_25", "149_26", "149_27", "149_28", "149_29", "149_30", "149_31", "149_32", "150_0", "150_1", "150_2", "150_3", "150_4", "150_5", "150_6", "150_7", "150_8", "150_9", "150_10", "150_11", "150_12", "150_13", "150_14", "150_15", "150_16", "150_17", "150_18", "150_19", "150_20", "150_21", "150_22", "150_23", "150_24", "150_25", "150_26", "150_27", "150_28", "150_29", "150_30", "150_31", "150_32", "151_0", "151_1", "151_2", "151_3", "151_4", "151_5", "151_6", "151_7", "151_8", "151_9", "151_10", "151_11", "151_12", "151_13", "151_14", "151_15", "151_16", "151_17", "151_18", "151_19", "151_20", "151_21", "151_22", "151_23", "151_24", "151_25", "151_26", "152_0", "152_1", "152_2", "152_3", "152_4", "152_5", "152_6", "152_7", "152_8", "152_9", "152_10", "152_11", "152_12", "152_13", "152_14", "152_15", "152_16", "152_17", "152_18", "153_0", "153_1", "153_2", "153_3", "153_4", "153_5", "153_6", "153_7", "153_8", "153_9", "153_10", "153_11", "153_12", "153_13", "153_14", "153_15", "153_16", "153_17", "153_18", "154_0", "154_1", "154_2", "154_3", "154_4", "154_5", "154_6", "154_7", "154_8", "154_9", "154_10", "154_11", "154_12", "154_13", "154_14", "154_15", "154_16", "154_17", "154_18", "155_0", "155_1", "155_2", "155_3", "155_4", "155_5", "155_6", "155_7", "155_8", "155_9", "155_10", "155_11", "155_12", "155_13", "155_14", "155_15", "155_16", "155_17", "155_18", "155_19", "155_20", "155_21", "155_22", "155_23", "155_24", "155_25", "155_26", "155_27", "155_28", "155_29", "155_30", "155_31", "155_32", "155_33", "155_34", "155_35", "155_36", "155_37", "155_38", "155_39", "155_40", "155_41", "155_42", "155_43", "155_44", "156_0", "156_1", "156_2", "156_3", "156_4", "156_5", "156_6", "156_7", "156_8", "156_9", "156_10", "156_11", "156_12", "156_13", "156_14", "156_15", "156_16", "156_17", "156_18", "156_19", "156_20", "156_21", "156_22", "156_23", "156_24", "156_25", "156_26", "156_27", "156_28", "156_29", "156_30", "156_31", "156_32", "156_33", "156_34", "156_35", "156_36", "156_37", "156_38", "156_39", "156_40", "156_41", "156_42", "156_43", "156_44", "157_0", "157_1", "157_2", "157_3", "157_4", "157_5", "157_6", "157_7", "157_8", "157_9", "157_10", "157_11", "157_12", "157_13", "157_14", "157_15", "157_16", "157_17", "157_18", "157_19", "157_20", "157_21", "157_22", "157_23", "157_24", "157_25", "157_26", "157_27", "157_28", "157_29", "157_30", "157_31", "157_32", "157_33", "157_34", "157_35", "157_36", "157_37", "157_38", "157_39", "157_40", "157_41", "157_42", "157_43", "157_44", "158_0", "158_1", "158_2", "158_3", "158_4", "158_5", "158_6", "158_7", "158_8", "158_9", "158_10", "158_11", "158_12", "158_13", "159_0", "159_1", "159_2", "159_3", "159_4", "159_5", "159_6", "159_7", "159_8", "159_9", "159_10", "159_11", "159_12", "159_13", "159_14", "159_15", "159_16", "159_17", "160_0", "160_1", "160_2", "160_3", "160_4", "160_5", "160_6", "160_7", "160_8", "160_9", "160_10", "160_11", "160_12", "160_13", "160_14", "160_15", "160_16", "160_17", "160_18", "160_19", "161_0", "161_1", "161_2", "161_3", "161_4", "161_5", "161_6", "161_7", "161_8", "161_9", "161_10", "161_11", "161_12", "161_13", "161_14", "161_15", "161_16", "161_17", "161_18", "161_19", "161_20", "161_21", "161_22", "161_23", "161_24", "161_25", "161_26", "161_27", "161_28", "162_0", "162_1", "162_2", "162_3", "162_4", "162_5", "162_6", "162_7", "162_8", "162_9", "162_10", "162_11", "162_12", "162_13", "162_14", "162_15", "162_16", "162_17", "162_18", "162_19", "162_20", "162_21", "162_22", "162_23", "162_24", "162_25", "162_26", "162_27", "162_28", "163_0", "163_1", "163_2", "163_3", "163_4", "163_5", "163_6", "163_7", "163_8", "163_9", "163_10", "163_11", "163_12", "163_13", "163_14", "163_15", "163_16", "163_17", "163_18", "163_19", "163_20", "163_21", "163_22", "163_23", "163_24", "163_25", "163_26", "163_27", "163_28", "164_0", "164_1", "164_2", "164_3", "164_4", "164_5", "164_6", "164_7", "164_8", "164_9", "164_10", "164_11", "164_12", "164_13", "164_14", "164_15", "164_16", "164_17", "164_18", "164_19", "164_20", "164_21", "164_22", "164_23", "164_24", "164_25", "164_26", "164_27", "164_28", "165_0", "165_1", "165_2", "165_3", "165_4", "165_5", "165_6", "165_7", "165_8", "165_9", "165_10", "165_11", "165_12", "165_13", "165_14", "165_15", "165_16", "165_17", "165_18", "165_19", "165_20", "165_21", "165_22", "165_23", "165_24", "165_25", "165_26", "165_27", "165_28", "166_0", "166_1", "166_2", "166_3", "166_4", "166_5", "166_6", "166_7", "166_8", "166_9", "166_10", "166_11", "166_12", "166_13", "166_14", "166_15", "166_16", "166_17", "166_18", "166_19", "166_20", "166_21", "166_22", "166_23", "166_24", "166_25", "166_26", "166_27", "166_28", "167_0", "167_1", "167_2", "167_3", "167_4", "167_5", "167_6", "167_7", "167_8", "167_9", "167_10", "167_11", "167_12", "167_13", "167_14", "167_15", "167_16", "167_17", "167_18", "167_19", "167_20", "167_21", "167_22", "167_23", "167_24", "167_25", "167_26", "167_27", "167_28", "168_0", "168_1", "168_2", "168_3", "168_4", "168_5", "168_6", "168_7", "168_8", "168_9", "168_10", "168_11", "168_12", "168_13", "168_14", "168_15", "168_16", "168_17", "168_18", "168_19", "168_20", "168_21", "168_22", "168_23", "168_24", "168_25", "168_26", "168_27", "168_28", "169_0", "169_1", "169_2", "169_3", "169_4", "169_5", "169_6", "169_7", "169_8", "169_9", "169_10", "169_11", "169_12", "169_13", "169_14", "169_15", "169_16", "169_17", "169_18", "169_19", "169_20", "169_21", "169_22", "169_23", "169_24", "169_25", "169_26", "169_27", "169_28", "170_0", "170_1", "170_2", "170_3", "170_4", "170_5", "170_6", "170_7", "170_8", "170_9", "170_10", "170_11", "170_12", "170_13", "170_14", "170_15", "170_16", "170_17", "170_18", "170_19", "170_20", "170_21", "170_22", "170_23", "170_24", "170_25", "170_26", "170_27", "170_28", "171_0", "171_1", "171_2", "171_3", "171_4", "171_5", "171_6", "171_7", "171_8", "171_9", "171_10", "171_11", "171_12", "171_13", "171_14", "171_15", "171_16", "171_17", "171_18", "171_19", "171_20", "171_21", "171_22", "171_23", "171_24", "171_25", "171_26", "171_27", "171_28", "172_0", "172_1", "172_2", "172_3", "172_4", "172_5", "172_6", "172_7", "172_8", "172_9", "172_10", "172_11", "172_12", "172_13", "172_14", "172_15", "172_16", "172_17", "172_18", "172_19", "172_20", "172_21", "172_22", "172_23", "172_24", "172_25", "172_26", "172_27", "172_28", "173_0", "173_1", "173_2", "173_3", "173_4", "173_5", "173_6", "173_7", "173_8", "173_9", "173_10", "173_11", "173_12", "173_13", "173_14", "173_15", "173_16", "173_17", "173_18", "173_19", "173_20", "173_21", "173_22", "173_23", "173_24", "173_25", "173_26", "173_27", "173_28", "174_0", "174_1", "174_2", "174_3", "174_4", "174_5", "174_6", "174_7", "174_8", "174_9", "174_10", "174_11", "174_12", "174_13", "174_14", "174_15", "174_16", "174_17", "174_18", "174_19", "174_20", "174_21", "174_22", "174_23", "174_24", "174_25", "174_26", "174_27", "174_28", "175_0", "175_1", "175_2", "175_3", "175_4", "175_5", "175_6", "175_7", "175_8", "175_9", "175_10", "175_11", "175_12", "175_13", "175_14", "175_15", "175_16", "175_17", "175_18", "175_19", "175_20", "175_21", "175_22", "175_23", "175_24", "175_25", "175_26", "175_27", "175_28", "176_0", "176_1", "176_2", "176_3", "176_4", "176_5", "176_6", "176_7", "176_8", "176_9", "176_10", "176_11", "176_12", "176_13", "176_14", "176_15", "176_16", "176_17", "176_18", "176_19", "176_20", "176_21", "176_22", "176_23", "176_24", "176_25", "176_26", "176_27", "176_28", "176_29", "176_30", "176_31", "176_32", "176_33", "176_34", "176_35", "176_36", "176_37", "176_38", "176_39", "176_40", "176_41", "176_42", "176_43", "176_44", "177_0", "177_1", "177_2", "177_3", "177_4", "177_5", "177_6", "177_7", "177_8", "177_9", "177_10", "177_11", "177_12", "177_13", "177_14", "177_15", "177_16", "177_17", "177_18", "178_0", "178_1", "178_2", "178_3", "178_4", "178_5", "178_6", "178_7", "178_8", "178_9", "178_10", "178_11", "178_12", "178_13", "178_14", "178_15", "178_16", "178_17", "178_18", "179_0", "179_1", "179_2", "179_3", "179_4", "179_5", "179_6", "179_7", "179_8", "179_9", "179_10", "179_11", "179_12", "179_13", "179_14", "179_15", "179_16", "179_17", "179_18", "180_0", "180_1", "180_2", "180_3", "180_4", "180_5", "180_6", "180_7", "180_8", "180_9", "180_10", "180_11", "180_12", "180_13", "180_14", "180_15", "180_16", "180_17", "180_18", "181_0", "181_1", "181_2", "181_3", "181_4", "181_5", "181_6", "181_7", "181_8", "181_9", "181_10", "181_11", "181_12", "181_13", "181_14", "181_15", "181_16", "181_17", "181_18", "182_0", "182_1", "182_2", "182_3", "182_4", "182_5", "182_6", "182_7", "182_8", "182_9", "182_10", "182_11", "182_12", "182_13", "182_14", "182_15", "182_16", "182_17", "182_18", "183_0", "183_1", "183_2", "183_3", "183_4", "183_5", "183_6", "183_7", "183_8", "183_9", "183_10", "183_11", "183_12", "183_13", "183_14", "183_15", "183_16", "183_17", "183_18", "184_0", "184_1", "184_2", "184_3", "184_4", "184_5", "184_6", "184_7", "184_8", "184_9", "184_10", "184_11", "184_12", "184_13", "184_14", "184_15", "184_16", "184_17", "184_18", "185_0", "185_1", "185_2", "185_3", "185_4", "185_5", "185_6", "185_7", "185_8", "185_9", "185_10", "185_11", "185_12", "185_13", "185_14", "185_15", "185_16", "185_17", "185_18", "186_0", "186_1", "186_2", "186_3", "186_4", "186_5", "186_6", "186_7", "186_8", "186_9", "186_10", "186_11", "186_12", "186_13", "186_14", "186_15", "186_16", "186_17", "186_18", "187_0", "187_1", "187_2", "187_3", "187_4", "187_5", "187_6", "187_7", "187_8", "187_9", "187_10", "187_11", "187_12", "187_13", "187_14", "187_15", "187_16", "187_17", "187_18", "188_0", "188_1", "188_2", "188_3", "188_4", "188_5", "188_6", "188_7", "188_8", "188_9", "188_10", "188_11", "188_12", "188_13", "188_14", "188_15", "188_16", "188_17", "188_18", "189_0", "189_1", "189_2", "189_3", "189_4", "189_5", "189_6", "189_7", "189_8", "189_9", "189_10", "189_11", "189_12", "189_13", "189_14", "189_15", "189_16", "189_17", "189_18", "190_0", "190_1", "190_2", "190_3", "190_4", "190_5", "190_6", "190_7", "190_8", "190_9", "190_10", "190_11", "190_12", "190_13", "190_14", "190_15", "190_16", "190_17", "190_18", "191_0", "191_1", "191_2", "191_3", "191_4", "191_5", "191_6", "191_7", "191_8", "191_9", "191_10", "191_11", "191_12", "191_13", "191_14", "191_15", "191_16", "191_17", "191_18", "192_0", "192_1", "192_2", "192_3", "192_4", "192_5", "192_6", "192_7", "192_8", "192_9", "192_10", "192_11", "192_12", "192_13", "192_14", "192_15", "192_16", "192_17", "192_18", "193_0", "193_1", "193_2", "193_3", "193_4", "193_5", "193_6", "193_7", "193_8", "193_9", "193_10", "193_11", "193_12", "193_13", "193_14", "193_15", "193_16", "193_17", "193_18", "194_0", "194_1", "194_2", "194_3", "194_4", "194_5", "194_6", "194_7", "194_8", "194_9", "194_10", "194_11", "194_12", "194_13", "194_14", "194_15", "194_16", "194_17", "194_18", "195_0", "195_1", "195_2", "195_3", "195_4", "195_5", "196_0", "196_1", "196_2", "196_3", "196_4", "196_5", "197_0", "197_1", "197_2", "197_3", "197_4", "197_5", "198_0", "198_1", "198_2", "198_3", "198_4", "198_5"]}